<!-- ASTRA -->
 <html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AZD0780 - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.05);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-subtitle {
            font-size: 24px;
            opacity: 0.95;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.9;
        }
        
        .status-badge {
            display: inline-block;
            background: rgba(255,255,255,0.2);
            padding: 8px 16px;
            border-radius: 20px;
            margin-top: 20px;
            font-weight: 600;
            backdrop-filter: blur(10px);
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
        }
        
        .nav-tab.active {
            color: #667eea;
            border-bottom: 3px solid #667eea;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: #667eea;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(102, 126, 234, 0.1);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #667eea;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #667eea;
        }
        
        .dosing-label {
            font-size: 14px;
            color: #888;
            margin-bottom: 5px;
        }
        
        .dosing-value {
            font-size: 24px;
            font-weight: bold;
            color: #333;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #667eea;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-1 { background: #e3f2fd; color: #1976d2; }
        .phase-2 { background: #f3e5f5; color: #7b1fa2; }
        .phase-3 { background: #e8f5e9; color: #388e3c; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 300px;
            gap: 20px;
            padding: 20px 0;
        }
        
        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
        }
        
        .bar {
            width: 100%;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(102, 126, 234, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #667eea;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 14px;
            color: #666;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f8f9fa 100%);
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .safety-percentage {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-estimate {
            font-size: 32px;
            font-weight: bold;
            color: #667eea;
            margin: 20px 0;
        }
        
        .market-projection {
            display: flex;
            align-items: center;
            gap: 20px;
            margin: 20px 0;
        }
        
        .projection-value {
            font-size: 24px;
            font-weight: bold;
            color: #333;
        }
        
        .projection-label {
            font-size: 14px;
            color: #666;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #667eea 0%, #764ba2 100%);
            border-radius: 4px;
            width: 45%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #667eea;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            border-left: 4px solid #667eea;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 200px;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">AZD0780</div>
                <div class="drug-subtitle">Oral PCSK9 Inhibitor (Small Molecule)</div>
                <div class="drug-company">AstraZeneca</div>
                <span class="status-badge">Phase III Ongoing (2025)</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Key Features
                        </div>
                        <ul class="info-list">
                            <li>First true oral small molecule PCSK9 inhibitor</li>
                            <li>Once-daily dosing (30 mg)</li>
                            <li>No meal restrictions required</li>
                            <li>~50% LDL-C reduction achieved</li>
                            <li>UK Innovation Passport (2023)</li>
                            <li>Potential neuroprotective effects</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Highlights
                        </div>
                        <ul class="info-list">
                            <li>Phase IIb PURSUIT: 50.7% LDL reduction</li>
                            <li>84% patients achieved LDL <70 mg/dL</li>
                            <li>Consistent efficacy across statin intensities</li>
                            <li>PCSK9 reduction >90%</li>
                            <li>Phase III trials recruiting (n>13,000)</li>
                            <li>MACE outcomes trial through 2029</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Position
                        </div>
                        <ul class="info-list">
                            <li>Part of AZ's $80B CVRM portfolio target</li>
                            <li>Menarini partnership for EU distribution</li>
                            <li>Fixed-dose combinations in development</li>
                            <li>Competing with Merck's MK-0616</li>
                            <li>Projected $1-5B market by 2030</li>
                            <li>Patent protection to late 2030s</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Unique Differentiation</div>
                    <div class="highlight-content">
                        AZD0780 stands out as the first traditional small molecule PCSK9 inhibitor (vs peptide-based competitors), 
                        with potential advantages in manufacturing scalability and tissue distribution. Preliminary data showing 
                        reduction in Alzheimer's biomarkers (CSF p-tau217) suggests possible neuroprotective benefits beyond 
                        cardiovascular effects, though this remains exploratory.
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                    </div>
                    <div class="mechanism-content">
                        AZD0780 is an investigational <span class="mechanism-highlight">oral small-molecule inhibitor of PCSK9</span>. 
                        It binds with high affinity to the <span class="mechanism-highlight">C-terminal domain of PCSK9</span>, 
                        stabilizing the PCSK9-LDL receptor (LDL-R) complex and preventing PCSK9-mediated lysosomal degradation 
                        of LDL-R on hepatocytes. This unique mechanism allows for:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li>Increased recycling and surface expression of LDL-R</li>
                            <li>Enhanced hepatic uptake and clearance of LDL-C</li>
                            <li>Substantial reductions in serum LDL-C levels (~50%)</li>
                            <li>>90% reduction in free PCSK9 levels</li>
                        </ul>
                        Unlike macrocyclic peptides (e.g., MK-0616), AZD0780 is a <span class="mechanism-highlight">traditional small molecule</span>, 
                        potentially offering advantages in manufacturing scalability and tissue distribution. Its extracellular 
                        action minimizes off-target intracellular effects seen with some lipid therapies.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíä</div>
                        Dosing Information
                    </div>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Administration</div>
                            <div class="dosing-value">Oral, QD</div>
                            <div class="dosing-detail">Once-daily tablet</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Primary Dose</div>
                            <div class="dosing-value">30 mg</div>
                            <div class="dosing-detail">Phase IIb optimal dose</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Dose Range</div>
                            <div class="dosing-value">5-60 mg</div>
                            <div class="dosing-detail">Evaluated in trials</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Food Requirements</div>
                            <div class="dosing-value">None</div>
                            <div class="dosing-detail">Can be taken without meals</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Onset</div>
                            <div class="dosing-value">2 weeks</div>
                            <div class="dosing-detail">LDL-C reduction begins</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Steady State</div>
                            <div class="dosing-value">4-12 weeks</div>
                            <div class="dosing-detail">Full effect achieved</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Advantages</div>
                    <div class="highlight-content">
                        No dose adjustments needed for renal/hepatic impairment based on available data. High bioavailability 
                        unaffected by food enhances patient convenience. Daily dosing prioritizes patient autonomy compared to 
                        inclisiran's biannual injections, though relies on adherence for sustained effects.
                    </div>
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="timeline-container">
                    <div class="timeline-header">FDA/EMA Regulatory Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2023</div>
                                <div class="timeline-title">Preclinical Development</div>
                                <div class="timeline-description">Optimization of small-molecule scaffold for oral bioavailability</div>
                                <div class="timeline-details">
                                    Focus on developing a traditional small molecule with high oral bioavailability 
                                    and PCSK9 binding affinity. Extensive preclinical safety and efficacy studies.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023</div>
                                <div class="timeline-title">Phase I Initiation & UK Innovation Passport</div>
                                <div class="timeline-description">Single/multiple ascending doses in healthy and hypercholesterolemia patients</div>
                                <div class="timeline-details">
                                    52% LDL-C reduction achieved on top of rosuvastatin. UK MHRA granted Innovation Passport 
                                    under ILAP to expedite development and access.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May 29, 2024</div>
                                <div class="timeline-title">Phase I Results Presented</div>
                                <div class="timeline-description">ESC 2024 presentation, advancement to Phase II</div>
                                <div class="timeline-details">
                                    Positive safety and efficacy data presented at European Society of Cardiology. 
                                    Decision to advance to Phase II trials based on promising results.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 31, 2025</div>
                                <div class="timeline-title">Phase IIb PURSUIT Results</div>
                                <div class="timeline-description">Topline results announced at ACC 2025</div>
                                <div class="timeline-details">
                                    50.7% LDL reduction confirmed. 84% of patients achieved guideline goals. 
                                    Regulatory consultations with FDA and EMA ongoing.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May-June 2025</div>
                                <div class="timeline-title">Phase III Program Launch</div>
                                <div class="timeline-description">Multiple Phase III trials initiated</div>
                                <div class="timeline-details">
                                    D7960C00012 (ASCVD/high-risk), NCT07000123 (HeFH), D7960C00013 (HeFH/ASCVD), 
                                    and D7960C00015 (MACE outcomes) trials started. Total enrollment >13,000 patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Mid-2027 (Projected)</div>
                                <div class="timeline-title">NDA/MAA Filing</div>
                                <div class="timeline-description">Regulatory submission based on LDL data</div>
                                <div class="timeline-details">
                                    Expected filing with FDA and EMA based on Phase III LDL-C reduction data. 
                                    Potential EMA-first strategy via Menarini partnership.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2029 (Projected)</div>
                                <div class="timeline-title">MACE Outcomes Data</div>
                                <div class="timeline-description">Phase III outcomes trial completion</div>
                                <div class="timeline-details">
                                    D7960C00015 trial with 10,000 patients expected to provide definitive MACE data. 
                                    Will support expanded indications and broader reimbursement.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Strategy</div>
                    <div class="highlight-content">
                        Development has advanced steadily without reported clinical holds, CRLs, or significant delays. 
                        Focus on LDL-C surrogates for initial submissions, similar to prior PCSK9 therapies. 
                        Potential EMA-first strategy due to European partnerships. Innovation Passport from UK MHRA 
                        provides expedited pathway in UK market.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>Population</th>
                            <th>N</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Phase I<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-1">Phase I</span></td>
                            <td>Healthy/Hypercholesterolemia</td>
                            <td>~100</td>
                            <td>Safety/PK/PD</td>
                            <td>52% LDL-C reduction on rosuvastatin<br>Total ~78% from baseline<br>PCSK9 >90% reduction</td>
                        </tr>
                        <tr>
                            <td>Phase IIa<br><small>2024</small></td>
                            <td><span class="trial-phase phase-2">Phase II</span></td>
                            <td>Add-on to statins</td>
                            <td>~60</td>
                            <td>% LDL-C change at week 12</td>
                            <td>~52% reduction achieved</td>
                        </tr>
                        <tr>
                            <td>PURSUIT<br><small>NCT06173570</small></td>
                            <td><span class="trial-phase phase-2">Phase IIb</span></td>
                            <td>Hyperlipidemia</td>
                            <td>428</td>
                            <td>% LDL-C change at week 12</td>
                            <td>50.7% reduction (30 mg)<br>84% achieved <70 mg/dL<br>ApoB/non-HDL-C ~40-50%<br>Lp(a) ~20%, hsCRP reduced</td>
                        </tr>
                        <tr>
                            <td>D7960C00012<br><small>NCT07000136</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>ASCVD/High-risk</td>
                            <td>~2,500</td>
                            <td>% LDL-C change at week 24</td>
                            <td>Ongoing (Started May 2025)</td>
                        </tr>
                        <tr>
                            <td>D7960C00013<br><small>NCT07000123</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>HeFH/ASCVD</td>
                            <td>~300</td>
                            <td>% LDL-C change at week 24</td>
                            <td>Ongoing (Started June 2025)</td>
                        </tr>
                        <tr>
                            <td>D7960C00015<br><small>NCT07000357</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>ASCVD</td>
                            <td>~10,000</td>
                            <td>MACE (CV death, MI, stroke)</td>
                            <td>Ongoing (Ends ~2029)</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">LDL-C Reduction Across Trials</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 52%;">
                                <div class="bar-value">52%</div>
                            </div>
                            <div class="bar-label">Phase I<br>+Rosuvastatin</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 78%;">
                                <div class="bar-value">78%</div>
                            </div>
                            <div class="bar-label">Phase I<br>Total from Baseline</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 52%;">
                                <div class="bar-value">52%</div>
                            </div>
                            <div class="bar-label">Phase IIa<br>Week 12</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 50.7%;">
                                <div class="bar-value">50.7%</div>
                            </div>
                            <div class="bar-label">PURSUIT<br>30mg Dose</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Secondary Endpoints - PURSUIT Trial</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 45%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">45%</div>
                            </div>
                            <div class="bar-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 45%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">45%</div>
                            </div>
                            <div class="bar-label">Non-HDL-C<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 20%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">20%</div>
                            </div>
                            <div class="bar-label">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 84%; background: linear-gradient(180deg, #ff9800 0%, #f57c00 100%);">
                                <div class="bar-value">84%</div>
                            </div>
                            <div class="bar-label">Patients<br><70 mg/dL</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Exploratory Finding: Neuroprotective Potential</div>
                    <div class="highlight-content">
                        Preliminary data from BROADWAY trial substudy showed reduction in cerebrospinal fluid phospho-tau217 
                        biomarkers, suggesting potential neuroprotective effects via brain PCSK9 modulation. While exploratory, 
                        this could differentiate AZD0780 if further research confirms cognitive benefits.
                    </div>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-percentage">38.2%</div>
                        <div class="safety-label">Overall AEs (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">32.6%</div>
                        <div class="safety-label">Overall AEs (Placebo)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">3%</div>
                        <div class="safety-label">Serious AEs (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">6%</div>
                        <div class="safety-label">Serious AEs (Placebo)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">1.5%</div>
                        <div class="safety-label">Discontinuation (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">2.3%</div>
                        <div class="safety-label">Discontinuation (Placebo)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            Common Adverse Events (>5%)
                        </div>
                        <ul class="info-list">
                            <li>Headache (6-8%)</li>
                            <li>Nausea (4-6%, mild)</li>
                            <li>Diarrhea (4-6%, mild)</li>
                            <li>All mild to moderate severity</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            No Safety Signals
                        </div>
                        <ul class="info-list">
                            <li>No liver enzyme elevations</li>
                            <li>No CK elevations</li>
                            <li>No glucose/glycemic effects</li>
                            <li>No blood pressure increases</li>
                            <li>No myalgia signals</li>
                            <li>No neurocognitive effects</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚ÑπÔ∏è</div>
                            Low LDL-C Safety
                        </div>
                        <ul class="info-list">
                            <li>~20% achieved LDL <25 mg/dL</li>
                            <li>No cognitive adverse events</li>
                            <li>Class meta-analyses show no impairment</li>
                            <li>Safe even with LDL <15 mg/dL over 5+ years</li>
                            <li>Brain lipids preserved with PCSK9 inhibition</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Safety Profile Summary</div>
                    <div class="highlight-content">
                        AZD0780 exhibits a favorable safety profile comparable to placebo, with ~1,000 patients exposed by 2025. 
                        No black-box warnings projected. Small-molecule nature avoids immunogenicity issues of antibodies, 
                        and extracellular action limits organ toxicity. No renal effects or organ-specific toxicity expected. 
                        Post-Phase III monitoring planned for rare events.
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="price-estimate">$4,000 - $6,000/year</div>
                    <div style="color: #666; margin-bottom: 30px;">Projected annual cost (potentially discounted for volume vs. injectables)</div>
                    
                    <div class="market-projection">
                        <div>
                            <div class="projection-value">$1-5 Billion</div>
                            <div class="projection-label">Market potential by 2030</div>
                        </div>
                        <div>
                            <div class="projection-value">70-80%</div>
                            <div class="projection-label">Expected PA denial rate initially</div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Payer Considerations
                        </div>
                        <ul class="info-list">
                            <li>Initially restricted to high-risk/statin-intolerant</li>
                            <li>Similar PA requirements to mAbs expected</li>
                            <li>Pharmacy benefit eases access vs. medical</li>
                            <li>Outcomes data key for broader coverage</li>
                            <li>Volume-based pricing negotiations likely</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Market Access Strategy
                        </div>
                        <ul class="info-list">
                            <li>Broader GP use vs. specialist-only injectables</li>
                            <li>Adherence programs needed for daily dosing</li>
                            <li>Fixed-dose combinations for convenience</li>
                            <li>Potential rosuvastatin/ezetimibe combos</li>
                            <li>Menarini partnership for EU distribution</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Competitive Positioning
                        </div>
                        <ul class="info-list">
                            <li>Competing with Merck's MK-0616</li>
                            <li>Small molecule vs. peptide differentiation</li>
                            <li>Part of AZ's CV portfolio bundling</li>
                            <li>Potential neuro indication differentiation</li>
                            <li>Manufacturing scalability advantage</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Outlook</div>
                    <div class="highlight-content">
                        As orals enter market, potential to disrupt inclisiran's position if priced competitively. 
                        Daily pill format favors primary care adoption but requires adherence focus. AZ's existing 
                        CV portfolio (including potential obicetrapib CETP inhibitor) enables bundling strategies. 
                        By 2030, oral PCSK9 inhibitors may dominate market, with AZD0780's small molecule nature 
                        and combination potential supporting its niche in multi-drug regimens.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Preclinical</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 20%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase I</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 35%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase II</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 45%;">
                        <div class="milestone-dot" style="background: #667eea;"></div>
                        <div class="milestone-label"><strong>Phase III (Current)</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 70%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Approval (2027)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">MACE Data (2029)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Future Development
                        </div>
                        <ul class="info-list">
                            <li>Fixed-dose combinations with statins/ezetimibe</li>
                            <li>Potential neuro indications (tau biomarkers)</li>
                            <li>Part of AZ's $80B CVRM revenue target</li>
                            <li>Integration with obicetrapib (CETP inhibitor)</li>
                            <li>Single-pill multi-mechanism therapy</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Landscape 2030
                        </div>
                        <ul class="info-list">
                            <li>Multiple oral PCSK9 options expected</li>
                            <li>Competition from gene therapies (Verve)</li>
                            <li>Generics post-patent (late 2030s)</li>
                            <li>Inclisiran/mAbs relegated to niches</li>
                            <li>Triple therapy for highest-risk patients</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Differentiation
                        </div>
                        <ul class="info-list">
                            <li>Small molecule vs. peptide competitors</li>
                            <li>Manufacturing scalability advantage</li>
                            <li>Broader tissue distribution potential</li>
                            <li>Portfolio synergies with AZ CV drugs</li>
                            <li>Possible cognitive benefit claims</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-term Outlook</div>
                    <div class="highlight-content">
                        By 2030, oral PCSK9 inhibitors likely to dominate market, potentially displacing injectable 
                        options for most patients. AZD0780's differentiation through small molecule nature, combination 
                        potential, and possible neuroprotective effects positions it well in multi-drug regimens. 
                        Patent protection to late 2030s provides sustainability window before generic entry. Success 
                        depends on outcomes data, pricing strategy, and ability to compete with Merck's first-mover 
                        advantage.
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>

<!-- LIB003 (Lerodalcibep) - Comprehensive Drug Profile -->
 <html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>LIB003 (Lerodalcibep) - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: rgba(255,255,255,0.25);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            backdrop-filter: blur(10px);
            font-size: 16px;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 201, 255, 0.1);
        }
        
        .nav-tab.active {
            color: #00c9ff;
            border-bottom: 3px solid #00c9ff;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #e0f7fa 0%, #b2dfdb 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(0, 201, 255, 0.15);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #00acc1;
        }
        
        .innovation-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ffd89b 0%, #19547b 100%);
            color: white;
            padding: 5px 12px;
            border-radius: 15px;
            font-size: 14px;
            font-weight: 600;
            margin-left: 10px;
        }
        
        .dosing-comparison {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
            position: relative;
        }
        
        .dosing-card.highlighted {
            border-color: #00c9ff;
            background: linear-gradient(135deg, rgba(0, 201, 255, 0.05) 0%, rgba(146, 254, 157, 0.05) 100%);
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(0, 201, 255, 0.2);
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .dosing-frequency {
            font-size: 28px;
            font-weight: bold;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .dosing-product {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-top: 10px;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
            margin-top: 5px;
        }
        
        .injections-year {
            font-size: 12px;
            color: #999;
            margin-top: 10px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #00c9ff;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #00c9ff;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-2 { background: #e1f5fe; color: #0277bd; }
        .phase-3 { background: #e8f5e9; color: #2e7d32; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 300px;
            gap: 30px;
            padding: 20px 0;
            justify-content: center;
        }
        
        .bar-group {
            flex: 0 0 auto;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
            min-width: 100px;
        }
        
        .bar {
            width: 80px;
            background: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(0, 201, 255, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #00c9ff;
            white-space: nowrap;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 14px;
            color: #666;
            max-width: 100px;
        }
        
        .comparison-bar {
            background: linear-gradient(180deg, #ff6b6b 0%, #ff8e53 100%);
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f0f9ff 100%);
            border: 2px solid #e0f7fa;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #00c9ff;
        }
        
        .safety-icon {
            font-size: 36px;
            margin-bottom: 10px;
        }
        
        .safety-percentage {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .competitive-advantages {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .advantage-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            border-left: 4px solid;
            border-image: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%) 1;
        }
        
        .advantage-title {
            font-weight: bold;
            color: #00acc1;
            margin-bottom: 10px;
        }
        
        .advantage-description {
            color: #666;
            font-size: 14px;
            line-height: 1.6;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 201, 255, 0.1) 0%, rgba(146, 254, 157, 0.1) 100%);
            border-left: 4px solid #00c9ff;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00acc1;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 4px;
            width: 65%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00c9ff;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .fast-track-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff6b6b 0%, #ff8e53 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: 600;
            font-size: 14px;
            margin: 10px 0;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 200px;
                flex-wrap: wrap;
            }
            
            .dosing-comparison {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">LIB003</div>
                <div class="drug-generic">Lerodalcibep</div>
                <div class="drug-subtitle">Third-Generation PCSK9 Inhibitor</div>
                <div class="drug-company">LIB Therapeutics</div>
                <span class="status-badge">Phase 3 Complete ‚Ä¢ FDA Filing Expected 2024-2025</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Innovation Profile
                        </div>
                        <ul class="info-list">
                            <li>Novel adnectin-albumin fusion protein</li>
                            <li>Smaller molecule than mAbs (~1.2 mL injection)</li>
                            <li>Once-monthly dosing (12 injections/year)</li>
                            <li>No immunogenicity detected over 52 weeks</li>
                            <li>FDA Fast Track designation granted</li>
                            <li>Technology originated from BMS, optimized by LIB</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Performance
                        </div>
                        <ul class="info-list">
                            <li>LIBerate-HR: 56% LDL reduction at 52 weeks</li>
                            <li>Peak efficacy: Up to 70% LDL reduction</li>
                            <li>90%+ patients achieved guideline goals</li>
                            <li>Co-primary endpoints met at 24 & 52 weeks</li>
                            <li>HoFH: ~10% reduction (meaningful in this population)</li>
                            <li>Consistent efficacy in HeFH patients</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Market Position
                        </div>
                        <ul class="info-list">
                            <li>Bridges gap between Q2W mAbs and biannual inclisiran</li>
                            <li>Potential for self-administration via autoinjector</li>
                            <li>Pharmacy benefit eligible (vs medical for inclisiran)</li>
                            <li>Expected pricing 20% below existing mAbs</li>
                            <li>Patent protection into late 2030s</li>
                            <li>May need partner for large-scale commercialization</li>
                        </ul>
                    </div>
                </div>
                
                <div class="dosing-comparison">
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q2W</div>
                        <div class="dosing-product">Repatha/Praluent</div>
                        <div class="dosing-detail">Standard mAbs</div>
                        <div class="injections-year">26 injections/year</div>
                    </div>
                    <div class="dosing-card highlighted">
                        <div class="dosing-frequency">Monthly</div>
                        <div class="dosing-product">LIB003</div>
                        <div class="dosing-detail">Lerodalcibep</div>
                        <div class="injections-year">12 injections/year</div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q4W</div>
                        <div class="dosing-product">Praluent</div>
                        <div class="dosing-detail">Optional dosing</div>
                        <div class="injections-year">12 injections/year</div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Biannual</div>
                        <div class="dosing-product">Inclisiran</div>
                        <div class="dosing-detail">siRNA therapy</div>
                        <div class="injections-year">2 injections/year</div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Key Differentiation</div>
                    <div class="highlight-content">
                        LIB003 represents a "third-generation" approach to PCSK9 inhibition, using novel adnectin technology 
                        rather than traditional antibodies. Its monthly dosing offers a sweet spot between frequent mAb injections 
                        and very infrequent inclisiran dosing, potentially improving adherence while maintaining consistent LDL control. 
                        The smaller injection volume (1.2 mL) and lack of immunogenicity over 52 weeks demonstrate the success of 
                        its engineered protein design.
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                        <span class="innovation-badge">Third-Generation PCSK9i</span>
                    </div>
                    <div class="mechanism-content">
                        Lerodalcibep is a <span class="mechanism-highlight">novel small binding protein</span> consisting of an 
                        <span class="mechanism-highlight">adnectin fused to human albumin</span>. Unlike traditional monoclonal antibodies:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li><strong>Adnectin component:</strong> A small engineered protein based on fibronectin that specifically binds PCSK9</li>
                            <li><strong>Albumin fusion:</strong> Extends half-life to enable monthly dosing</li>
                            <li><strong>Smaller size:</strong> Being smaller than mAbs allows for highly concentrated, low-volume injections</li>
                            <li><strong>Same endpoint:</strong> Prevents PCSK9 from degrading LDL receptors, increasing LDL clearance</li>
                        </ul>
                        <br>
                        The mechanism achieves <span class="mechanism-highlight">near-maximal PCSK9 suppression</span> with a single 
                        300 mg dose, resulting in up to <span class="mechanism-highlight">70% LDL reduction</span> at peak effect. 
                        The adnectin technology originated at Bristol-Myers Squibb and was optimized by LIB Therapeutics specifically 
                        for superior binding affinity and extended duration.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíâ</div>
                        Dosing Specifications
                    </div>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin-top: 20px;">
                        <div class="dosing-card">
                            <div class="dosing-label">Dose</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">300 mg</div>
                            <div class="dosing-detail">Fixed dose, subcutaneous</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Frequency</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">Monthly</div>
                            <div class="dosing-detail">Once every 4 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Volume</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">1.2 mL</div>
                            <div class="dosing-detail">Comfortable injection size</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">12</div>
                            <div class="dosing-detail">vs 26 for Q2W mAbs</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Advantages</div>
                    <div class="highlight-content">
                        Monthly dosing maintains consistently low LDL levels with less peak-trough variation than Q2W regimens. 
                        The schedule aligns well with typical monthly physician visits for high-risk patients. The small injection 
                        volume (1.2 mL) improves patient comfort compared to larger volume injections. Prefilled syringes used in 
                        trials, with autoinjector device likely for commercial launch enabling self-administration.
                    </div>
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="fast-track-badge">FDA Fast Track Designation Granted</div>
                
                <div class="timeline-container">
                    <div class="timeline-header">Regulatory Development Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2020</div>
                                <div class="timeline-title">Technology Acquisition</div>
                                <div class="timeline-description">LIB Therapeutics acquired adnectin platform from BMS</div>
                                <div class="timeline-details">
                                    Original adnectin PCSK9 inhibitor was in Phase 1 at BMS. LIB optimized the molecule 
                                    for improved binding, stability, and half-life extension via albumin fusion.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2020-2022</div>
                                <div class="timeline-title">Phase 2 Development</div>
                                <div class="timeline-description">Dose-finding and proof of concept studies</div>
                                <div class="timeline-details">
                                    Demonstrated up to 70% LDL-C reduction at peak effect. Single 300 mg dose achieved 
                                    near-maximal PCSK9 suppression. No immunogenicity concerns identified.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023</div>
                                <div class="timeline-title">Phase 3 Trials Initiated</div>
                                <div class="timeline-description">LIBerate-HR and LIBerate-FH trials launched</div>
                                <div class="timeline-details">
                                    FDA Fast Track designation granted for HeFH and secondary prevention. 
                                    Two pivotal trials enrolling high-risk and familial hypercholesterolemia patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 2024 (ACC)</div>
                                <div class="timeline-title">LIBerate-HR Results</div>
                                <div class="timeline-description">52-week data presented at ACC 2024</div>
                                <div class="timeline-details">
                                    56% LDL reduction vs placebo over 52 weeks. Co-primary endpoints met. 
                                    No safety, tolerability, or immunogenicity concerns. Over 90% achieved guideline goals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Mid-2024</div>
                                <div class="timeline-title">Filing Preparation Announced</div>
                                <div class="timeline-description">Company announces regulatory submission plans</div>
                                <div class="timeline-details">
                                    LIB Therapeutics indicated plans to file with FDA in late 2024 or early 2025. 
                                    Partnered manufacturing secured. No CRLs or holds reported.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Late 2024/Early 2025</div>
                                <div class="timeline-title">FDA/EMA Submissions</div>
                                <div class="timeline-description">BLA filing expected</div>
                                <div class="timeline-details">
                                    Simultaneous FDA and EMA submissions planned. Fast Track designation should expedite 
                                    FDA review. Manufacturing and immunogenicity data package complete.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2025 (Projected)</div>
                                <div class="timeline-title">Potential Approval</div>
                                <div class="timeline-description">Expected regulatory decisions</div>
                                <div class="timeline-details">
                                    Approval likely based on LDL surrogate endpoint, similar to prior PCSK9 inhibitors. 
                                    Broad label expected similar to Repatha. Post-marketing outcomes trial may be required.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Advantages</div>
                    <div class="highlight-content">
                        No regulatory holds or CRLs reported to date. FDA Fast Track designation indicates agency support for 
                        expedited review. The novel adnectin platform has prior FDA exposure from BMS's earlier work, reducing 
                        regulatory uncertainty. Strong Phase 3 data with no immunogenicity concerns over 52 weeks addresses 
                        key regulatory questions for novel protein therapeutics. LIB has secured partnered manufacturing to 
                        avoid inclisiran-type delays.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>Population</th>
                            <th>N</th>
                            <th>Duration</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Phase 2<br><small>2020-2022</small></td>
                            <td><span class="trial-phase phase-2">Phase 2</span></td>
                            <td>Hypercholesterolemia</td>
                            <td>~150</td>
                            <td>12 weeks</td>
                            <td>Dose-finding, LDL-C reduction</td>
                            <td>Up to 70% LDL reduction at peak<br>300 mg dose selected<br>Near-maximal PCSK9 suppression</td>
                        </tr>
                        <tr>
                            <td>LIBerate-HR<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>High CV risk<br>on max therapy</td>
                            <td>922</td>
                            <td>52 weeks</td>
                            <td>% LDL-C change at 24 & 52 weeks</td>
                            <td>56% LDL reduction at 52 weeks<br>62% reduction at 24 weeks<br>>90% achieved goals<br>No immunogenicity</td>
                        </tr>
                        <tr>
                            <td>LIBerate-FH<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>HeFH patients</td>
                            <td>~450</td>
                            <td>24 weeks</td>
                            <td>% LDL-C reduction</td>
                            <td>Similar efficacy to LIBerate-HR<br>>90% achieved European goals<br>Well-tolerated</td>
                        </tr>
                        <tr>
                            <td>HoFH Study<br><small>Interim data</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>Homozygous FH</td>
                            <td>~60</td>
                            <td>24 weeks</td>
                            <td>% LDL-C reduction</td>
                            <td>~10% LDL reduction<br>(Meaningful in HoFH)<br>Similar to Repatha in HoFH</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">LDL-C Reduction Comparison</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 70%;">
                                <div class="bar-value">70%</div>
                            </div>
                            <div class="bar-label">Phase 2<br>Peak Effect</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 62%;">
                                <div class="bar-value">62%</div>
                            </div>
                            <div class="bar-label">LIBerate-HR<br>24 weeks</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 56%;">
                                <div class="bar-value">56%</div>
                            </div>
                            <div class="bar-label">LIBerate-HR<br>52 weeks</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar comparison-bar" style="height: 60%;">
                                <div class="bar-value">~60%</div>
                            </div>
                            <div class="bar-label">Repatha<br>Typical</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar comparison-bar" style="height: 50%;">
                                <div class="bar-value">~50%</div>
                            </div>
                            <div class="bar-label">Inclisiran<br>Typical</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Achievement of Guideline Goals</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 90%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">>90%</div>
                            </div>
                            <div class="bar-label">LIB003<br>Achieved Goals</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 120%; background: linear-gradient(180deg, #2196f3 0%, #1565c0 100%);">
                                <div class="bar-value">~120 mg/dL</div>
                            </div>
                            <div class="bar-label">Baseline<br>LDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 60%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">~60 mg/dL</div>
                            </div>
                            <div class="bar-label">On-Treatment<br>LDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 130%; background: linear-gradient(180deg, #ff6b6b 0%, #d32f2f 100%);">
                                <div class="bar-value">~130 mg/dL</div>
                            </div>
                            <div class="bar-label">Placebo<br>LDL-C</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Clinical Outcomes Perspective</div>
                    <div class="highlight-content">
                        While no cardiovascular outcomes trial has been completed, the consistent 56-62% LDL reduction 
                        places lerodalcibep in the same efficacy range as approved PCSK9 inhibitors with proven CV benefit. 
                        The 52-week durability data is particularly strong. LIB Therapeutics may need a partner to fund 
                        a large outcomes trial, but approval will likely proceed based on LDL surrogate endpoint. 
                        The HoFH data (~10% reduction) provides a potential niche indication in this ultra-rare population.
                    </div>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-icon">‚úÖ</div>
                        <div class="safety-percentage">0%</div>
                        <div class="safety-label">Immunogenicity<br>Over 52 Weeks</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üî¨</div>
                        <div class="safety-percentage">Similar</div>
                        <div class="safety-label">AE Rate<br>vs Placebo</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üíä</div>
                        <div class="safety-percentage">0</div>
                        <div class="safety-label">Treatment-Related<br>Serious AEs</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üß¨</div>
                        <div class="safety-percentage">None</div>
                        <div class="safety-label">Liver/CK<br>Elevations</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üß†</div>
                        <div class="safety-percentage">None</div>
                        <div class="safety-label">Neurocognitive<br>Effects</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üíâ</div>
                        <div class="safety-percentage">Low</div>
                        <div class="safety-label">Injection Site<br>Reactions</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            Common Adverse Events
                        </div>
                        <ul class="info-list">
                            <li>Influenza-like symptoms (~5%)</li>
                            <li>Nasopharyngitis (~5%)</li>
                            <li>Similar rates to placebo</li>
                            <li>Mild injection site reactions (rare)</li>
                            <li>No pattern of concerning AEs</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üõ°Ô∏è</div>
                            Key Safety Findings
                        </div>
                        <ul class="info-list">
                            <li>No neutralizing antibodies detected</li>
                            <li>No safety or tolerability concerns vs placebo</li>
                            <li>No liver enzyme elevations</li>
                            <li>No creatine kinase elevations</li>
                            <li>No cognitive impairment reported</li>
                            <li>Clean profile over 52 weeks</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîç</div>
                            Theoretical Considerations
                        </div>
                        <ul class="info-list">
                            <li>Adnectin scaffold highly specific to PCSK9</li>
                            <li>No off-target binding observed</li>
                            <li>Smaller size may reduce injection site inflammation</li>
                            <li>Monthly dosing reduces injection fatigue</li>
                            <li>Protein-based, no CYP interactions</li>
                            <li>Extracellular action limits organ toxicity</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Safety Profile Summary</div>
                    <div class="highlight-content">
                        The complete absence of immunogenicity over 52 weeks is particularly impressive for a novel engineered 
                        protein therapeutic, validating the adnectin-albumin fusion design. Safety profile essentially mirrors 
                        placebo aside from expected mild injection reactions and common viral symptoms. The lack of any 
                        treatment-related serious adverse events, liver/muscle effects, or neurocognitive signals positions 
                        lerodalcibep's safety on par with or slightly better than first-generation mAbs. Post-market surveillance 
                        will monitor for rare events in larger populations.
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="competitive-advantages">
                        <div class="advantage-card">
                            <div class="advantage-title">Dosing Convenience</div>
                            <div class="advantage-description">
                                Monthly dosing offers sweet spot between Q2W mAbs and biannual inclisiran. 
                                12 injections/year vs 26 for standard mAbs.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Distribution Flexibility</div>
                            <div class="advantage-description">
                                Can be distributed through specialty pharmacy (pharmacy benefit) avoiding 
                                buy-and-bill complexities that challenged inclisiran's US launch.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Pricing Strategy</div>
                            <div class="advantage-description">
                                Expected to price ~20% below existing mAbs to drive adoption as new entrant. 
                                May trigger formulary preferences if cost-effective.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Small Volume</div>
                            <div class="advantage-description">
                                1.2 mL injection volume more comfortable than larger injections. 
                                Autoinjector device planned for self-administration.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Payer Considerations
                        </div>
                        <ul class="info-list">
                            <li>Initially require same PA justification as other PCSK9i</li>
                            <li>Potential formulary preference if priced lower</li>
                            <li>Pharmacy benefit simplifies access vs medical</li>
                            <li>Monthly schedule aligns with specialty pharmacy</li>
                            <li>Class outcomes data supports coverage</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Target Markets
                        </div>
                        <ul class="info-list">
                            <li>Statin-intolerant patients (50-60% LDL reduction)</li>
                            <li>Patients preferring monthly vs Q2W schedule</li>
                            <li>Those who can't adhere to biweekly injections</li>
                            <li>HoFH patients (niche ultra-rare indication)</li>
                            <li>VA and integrated health systems</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üåç</div>
                            Global Strategy
                        </div>
                        <ul class="info-list">
                            <li>Simultaneous US/EU filing planned</li>
                            <li>May need big pharma partner for scale</li>
                            <li>Europe pricing critical vs inclisiran (~‚Ç¨2000/dose)</li>
                            <li>NHS unlikely to switch from inclisiran deal</li>
                            <li>Focus on markets without existing contracts</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Outlook</div>
                    <div class="highlight-content">
                        LIB003 enters market as an "intermediate option" - more convenient than Q2W mAbs but more frequent 
                        than inclisiran. Success depends on pricing strategy and distribution efficiency. Avoiding buy-and-bill 
                        by using specialty pharmacy channels could accelerate uptake. The 2025-2026 launch window gives 
                        opportunity to establish market share before oral PCSK9 inhibitors arrive. Small company status 
                        may necessitate partnership for full commercial potential. Best positioned for statin-intolerant 
                        patients and those seeking monthly regimen alignment with other chronic therapies.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Technology<br>Acquisition</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 25%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 2</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 50%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 3</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 65%;">
                        <div class="milestone-dot" style="background: #00c9ff;"></div>
                        <div class="milestone-label"><strong>Filing (Current)</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 75%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Approval<br>(2025)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Biosimilar<br>Competition<br>(~2028)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Near-Term Outlook (2025-2027)
                        </div>
                        <ul class="info-list">
                            <li>FDA approval expected 2025</li>
                            <li>Critical window before oral PCSK9i dominance</li>
                            <li>Build market share with aggressive pricing</li>
                            <li>Potential head-to-head vs Repatha study</li>
                            <li>Partnership likely for outcomes trial</li>
                            <li>HoFH indication provides differentiation</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Threats
                        </div>
                        <ul class="info-list">
                            <li>Oral PCSK9i (MK-0616, AZD0780) by 2027</li>
                            <li>Biosimilar mAbs expected ~2028</li>
                            <li>Gene therapy eventual long-term threat</li>
                            <li>Inclisiran gaining traction with health systems</li>
                            <li>Price pressure from multiple entrants</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üöÄ</div>
                            Innovation Potential
                        </div>
                        <ul class="info-list">
                            <li>Longer-acting depot formulation possible</li>
                            <li>Combination with inclisiran for extreme cases</li>
                            <li>Platform applicable to other targets</li>
                            <li>Autoinjector device for home use</li>
                            <li>Patent protection to late 2030s</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-Term Sustainability</div>
                    <div class="highlight-content">
                        LIB003 represents an important interim competitor that raises the bar for convenience vs Q2W mAbs. 
                        Its window of opportunity is 2025-2028, before oral PCSK9 inhibitors and biosimilars reshape the market. 
                        Long-term survival depends on demonstrating clinical advantages (adherence, outcomes) or finding niches 
                        (HoFH, combination therapy). The adnectin platform technology could be applied to other therapeutic 
                        targets, providing pipeline beyond PCSK9. Monthly injections may retain relevance for patients preferring 
                        injections over daily pills or those with adherence challenges. Critical to establish strong market 
                        position quickly before landscape shifts dramatically.
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>

<!-- MK-0616 -->

<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MK-0616 (Enlicitide Decanoate) - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.08);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            font-size: 16px;
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
            animation: pulse 2s infinite;
        }
        
        @keyframes pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }
        
        .first-in-class {
            display: inline-block;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            padding: 8px 16px;
            border-radius: 20px;
            margin-left: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 83, 156, 0.1);
        }
        
        .nav-tab.active {
            color: #00539C;
            border-bottom: 3px solid #00539C;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .game-changer-banner {
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            color: white;
            padding: 25px;
            border-radius: 15px;
            margin-bottom: 30px;
            box-shadow: 0 5px 20px rgba(76, 175, 80, 0.3);
        }
        
        .game-changer-banner h3 {
            font-size: 24px;
            margin-bottom: 10px;
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #e3f2fd 0%, #bbdefb 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(0, 83, 156, 0.15);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #00539C;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
            position: relative;
        }
        
        .dosing-card.optimal {
            border-color: #4caf50;
            background: linear-gradient(135deg, rgba(76, 175, 80, 0.05) 0%, rgba(46, 125, 50, 0.05) 100%);
            transform: scale(1.05);
        }
        
        .dosing-card.optimal::after {
            content: '‚úì Optimal';
            position: absolute;
            top: -10px;
            right: 10px;
            background: #4caf50;
            color: white;
            padding: 5px 10px;
            border-radius: 15px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .dosing-dose {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .dosing-efficacy {
            font-size: 24px;
            font-weight: bold;
            color: #4caf50;
            margin: 10px 0;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
        }
        
        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
            margin: 30px 0;
        }
        
        .comparison-card {
            background: white;
            border-radius: 12px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .comparison-card h4 {
            color: #00539C;
            margin-bottom: 15px;
            font-size: 18px;
        }
        
        .comparison-card ul {
            list-style: none;
            padding: 0;
        }
        
        .comparison-card li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            display: flex;
            align-items: center;
        }
        
        .comparison-card li:last-child {
            border-bottom: none;
        }
        
        .advantage-icon {
            color: #4caf50;
            margin-right: 10px;
            font-size: 20px;
        }
        
        .consideration-icon {
            color: #ff9800;
            margin-right: 10px;
            font-size: 20px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #00539C 0%, #003A70 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-content.future {
            background: linear-gradient(135deg, #fff3cd 0%, #ffeaa7 100%);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #00539C;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-dot.future {
            background: #ff9800;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-1 { background: #e3f2fd; color: #1976d2; }
        .phase-2 { background: #f3e5f5; color: #7b1fa2; }
        .phase-3 { background: #e8f5e9; color: #388e3c; }
        
        .trial-status {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .status-complete { background: #d4edda; color: #155724; }
        .status-ongoing { background: #fff3cd; color: #856404; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 350px;
            gap: 20px;
            padding: 20px 0;
            justify-content: space-evenly;
        }
        
        .bar-group {
            flex: 0 0 auto;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
            min-width: 80px;
        }
        
        .bar {
            width: 60px;
            background: linear-gradient(180deg, #00539C 0%, #003A70 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
            animation: growUp 1s ease-out;
        }
        
        @keyframes growUp {
            from { height: 0; }
        }
        
        .bar.optimal {
            background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);
        }
        
        .bar.secondary {
            background: linear-gradient(180deg, #9e9e9e 0%, #616161 100%);
        }
        
        .bar.lpa {
            background: linear-gradient(180deg, #ff9800 0%, #f57c00 100%);
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(0, 83, 156, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #00539C;
            white-space: nowrap;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 13px;
            color: #666;
            max-width: 80px;
        }
        
        .dose-response-curve {
            background: white;
            padding: 30px;
            border-radius: 15px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f0f7ff 100%);
            border: 2px solid #e3f2fd;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #00539C;
        }
        
        .safety-percentage {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-projection {
            text-align: center;
            margin: 30px 0;
        }
        
        .price-range {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .price-comparison {
            font-size: 16px;
            color: #666;
            margin-top: 10px;
        }
        
        .market-metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .metric-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            text-align: center;
            border-top: 4px solid #00539C;
        }
        
        .metric-value {
            font-size: 28px;
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .metric-label {
            font-size: 14px;
            color: #666;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 83, 156, 0.1) 0%, rgba(0, 58, 112, 0.1) 100%);
            border-left: 4px solid #00539C;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00539C 0%, #003A70 100%);
            border-radius: 4px;
            width: 75%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00539C;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .adherence-comparison {
            background: #fff3cd;
            border-left: 4px solid #ff9800;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 250px;
                overflow-x: auto;
            }
            
            .comparison-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">MK-0616</div>
                <div class="drug-generic">Enlicitide Decanoate</div>
                <div class="drug-subtitle">First-in-Class Oral PCSK9 Inhibitor</div>
                <div class="drug-company">Merck & Co., Inc.</div>
                <span class="status-badge">Phase 3 Complete</span>
                <span class="first-in-class">üéØ FIRST ORAL PCSK9i</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="game-changer-banner">
                    <h3>üéØ Game-Changing Innovation</h3>
                    <p>First oral PCSK9 inhibitor - No injections required! Daily tablet provides similar efficacy to injectable monoclonal antibodies (60-65% LDL reduction) with the convenience of oral administration. This could transform PCSK9 inhibition from specialist injectable therapy to primary care oral treatment.</p>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Key Innovation
                        </div>
                        <ul class="info-list">
                            <li>Macrocyclic peptide (MW ~1 kDa)</li>
                            <li>Survives GI degradation through cyclization</li>
                            <li>>90% PCSK9 suppression (mAb-comparable)</li>
                            <li>Acts extracellularly in plasma</li>
                            <li>No CYP metabolism or drug interactions</li>
                            <li>Once-daily oral dosing</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Performance
                        </div>
                        <ul class="info-list">
                            <li>Phase 3 met primary endpoints (June 2025)</li>
                            <li>60-65% LDL-C reduction at optimal doses</li>
                            <li>>80% patients achieve <70 mg/dL LDL</li>
                            <li>ApoB/non-HDL-C: 45-55% reduction</li>
                            <li>Lp(a): 20-30% reduction</li>
                            <li>14,000-patient outcomes trial ongoing</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Advantages
                        </div>
                        <ul class="info-list">
                            <li>First-mover in oral PCSK9 space</li>
                            <li>Broad GP prescribing potential</li>
                            <li>Pharmacy benefit (not medical)</li>
                            <li>No injection site reactions</li>
                            <li>At-home convenience</li>
                            <li>Potentially lower cost than injectables</li>
                        </ul>
                    </div>
                </div>
                
                <div class="comparison-grid">
                    <div class="comparison-card">
                        <h4><span class="advantage-icon">‚úÖ</span> Advantages vs Injectables</h4>
                        <ul>
                            <li><span class="advantage-icon">‚úì</span> No needles or injection training</li>
                            <li><span class="advantage-icon">‚úì</span> At-home self-administration</li>
                            <li><span class="advantage-icon">‚úì</span> No injection site reactions</li>
                            <li><span class="advantage-icon">‚úì</span> Broader prescriber base</li>
                            <li><span class="advantage-icon">‚úì</span> Simpler distribution (pharmacy)</li>
                            <li><span class="advantage-icon">‚úì</span> Potentially lower cost</li>
                        </ul>
                    </div>
                    <div class="comparison-card">
                        <h4><span class="consideration-icon">‚ö†Ô∏è</span> Considerations</h4>
                        <ul>
                            <li><span class="consideration-icon">‚Ä¢</span> Daily dosing vs Q2W/Q6M injections</li>
                            <li><span class="consideration-icon">‚Ä¢</span> Adherence challenges (~50% real-world)</li>
                            <li><span class="consideration-icon">‚Ä¢</span> More frequent than inclisiran</li>
                            <li><span class="consideration-icon">‚Ä¢</span> Requires daily patient action</li>
                            <li><span class="consideration-icon">‚Ä¢</span> GI tolerability in some patients</li>
                            <li><span class="consideration-icon">‚Ä¢</span> No supervised administration</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                    </div>
                    <div class="mechanism-content">
                        Enlicitide decanoate is a <span class="mechanism-highlight">macrocyclic peptide</span> designed as an 
                        <span class="mechanism-highlight">oral PCSK9 inhibitor</span>. Key mechanistic features:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li><strong>Molecular design:</strong> Small cyclic peptide (~1 kDa) engineered for oral bioavailability</li>
                            <li><strong>GI stability:</strong> Survives digestive enzymes through cyclization and structural modifications</li>
                            <li><strong>Target binding:</strong> Binds with high affinity to circulating PCSK9 in plasma</li>
                            <li><strong>Mode of action:</strong> Prevents PCSK9 interaction with LDL receptors on hepatocytes</li>
                            <li><strong>Downstream effects:</strong> Inhibits PCSK9-mediated LDL-R degradation ‚Üí Increased LDL-R recycling ‚Üí Enhanced LDL clearance</li>
                            <li><strong>PCSK9 suppression:</strong> Achieves >90% reduction in free PCSK9 (comparable to mAbs)</li>
                            <li><strong>Extracellular action:</strong> Works in plasma without entering cells (no CYP interactions)</li>
                        </ul>
                        <br>
                        Unlike injectable mAbs (large proteins requiring SC administration) or inclisiran (siRNA silencing gene expression 
                        intracellularly), enlicitide provides <span class="mechanism-highlight">oral PCSK9 inhibition</span> with similar 
                        downstream effects on LDL-R upregulation.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíä</div>
                        Dosing Regimens & Efficacy
                    </div>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-dose">6 mg</div>
                            <div class="dosing-efficacy">41.2%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Moderate efficacy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-dose">12 mg</div>
                            <div class="dosing-efficacy">55.7%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Good efficacy</div>
                        </div>
                        <div class="dosing-card optimal">
                            <div class="dosing-dose">18 mg</div>
                            <div class="dosing-efficacy">59.7%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Near-maximal effect</div>
                        </div>
                        <div class="dosing-card optimal">
                            <div class="dosing-dose">30 mg</div>
                            <div class="dosing-efficacy">60.9%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Maximum efficacy</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Characteristics</div>
                    <div class="highlight-content">
                        Once-daily oral administration. Tablet formulation designed for GI stability. No dose adjustments 
                        specified for renal/hepatic impairment. Minimal food effect. Rapid onset with LDL-C reductions 
                        within 2 weeks, steady-state by weeks 4-8. Efficacy plateau observed at 18-30 mg doses, 
                        suggesting maximal PCSK9 inhibition achieved.
                    </div>
                </div>
                
                <div class="adherence-comparison">
                    <strong>‚ö†Ô∏è Adherence Consideration:</strong> Real-world adherence to daily medications typically ~50% at 1 year. 
                    Digital adherence tools and patient support programs planned. Compare to inclisiran's guaranteed compliance 
                    via supervised biannual injections. Success depends on managing adherence challenges through technology 
                    and patient engagement.
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="timeline-container">
                    <div class="timeline-header">FDA Development Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2021</div>
                                <div class="timeline-title">Preclinical Development</div>
                                <div class="timeline-description">Macrocyclic peptide optimization</div>
                                <div class="timeline-details">
                                    Extensive work on peptide cyclization, GI stability, and oral bioavailability. 
                                    Developed proprietary formulation to survive digestive enzymes.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">November 2021</div>
                                <div class="timeline-title">Phase 1 Results (AHA 2021)</div>
                                <div class="timeline-description">First human data presented</div>
                                <div class="timeline-details">
                                    Single/multiple ascending doses showed >90% PCSK9 reduction, LDL-C drops up to 65%. 
                                    Established proof-of-concept for oral PCSK9 inhibition.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 2022</div>
                                <div class="timeline-title">Phase 2a Completion</div>
                                <div class="timeline-description">Confirmed efficacy in hypercholesterolemia</div>
                                <div class="timeline-details">
                                    Add-on to statins showed ~65% LDL reduction. Safety profile comparable to placebo. 
                                    No GI tolerability issues observed.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 6, 2023</div>
                                <div class="timeline-title">Phase 2b Results (ACC 2023)</div>
                                <div class="timeline-description">Dose-response established</div>
                                <div class="timeline-details">
                                    NCT05261126: 381 patients, 41-61% LDL reduction dose-dependent. 
                                    FDA agreement on Phase 3 design obtained. No safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">August 25, 2023</div>
                                <div class="timeline-title">CORALreef Program Launch</div>
                                <div class="timeline-description">Phase 3 trials initiated</div>
                                <div class="timeline-details">
                                    Three pivotal trials started: Lipids (n=2,700), HeFH (n=300), and Outcomes (n=14,000). 
                                    Largest oral PCSK9 inhibitor program to date.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">June 9, 2025</div>
                                <div class="timeline-title">‚úÖ Positive Phase 3 Results</div>
                                <div class="timeline-description">Primary endpoints met</div>
                                <div class="timeline-details">
                                    CORALreef HeFH and AddOn trials successful. 60-65% LDL reduction confirmed. 
                                    Safety profile maintained. >80% achieved guideline goals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 2025</div>
                                <div class="timeline-title">Pediatric Trial Start</div>
                                <div class="timeline-description">Phase 2/3 in pediatric HeFH</div>
                                <div class="timeline-details">
                                    NCT07058077 initiated for pediatric indication. N=200 patients. 
                                    Expands potential patient population.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">Mid-2026 (Projected)</div>
                                <div class="timeline-title">NDA Filing</div>
                                <div class="timeline-description">FDA submission expected</div>
                                <div class="timeline-details">
                                    Based on LDL-C surrogate endpoint data. Priority review possible given 
                                    first-in-class oral status. 6-12 month review anticipated.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">2027 (Projected)</div>
                                <div class="timeline-title">FDA Approval</div>
                                <div class="timeline-description">First oral PCSK9i launch</div>
                                <div class="timeline-details">
                                    Potential approval for hypercholesterolemia and HeFH. Broad label expected 
                                    similar to existing PCSK9 inhibitors.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">2029 (Projected)</div>
                                <div class="timeline-title">Outcomes Data</div>
                                <div class="timeline-description">CORALreef Outcomes completion</div>
                                <div class="timeline-details">
                                    14,000-patient MACE trial results. Expected to show 15-20% CV risk reduction. 
                                    Will support label expansion and broader reimbursement.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Status</div>
                    <div class="highlight-content">
                        No clinical holds or CRLs throughout development. FDA agreement on trial designs secured. 
                        Global development aligned with FDA pathway (no separate EMA timeline announced). 
                        Leveraging established PCSK9 regulatory precedent for LDL-based approval. 
                        Manufacturing of complex peptide validated. First-in-class status may expedite review.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                            <th>Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Dose Escalation<br><small>2021</small></td>
                            <td><span class="trial-phase phase-1">Phase 1</span></td>
                            <td>~100</td>
                            <td>Healthy/HC</td>
                            <td>Safety/PK/PD</td>
                            <td>LDL-C ‚Üì65%<br>PCSK9 ‚Üì>90%</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>Add-on to Statins<br><small>2022</small></td>
                            <td><span class="trial-phase phase-2">Phase 2a</span></td>
                            <td>~60</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 14</td>
                            <td>~65% reduction</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>NCT05261126<br><small>2023</small></td>
                            <td><span class="trial-phase phase-2">Phase 2b</span></td>
                            <td>381</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 8</td>
                            <td>41-61% reduction<br>(dose-dependent)</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef Lipids<br><small>NCT05952856</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~2,700</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 24</td>
                            <td>Met primary endpoint<br>>80% achieved <70 mg/dL</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef HeFH<br><small>NCT05952869</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~300</td>
                            <td>HeFH</td>
                            <td>% LDL-C at week 24</td>
                            <td>60-65% reduction</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef Outcomes<br><small>NCT06008756</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~14,000</td>
                            <td>ASCVD/High-risk</td>
                            <td>MACE reduction</td>
                            <td>Pending (2029)</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                        <tr>
                            <td>Pediatric HeFH<br><small>NCT07058077</small></td>
                            <td><span class="trial-phase phase-2">Phase 2/3</span></td>
                            <td>~200</td>
                            <td>Pediatric HeFH</td>
                            <td>% LDL-C at week 24</td>
                            <td>Pending</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                        <tr>
                            <td>Open-Label Extension<br><small>NCT06492291</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~3,000</td>
                            <td>Previous participants</td>
                            <td>Long-term safety</td>
                            <td>Ongoing</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Phase 2b Dose-Response: LDL-C Reduction at Week 8</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 41.2%;">
                                <div class="bar-value">41.2%</div>
                            </div>
                            <div class="bar-label">6 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 55.7%;">
                                <div class="bar-value">55.7%</div>
                            </div>
                            <div class="bar-label">12 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 59.7%;">
                                <div class="bar-value">59.7%</div>
                            </div>
                            <div class="bar-label">18 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 60.9%;">
                                <div class="bar-value">60.9%</div>
                            </div>
                            <div class="bar-label">30 mg QD</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Secondary Endpoints & Achievement Rates</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar secondary" style="height: 50%;">
                                <div class="bar-value">45-55%</div>
                            </div>
                            <div class="bar-label">ApoB Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar secondary" style="height: 50%;">
                                <div class="bar-value">45-55%</div>
                            </div>
                            <div class="bar-label">Non-HDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar lpa" style="height: 25%;">
                                <div class="bar-value">20-30%</div>
                            </div>
                            <div class="bar-label">Lp(a)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 80%;">
                                <div class="bar-value">>80%</div>
                            </div>
                            <div class="bar-label">Achieved<br><70 mg/dL</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 90%;">
                                <div class="bar-value">>90%</div>
                            </div>
                            <div class="bar-label">PCSK9<br>Suppression</div>
                        </div>
                    </div>
                </div>
                
                <div class="dose-response-curve">
                    <h3 class="chart-title">Dose-Response Relationship</h3>
                    <svg viewBox="0 0 600 300" style="width: 100%; height: 300px;">
                        <defs>
                            <linearGradient id="curveGradient" x1="0%" y1="0%" x2="100%" y2="0%">
                                <stop offset="0%" style="stop-color:#00539C;stop-opacity:1" />
                                <stop offset="100%" style="stop-color:#4caf50;stop-opacity:1" />
                            </linearGradient>
                        </defs>
                        
                        <!-- Grid lines -->
                        <line x1="50" y1="250" x2="550" y2="250" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="200" x2="550" y2="200" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="150" x2="550" y2="150" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="100" x2="550" y2="100" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="50" x2="550" y2="50" stroke="#e0e0e0" stroke-width="1"/>
                        
                        <!-- Axes -->
                        <line x1="50" y1="250" x2="550" y2="250" stroke="#333" stroke-width="2"/>
                        <line x1="50" y1="250" x2="50" y2="30" stroke="#333" stroke-width="2"/>
                        
                        <!-- Dose-response curve -->
                        <path d="M 100 180 Q 200 120, 300 80 T 500 70" stroke="url(#curveGradient)" stroke-width="3" fill="none"/>
                        
                        <!-- Data points -->
                        <circle cx="100" cy="180" r="5" fill="#00539C"/>
                        <circle cx="200" cy="120" r="5" fill="#00539C"/>
                        <circle cx="300" cy="80" r="5" fill="#4caf50"/>
                        <circle cx="400" cy="75" r="5" fill="#4caf50"/>
                        <circle cx="500" cy="70" r="5" fill="#4caf50"/>
                        
                        <!-- Labels -->
                        <text x="100" y="270" text-anchor="middle" font-size="12">6mg</text>
                        <text x="200" y="270" text-anchor="middle" font-size="12">12mg</text>
                        <text x="300" y="270" text-anchor="middle" font-size="12">18mg</text>
                        <text x="400" y="270" text-anchor="middle" font-size="12">24mg</text>
                        <text x="500" y="270" text-anchor="middle" font-size="12">30mg</text>
                        
                        <text x="30" y="255" text-anchor="middle" font-size="12">0%</text>
                        <text x="30" y="205" text-anchor="middle" font-size="12">20%</text>
                        <text x="30" y="155" text-anchor="middle" font-size="12">40%</text>
                        <text x="30" y="105" text-anchor="middle" font-size="12">60%</text>
                        <text x="30" y="55" text-anchor="middle" font-size="12">80%</text>
                        
                        <!-- Plateau annotation -->
                        <rect x="280" y="45" width="240" height="40" fill="rgba(76, 175, 80, 0.1)" rx="5"/>
                        <text x="400" y="65" text-anchor="middle" font-size="13" fill="#2e7d32" font-weight="600">Efficacy Plateau</text>
                        <text x="400" y="80" text-anchor="middle" font-size="11" fill="#666">18-30mg optimal range</text>
                    </svg>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="highlight-box">
                    <div class="highlight-title">Safety Overview</div>
                    <div class="highlight-content">
                        ~4,000 patients exposed by 2025 with placebo-like safety profile. No black-box warnings anticipated. 
                        Acts extracellularly without CYP metabolism, minimizing drug interactions and organ toxicity. 
                        No injection site reactions (oral administration advantage).
                    </div>
                </div>
                
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-percentage">6-8%</div>
                        <div class="safety-label">Headache</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">5-7%</div>
                        <div class="safety-label">Nasopharyngitis</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">4-6%</div>
                        <div class="safety-label">GI symptoms<br>(mild)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><2%</div>
                        <div class="safety-label">Serious AEs</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">1-2%</div>
                        <div class="safety-label">Discontinuation</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><1%</div>
                        <div class="safety-label">Anti-drug<br>antibodies</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><3%</div>
                        <div class="safety-label">Myalgia</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">0%</div>
                        <div class="safety-label">Injection site<br>reactions</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            No Safety Signals
                        </div>
                        <ul class="info-list">
                            <li>No liver enzyme elevations</li>
                            <li>No CK elevations</li>
                            <li>No glucose/diabetes signal</li>
                            <li>No blood pressure effects</li>
                            <li>No dose-related GI issues</li>
                            <li>No immunogenicity concerns</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üß†</div>
                            Neurocognitive Safety
                        </div>
                        <ul class="info-list">
                            <li>No signals in trials</li>
                            <li>~30% achieved LDL <25 mg/dL safely</li>
                            <li>Confusion/amnesia <1%</li>
                            <li>Consistent with PCSK9 class data</li>
                            <li>No harm even at LDL <15 mg/dL</li>
                            <li>Oral route unlikely to differ</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üíä</div>
                            Unique Safety Advantages
                        </div>
                        <ul class="info-list">
                            <li>No injection site reactions (oral)</li>
                            <li>GI tolerability generally good</li>
                            <li>No CYP metabolism interactions</li>
                            <li>Acts extracellularly only</li>
                            <li>Low immunogenicity (<1%)</li>
                            <li>Peptide-specific design</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="price-projection">
                        <div class="price-range">$4,000 - $6,000</div>
                        <div class="price-comparison">Projected annual cost (vs $5,800 for injectable mAbs)</div>
                    </div>
                    
                    <div class="market-metrics">
                        <div class="metric-card">
                            <div class="metric-value">$2-8B</div>
                            <div class="metric-label">Market potential by 2032</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">~50%</div>
                            <div class="metric-label">Expected real-world adherence</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">80%</div>
                            <div class="metric-label">Initial PA denial rate</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">10x</div>
                            <div class="metric-label">Broader prescriber base</div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Reimbursement Strategy
                        </div>
                        <ul class="info-list">
                            <li>Initial restriction to high-risk/statin-intolerant</li>
                            <li>Similar PA requirements to mAbs initially</li>
                            <li>Pharmacy benefit simplifies vs medical</li>
                            <li>Outcomes data (2029) key for expansion</li>
                            <li>Volume-based pricing possible</li>
                            <li>Digital adherence programs planned</li>
                        </ul>
                    </div>
                    
                   <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Market Access Advantages
                        </div>
                        <ul class="info-list">
                            <li>Broad GP prescribing (not specialist-only)</li>
                            <li>No injection training required</li>
                            <li>At-home self-administration</li>
                            <li>Simpler distribution via pharmacies</li>
                            <li>Potential for mail-order delivery</li>
                            <li>Lower infrastructure requirements</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Competitive Positioning
                        </div>
                        <ul class="info-list">
                            <li>First-mover advantage in oral PCSK9</li>
                            <li>Most significant threat to inclisiran</li>
                            <li>AstraZeneca's AZD0780 following</li>
                            <li>Merck's CV marketing expertise</li>
                            <li>Potential for fixed-dose combos</li>
                            <li>Volume play vs premium pricing</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Strategy</div>
                    <div class="highlight-content">
                        MK-0616 could transform PCSK9 inhibition from specialist injectable to primary care oral therapy. 
                        Success depends on competitive pricing, managing adherence challenges, and demonstrating CV outcomes by 2029. 
                        Merck's history with blockbuster CV drugs (Zetia, Vytorin) and large Phase 3 program indicate 
                        commitment to broad market penetration. Pharmacy benefit distribution avoids buy-and-bill complexities 
                        that challenged inclisiran's US launch.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Preclinical</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 20%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 1</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 40%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 2</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 60%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 3</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 75%;">
                        <div class="milestone-dot" style="background: #00539C;"></div>
                        <div class="milestone-label"><strong>Current</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 85%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Filing<br>(2026)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Launch<br>(2027)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Near-Term Development
                        </div>
                        <ul class="info-list">
                            <li>NDA filing expected mid-2026</li>
                            <li>Potential approval 2027</li>
                            <li>First oral PCSK9i to market</li>
                            <li>Pediatric indication development</li>
                            <li>Open-label extension ongoing</li>
                            <li>CORALreef Outcomes through 2029</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üöÄ</div>
                            Pipeline Expansion
                        </div>
                        <ul class="info-list">
                            <li>Fixed-dose combos (+ ezetimibe/statin)</li>
                            <li>Primary prevention studies possible</li>
                            <li>All-in-one lipid pill potential</li>
                            <li>Patent protection to late 2030s</li>
                            <li>Manufacturing scalability advantage</li>
                            <li>Global expansion post-FDA</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Landscape
                        </div>
                        <ul class="info-list">
                            <li>AstraZeneca's AZD0780 ~1-2 years behind</li>
                            <li>Multiple oral PCSK9i by 2030</li>
                            <li>Gene therapies distant threat (2030s)</li>
                            <li>Biosimilar mAbs coming ~2028</li>
                            <li>Inclisiran's biannual advantage</li>
                            <li>Price competition expected</li>
                        </ul>
                    </div>
                </div>
                
                <div class="game-changer-banner" style="background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);">
                    <h3>üèÜ Market Transformation Potential</h3>
                    <p>MK-0616 heralds a convenience battle: pills versus injections. Historically in medicine, pills win due to 
                    patient and provider preference when efficacy and safety are equivalent. If MK-0616 maintains its stellar 
                    trial results, it could become the dominant PCSK9 inhibitor by 2030, relegating injectables to specific 
                    niches (adherence-challenged patients). The ability to prescribe through primary care could expand the 
                    PCSK9 market 5-10x beyond current specialist-driven injectable use.</p>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-Term Outlook</div>
                    <div class="highlight-content">
                        By 2030, oral PCSK9 inhibitors likely to dominate market if adherence challenges are managed. 
                        MK-0616's first-mover advantage critical for establishing market share before competition. 
                        Merck's development of fixed-dose combinations could create an "all-in-one" lipid management pill. 
                        Success of CORALreef Outcomes trial (2029) will determine whether oral PCSK9i can match 
                        injectable outcomes and secure broad reimbursement. Patent life to late 2030s provides 
                        sustainable revenue window before generic competition.
                    </div>
                </div>
                
                <div class="adherence-comparison">
                    <strong>Critical Success Factor:</strong> Managing the adherence paradox - while daily pills are more 
                    convenient than injections, real-world adherence to daily medications is typically only ~50% at 1 year. 
                    Merck's investment in digital adherence tools, patient support programs, and potentially smart packaging 
                    will be essential to realize the full potential of oral PCSK9 inhibition. The convenience of at-home 
                    administration must translate to sustained daily compliance to match the guaranteed effect of supervised 
                    biannual inclisiran injections.
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
        
        // Animate bars on scroll
        const observerOptions = {
            threshold: 0.5
        };
        
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growUp 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.bar-chart').forEach(el => {
            observer.observe(el);
        });
        
        // Animate progress bar
        const progressObserver = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const progress = entry.target.querySelector('.pipeline-progress');
                    if (progress) {
                        progress.style.animation = 'progressGrow 2s ease-out';
                    }
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.pipeline-timeline').forEach(el => {
            progressObserver.observe(el);
        });
    </script>
    
    <style>
        /* Ensure all styles from the original are included */
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.08);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            font-size: 16px;
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
            animation: pulse 2s infinite;
        }
        
        @keyframes pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }
        
        .first-in-class {
            display: inline-block;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            padding: 8px 16px;
            border-radius: 20px;
            margin-left: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 83, 156, 0.1);
        }
        
        .nav-tab.active {
            color: #00539C;
            border-bottom: 3px solid #00539C;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .game-changer-banner {
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            color: white;
            padding: 25px;
            border-radius: 15px;
            margin-bottom: 30px;
            box-shadow: 0 5px 20px rgba(76, 175, 80, 0.3);
        }
        
        .game-changer-banner h3 {
            font-size: 24px;
            margin-bottom: 10px;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 83, 156, 0.1) 0%, rgba(0, 58, 112, 0.1) 100%);
            border-left: 4px solid #00539C;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00539C 0%, #003A70 100%);
            border-radius: 4px;
            width: 75%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00539C;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .adherence-comparison {
            background: #fff3cd;
            border-left: 4px solid #ff9800;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-projection {
            text-align: center;
            margin: 30px 0;
        }
        
        .price-range {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .price-comparison {
            font-size: 16px;
            color: #666;
            margin-top: 10px;
        }
        
        .market-metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .metric-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            text-align: center;
            border-top: 4px solid #00539C;
        }
        
        .metric-value {
            font-size: 28px;
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .metric-label {
            font-size: 14px;
            color: #666;
        }
    </style>
</body>
</html>

<!-- Pralent -->

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Praluent¬Æ (alirocumab) - Comprehensive Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 50%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(35deg);
        }

        .drug-title {
            position: relative;
            z-index: 1;
        }

        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
        }

        .drug-subtitle {
            font-size: 24px;
            opacity: 0.9;
            margin-bottom: 5px;
        }

        .drug-company {
            font-size: 18px;
            opacity: 0.8;
        }

        .badge-first {
            display: inline-block;
            background: rgba(255,255,255,0.3);
            padding: 5px 15px;
            border-radius: 20px;
            margin-top: 10px;
            font-size: 14px;
            font-weight: 600;
        }

        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e9ecef;
            padding: 0;
            overflow-x: auto;
        }

        .nav-tab {
            padding: 20px 30px;
            cursor: pointer;
            border: none;
            background: none;
            font-size: 16px;
            font-weight: 500;
            color: #6c757d;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }

        .nav-tab:hover {
            color: #f5576c;
            background: rgba(245, 87, 108, 0.05);
        }

        .nav-tab.active {
            color: #f5576c;
            background: white;
        }

        .nav-tab.active::after {
            content: '';
            position: absolute;
            bottom: -2px;
            left: 0;
            right: 0;
            height: 3px;
            background: linear-gradient(90deg, #f093fb 0%, #f5576c 100%);
        }

        .content {
            padding: 40px;
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .section {
            margin-bottom: 40px;
        }

        .section-title {
            font-size: 28px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 3px solid #f5576c;
        }

        .mechanism-card {
            background: linear-gradient(135deg, #ffeaa7 0%, #fdcb6e 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }

        .mechanism-title {
            font-size: 22px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 15px;
        }

        .mechanism-content {
            color: #5a6c7d;
            line-height: 1.8;
            font-size: 16px;
        }

        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .dosing-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.2);
            border-color: #f5576c;
        }

        .dosing-label {
            font-size: 14px;
            color: #6c757d;
            margin-bottom: 10px;
        }

        .dosing-value {
            font-size: 28px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .dosing-detail {
            font-size: 14px;
            color: #5a6c7d;
        }

        .dosing-special {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
        }

        .dosing-special .dosing-label,
        .dosing-special .dosing-detail {
            color: rgba(255,255,255,0.9);
        }

        .dosing-special .dosing-value {
            color: white;
        }

        .timeline-container {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }

        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #f093fb 0%, #f5576c 100%);
            transform: translateX(-50%);
        }

        .timeline-item {
            position: relative;
            margin: 30px 0;
            display: flex;
            align-items: center;
        }

        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }

        .timeline-content {
            width: 45%;
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
            cursor: pointer;
        }

        .timeline-content:hover {
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.3);
            border-color: #f5576c;
        }

        .timeline-date {
            font-size: 18px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 8px;
        }

        .timeline-description {
            font-size: 14px;
            color: #6c757d;
            line-height: 1.6;
        }

        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: white;
            border: 4px solid #f5576c;
            border-radius: 50%;
            z-index: 2;
        }

        .timeline-highlight {
            background: #fff3cd !important;
            border-color: #ffc107 !important;
        }

        .timeline-highlight .timeline-date {
            color: #d39e00;
        }

        .trials-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin-top: 20px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            border-radius: 12px;
            overflow: hidden;
        }

        .trials-table thead {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
        }

        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .trials-table tbody tr {
            border-bottom: 1px solid #e9ecef;
            transition: all 0.3s;
        }

        .trials-table tbody tr:hover {
            background: rgba(245, 87, 108, 0.05);
            transform: translateX(5px);
        }

        .trials-table td {
            padding: 15px;
            font-size: 14px;
            color: #5a6c7d;
        }

        .trial-name {
            font-weight: 600;
            color: #2c3e50;
        }

        .trial-phase {
            display: inline-block;
            padding: 4px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            background: #e9ecef;
            color: #6c757d;
        }

        .trial-phase.phase3 {
            background: #d4edda;
            color: #155724;
        }

        .landmark-trial {
            background: rgba(245, 87, 108, 0.05) !important;
        }

        .landmark-trial .trial-name {
            color: #f5576c;
            font-weight: bold;
        }

        .efficacy-bar-chart {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 300px;
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            margin: 0 10px;
        }

        .bar {
            width: 60px;
            background: linear-gradient(180deg, #f093fb 0%, #f5576c 100%);
            border-radius: 8px 8px 0 0;
            transition: all 0.3s;
            position: relative;
            margin-bottom: 10px;
        }

        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(245, 87, 108, 0.4);
        }

        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            color: #f5576c;
            font-size: 18px;
        }

        .bar-label {
            text-align: center;
            font-size: 12px;
            color: #6c757d;
            margin-top: 10px;
            max-width: 100px;
        }

        .mortality-highlight {
            background: linear-gradient(135deg, #74b9ff 0%, #0984e3 100%) !important;
        }

        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .safety-card {
            background: white;
            border: 1px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }

        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }

        .safety-title {
            font-size: 18px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }

        .safety-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            border-radius: 50%;
            margin-right: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
        }

        .safety-content {
            color: #6c757d;
            line-height: 1.8;
        }

        .safety-list {
            list-style: none;
            margin-top: 10px;
        }

        .safety-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f1f3f5;
            display: flex;
            justify-content: space-between;
        }

        .safety-list li:last-child {
            border-bottom: none;
        }

        .percentage {
            font-weight: 600;
            color: #f5576c;
        }

        .market-timeline {
            position: relative;
            padding: 30px 0;
        }

        .market-event {
            background: white;
            border-left: 4px solid #f5576c;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 12px 12px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
        }

        .market-event:hover {
            transform: translateX(10px);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.2);
        }

        .market-year {
            font-size: 20px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .market-description {
            color: #5a6c7d;
            line-height: 1.6;
        }

        .price-tag {
            display: inline-block;
            background: #ffeaa7;
            color: #2d3436;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .value-tag {
            display: inline-block;
            background: #74b9ff;
            color: white;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .competition-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .competitor-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .competitor-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
            border-color: #f5576c;
        }

        .competitor-name {
            font-size: 18px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .competitor-detail {
            font-size: 14px;
            color: #6c757d;
            margin: 5px 0;
        }

        .comparison-table {
            width: 100%;
            margin-top: 20px;
            border-collapse: separate;
            border-spacing: 0;
            border-radius: 12px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }

        .comparison-table thead {
            background: linear-gradient(135deg, #74b9ff 0%, #0984e3 100%);
            color: white;
        }

        .comparison-table th,
        .comparison-table td {
            padding: 15px;
            text-align: left;
        }

        .comparison-table tbody tr {
            border-bottom: 1px solid #e9ecef;
        }

        .comparison-table tbody tr:hover {
            background: rgba(116, 185, 255, 0.05);
        }

        .feature-name {
            font-weight: 600;
            color: #2c3e50;
        }

        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 10px auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">Praluent¬Æ (alirocumab)</div>
                <div class="drug-subtitle">PCSK9 Monoclonal Antibody</div>
                <div class="drug-company">Sanofi/Regeneron ‚Ä¢ FDA/EMA Approved 2015</div>
                <div class="badge-first">FIRST PCSK9 INHIBITOR APPROVED IN US</div>
            </div>
        </div>

        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('market')">Market & Commercial</button>
            <button class="nav-tab" onclick="showTab('comparison')">vs. Repatha</button>
        </div>

        <div class="content">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="section">
                    <h2 class="section-title">Mechanism of Action</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">PCSK9 Inhibition via Monoclonal Antibody</div>
                        <div class="mechanism-content">
                            Praluent is a fully human monoclonal antibody with high affinity binding to circulating PCSK9, preventing its interaction with LDL receptors on hepatocytes. This mechanism leads to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li style="margin: 8px 0;">Prevention of PCSK9-mediated LDL-R degradation</li>
                                <li style="margin: 8px 0;">Increased LDL-R density on liver cell surface</li>
                                <li style="margin: 8px 0;">Enhanced uptake and catabolism of LDL-C</li>
                                <li style="margin: 8px 0;">Substantial serum LDL-C reductions (50-60%)</li>
                                <li style="margin: 8px 0;">Rapid onset within days, peak effect by 4-8 weeks</li>
                            </ul>
                            <div style="margin-top: 20px; padding: 15px; background: rgba(245, 87, 108, 0.1); border-radius: 8px;">
                                <strong>Key Differentiators:</strong> Acts extracellularly in plasma with rapid onset compared to inclisiran's delayed gene-silencing mechanism. Equivalent to evolocumab in PCSK9 inhibition potency but offers lower starting dose for titration flexibility.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Dosing & Administration</h2>
                    <div class="dosing-grid">
                        <div class="dosing-card dosing-special">
                            <div class="dosing-label">Unique Starting Dose</div>
                            <div class="dosing-value">75 mg</div>
                            <div class="dosing-detail">Every 2 weeks (Q2W)<br>Lower than competitors</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Titrated Dose</div>
                            <div class="dosing-value">150 mg</div>
                            <div class="dosing-detail">Q2W if LDL-C target not met<br>(e.g., <70 mg/dL)</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Alternative Regimen</div>
                            <div class="dosing-value">300 mg</div>
                            <div class="dosing-detail">Every 4 weeks (Q4W)<br>Two 150 mg injections</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value">12-26</div>
                            <div class="dosing-detail">More than inclisiran (2-3)<br>Less than daily orals</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HoFH Dosing</div>
                            <div class="dosing-value">150 mg</div>
                            <div class="dosing-detail">Q2W maximum<br>Lower efficacy due to LDL-R dependency</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Pediatric (8+)</div>
                            <div class="dosing-value">Weight-based</div>
                            <div class="dosing-detail">HeFH/HoFH patients<br>FDA approved 2024</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Patient Populations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Approved Indications</div>
                        <div class="mechanism-content">
                            <strong>Adults:</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>Heterozygous Familial Hypercholesterolemia (HeFH)</li>
                                <li>Homozygous Familial Hypercholesterolemia (HoFH) - added 2021</li>
                                <li>Clinical ASCVD requiring additional LDL-C lowering</li>
                                <li>CV risk reduction (MI, stroke, unstable angina) - added 2019</li>
                                <li>Statin-intolerant patients (EMA broader indication)</li>
                            </ul>
                            <strong>Pediatric (Age 8+):</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>HeFH or HoFH patients (FDA 2024, EMA 2023)</li>
                                <li>Weight-based dosing considerations</li>
                            </ul>
                            <div style="margin-top: 15px; padding: 10px; background: #d4edda; border-radius: 5px;">
                                <strong>Advantage:</strong> Lower starting dose (75 mg) allows for better tolerability and titration flexibility compared to fixed-dose competitors
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="section">
                    <h2 class="section-title">FDA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content timeline-highlight">
                                <div class="timeline-date">July 24, 2015</div>
                                <div class="timeline-title">Initial FDA Approval - FIRST PCSK9i</div>
                                <div class="timeline-description">
                                    First PCSK9 inhibitor approved in US. For HeFH and clinical ASCVD as adjunct to diet/statins.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">April 26, 2019</div>
                                <div class="timeline-title">CV Outcomes Indication</div>
                                <div class="timeline-description">
                                    Label expansion for MI, stroke, and unstable angina reduction based on ODYSSEY OUTCOMES trial showing mortality benefit.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">April 1, 2021</div>
                                <div class="timeline-title">HoFH Indication</div>
                                <div class="timeline-description">
                                    Expanded to adults with homozygous familial hypercholesterolemia as adjunct to other therapies.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 11, 2024</div>
                                <div class="timeline-title">Pediatric Expansion</div>
                                <div class="timeline-description">
                                    Age limit lowered to 8+ years for HeFH patients, younger than competitor approvals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2025</div>
                                <div class="timeline-title">Latest Updates</div>
                                <div class="timeline-description">
                                    Updated pregnancy/lactation data from registries. No fetal harm signals but discontinuation advised. No new restrictions.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>

                    <h2 class="section-title">EMA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">September 23, 2015</div>
                                <div class="timeline-title">EMA Marketing Authorization</div>
                                <div class="timeline-description">
                                    Broader initial indication than FDA, including statin-intolerant patients. For primary hypercholesterolemia and mixed dyslipidemia.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 15, 2019</div>
                                <div class="timeline-title">CV Risk Reduction</div>
                                <div class="timeline-description">
                                    Expanded for CV risk reduction in adults with established atherosclerotic CVD.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2021</div>
                                <div class="timeline-title">HoFH Addition</div>
                                <div class="timeline-description">
                                    Added indication for homozygous familial hypercholesterolemia in adults.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023-2024</div>
                                <div class="timeline-title">Pediatric Extension</div>
                                <div class="timeline-description">
                                    Extended to ages 8+ for HeFH/HoFH. Continuous PBRERs show no new safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">October 2023</div>
                                <div class="timeline-title">Latest Revision</div>
                                <div class="timeline-description">
                                    2025 confirmations via variation reports. No withdrawals, though pricing negotiations ongoing in France.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <div class="section">
                    <h2 class="section-title">ODYSSEY Clinical Development Program</h2>
                    
                    <table class="trials-table">
                        <thead>
                            <tr>
                                <th>Trial Name</th>
                                <th>Phase</th>
                                <th>N</th>
                                <th>Year</th>
                                <th>Primary Endpoint</th>
                                <th>Key Results</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="trial-name">DF490336</td>
                                <td><span class="trial-phase">Phase 1</span></td>
                                <td>183</td>
                                <td>2013</td>
                                <td>PK/PD</td>
                                <td>LDL-C reductions up to 72%</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY MONO</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>103</td>
                                <td>2014</td>
                                <td>% LDL-C change at week 24</td>
                                <td>47% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY COMBO I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,036</td>
                                <td>2014</td>
                                <td>% LDL-C change at week 24</td>
                                <td>48-50% reduction with statins</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY FH I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>735</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 24 (HeFH)</td>
                                <td>~58% reduction in HeFH</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY OPTIONS I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>650</td>
                                <td>2015</td>
                                <td>% LDL-C change vs alternatives</td>
                                <td>Superior to doubling statin/adding ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY ALTERNATIVE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>314</td>
                                <td>2015</td>
                                <td>% LDL-C (statin-intolerant)</td>
                                <td>45% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY LONG TERM</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>2,341</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 24</td>
                                <td>61% reduction; exploratory MACE HR 0.52</td>
                            </tr>
                            <tr class="landmark-trial">
                                <td class="trial-name"><strong>ODYSSEY OUTCOMES</strong></td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td><strong>18,924</strong></td>
                                <td><strong>2018</strong></td>
                                <td><strong>MACE (CV death, MI, stroke, UA)</strong></td>
                                <td><strong>HR 0.85 (15% RRR); Mortality HR 0.85 (p=0.026)</strong></td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY CHOICE I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,158</td>
                                <td>2016</td>
                                <td>% LDL-C change (Q4W dosing)</td>
                                <td>52-59% reduction, Q4W confirmed</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY EAST</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>615</td>
                                <td>2019</td>
                                <td>% LDL-C change (Asian)</td>
                                <td>56% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY HoFH</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>69</td>
                                <td>2020</td>
                                <td>% LDL-C change (HoFH)</td>
                                <td>36% reduction</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY OUTCOMES OLE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>8,242</td>
                                <td>2023</td>
                                <td>Long-term MACE (up to 6 years)</td>
                                <td>Sustained MACE reduction, low AEs</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY KIDS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>42</td>
                                <td>2024</td>
                                <td>% LDL-C change (pediatric)</td>
                                <td>35-46% reduction</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Efficacy Outcomes</h2>
                    <div class="efficacy-bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 55%;">
                                <span class="bar-value">55%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(ODYSSEY OUTCOMES)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 61%; background: linear-gradient(180deg, #48dbfb 0%, #0984e3 100%);">
                                <span class="bar-value">61%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(LONG TERM)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 53%; background: linear-gradient(180deg, #fdcb6e 0%, #e17055 100%);">
                                <span class="bar-value">53 mg/dL</span>
                            </div>
                            <div class="bar-label">Median LDL<br>Achieved</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar mortality-highlight" style="height: 15%;">
                                <span class="bar-value" style="color: #0984e3;">15%</span>
                            </div>
                            <div class="bar-label">All-Cause Mortality<br>Reduction (p=0.026)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 15%; background: linear-gradient(180deg, #a29bfe 0%, #6c5ce7 100%);">
                                <span class="bar-value">15%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(Overall)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 24%; background: linear-gradient(180deg, #55efc4 0%, #00b894 100%);">
                                <span class="bar-value">24%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(LDL ‚â•100 mg/dL)</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">ODYSSEY OUTCOMES - Detailed Analysis</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Primary & Secondary Endpoints</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 20px;">
                                <div>
                                    <strong>Primary Composite MACE:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, nonfatal MI/stroke, UA hospitalization</li>
                                        <li><strong>HR 0.85 (95% CI: 0.78-0.93)</strong></li>
                                        <li><strong>15% relative risk reduction, p<0.001</strong></li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>All-Cause Mortality (Key Finding):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li><strong>HR 0.85 (95% CI: 0.73-0.98)</strong></li>
                                        <li><strong>15% reduction (3.5% vs 4.1%)</strong></li>
                                        <li><strong>Nominal p=0.026</strong></li>
                                    </ul>
                                </div>
                            </div>
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>Unique Finding:</strong> ODYSSEY OUTCOMES showed nominal mortality benefit not seen with evolocumab (FOURIER). Greatest benefit in patients with baseline LDL ‚â•100 mg/dL: MACE 24% RRR, death 29% RRR. Median follow-up 2.8 years.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Safety Profile Overview</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Cumulative Exposure:</strong> ~1.5-2 million patient-years by 2025<br>
                            <strong>Black Box Warnings:</strong> None<br>
                            <strong>Major Safety Signals:</strong> None identified<br>
                            <strong>Discontinuation Rate:</strong> ~2% due to adverse events<br>
                            <strong>Immunogenicity:</strong> Anti-drug antibodies ~5%, neutralizing <1%
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Common Adverse Events</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">1</div>
                                Most Common AEs
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Nasopharyngitis <span class="percentage">11.3%</span></li>
                                    <li>Injection site reactions <span class="percentage">7.2%</span></li>
                                    <li>Upper respiratory infection <span class="percentage">5.7%</span></li>
                                    <li>Influenza <span class="percentage">5.7%</span></li>
                                    <li>Myalgia <span class="percentage">5.4%</span></li>
                                    <li>UTI <span class="percentage">4.8%</span></li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">2</div>
                                Injection Site Reactions
                            </div>
                            <div class="safety-content">
                                Overall incidence: 7.2% (vs 5.1% placebo)
                                <ul class="safety-list">
                                    <li>Pruritus <span class="percentage">Most common</span></li>
                                    <li>Erythema <span class="percentage">Common</span></li>
                                    <li>Pain <span class="percentage">Less common</span></li>
                                </ul>
                                Higher than Repatha (5.7%) but generally mild
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">3</div>
                                Serious Adverse Events
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Overall SAEs <span class="percentage">4.8%</span></li>
                                    <li>Similar to placebo <span class="percentage">Yes</span></li>
                                    <li>Immunogenicity <span class="percentage">5% ADA</span></li>
                                    <li>Neutralizing antibodies <span class="percentage"><1%</span></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Neurocognitive & Metabolic Safety</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Long-Term Safety Data</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Neurocognitive Effects:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Neurocognitive AEs: 1.2% vs 0.7% placebo</li>
                                        <li>No association with LDL <25 mg/dL</li>
                                        <li>2025 meta-analyses confirm no link</li>
                                        <li>Rare reports non-causal</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Metabolic Effects:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>New-onset diabetes: HR 1.18 (slight increase)</li>
                                        <li>Similar to statin effect</li>
                                        <li>Ophthalmologic AEs: 1.3% (same as placebo)</li>
                                        <li>No cataract increase</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #fff3cd; border-radius: 8px;">
                                <strong>Real-World Evidence:</strong> 2025 data from Japan shows low AE rates consistent with trials. Benign profile in T1D patients. Similar to inclisiran but with more extensive long-term data.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Special Populations</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">P</div>
                                Pregnancy & Lactation
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ No fetal harm signals in registries</li>
                                    <li>‚Ä¢ Discontinuation advised during pregnancy</li>
                                    <li>‚Ä¢ Limited lactation data</li>
                                    <li>‚Ä¢ 2025 label update with registry data</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">S</div>
                                Statin-Intolerant
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ ODYSSEY ALTERNATIVE trial</li>
                                    <li>‚Ä¢ 45% LDL-C reduction</li>
                                    <li>‚Ä¢ Well-tolerated profile</li>
                                    <li>‚Ä¢ EMA broader indication</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">K</div>
                                Pediatric (8+)
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ ODYSSEY KIDS trial</li>
                                    <li>‚Ä¢ 35-46% LDL-C reduction</li>
                                    <li>‚Ä¢ Similar safety to adults</li>
                                    <li>‚Ä¢ Youngest approval age (8+)</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div id="market" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Pricing & Access Evolution</h2>
                    <div class="market-timeline">
                        <div class="market-event">
                            <div class="market-year">2015</div>
                            <div class="market-description">
                                <span class="price-tag">US: $14,000-14,600/year</span>
                                <span class="price-tag">EU: ~‚Ç¨5,000/year</span><br>
                                Launch as first PCSK9 inhibitor with high pricing leading to immediate payer pushback
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2018-2019</div>
                            <div class="market-description">
                                <span class="price-tag">60% price cut to $5,850/year</span><br>
                                Post-ODYSSEY OUTCOMES price reduction. Net ~$4,000 with rebates<br>
                                <span class="value-tag">Value-based contracts piloted</span>
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2019</div>
                            <div class="market-description">
                                Partnership restructure: Regeneron takes US rights, Sanofi maintains ex-US<br>
                                <span class="value-tag">Copay cards: $50/month for eligible</span>
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2025</div>
                            <div class="market-description">
                                <span class="price-tag">Annual sales: ~$400-500M</span><br>
                                Sales plateaued below Repatha. Competition from inclisiran and oral PCSK9i
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2027-2028</div>
                            <div class="market-description">
                                Patent expiry approaching. Biosimilars expected (Samsung Bioepis in pipeline)<br>
                                Projected 40-60% price reduction with biosimilar entry
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Access Innovations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Value-Based Contracting</div>
                        <div class="mechanism-content">
                            <strong>Unique Market Approach:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>First PCSK9i with value-based contracts (2018)</li>
                                <li>Refunds for CV events while on therapy</li>
                                <li>Copay assistance programs ($50/month)</li>
                                <li>OOP costs dropped 50% post-price cut</li>
                                <li>Medicare beneficiaries: $25-150/month</li>
                            </ul>
                            
                            <strong>Access Barriers (Similar to Repatha):</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>70-80% initial prior authorization denials</li>
                                <li>Requirements: statin intolerance/failure, high LDL (>100-130 mg/dL)</li>
                                <li>CV risk documentation needed</li>
                                <li>Uptake <5-10% of eligible patients</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Competitive Landscape</h2>
                    <div class="competition-grid">
                        <div class="competitor-card">
                            <div class="competitor-name">Repatha (evolocumab)</div>
                            <div class="competitor-detail">PCSK9 mAb - Amgen</div>
                            <div class="competitor-detail">Higher sales, similar efficacy</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Leqvio (inclisiran)</div>
                            <div class="competitor-detail">siRNA - Novartis</div>
                            <div class="competitor-detail">Twice-yearly dosing</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Oral PCSK9i</div>
                            <div class="competitor-detail">Multiple in development</div>
                            <div class="competitor-detail">Daily oral convenience</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Biosimilars</div>
                            <div class="competitor-detail">Samsung Bioepis et al.</div>
                            <div class="competitor-detail">Expected 2028+</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Future Outlook</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Market Evolution & Pipeline</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Near-Term (2025-2028):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Patent expiry US/EU ~2027-2028</li>
                                        <li>Limited lifecycle management</li>
                                        <li>Higher HoFH doses explored</li>
                                        <li>No new formulations planned</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Long-Term (2028-2035):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Biosimilars cut prices 40-60%</li>
                                        <li>Orals may dominate first-line</li>
                                        <li>Injections for non-adherent/acute</li>
                                        <li>Global biosimilar market $70B+</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: rgba(245, 87, 108, 0.1); border-radius: 8px;">
                                <strong>Legacy Position:</strong> Praluent pioneered PCSK9 inhibition as first FDA-approved agent. Mortality signal in ODYSSEY OUTCOMES remains unique differentiator. Focus shifting to Lp(a) inhibitors and next-generation lipid therapies.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Comparison Tab -->
            <div id="comparison" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Praluent vs. Repatha Head-to-Head Comparison</h2>
                    
                    <table class="comparison-table">
                        <thead>
                            <tr>
                                <th>Feature</th>
                                <th>Praluent (alirocumab)</th>
                                <th>Repatha (evolocumab)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="feature-name">FDA Approval</td>
                                <td>July 24, 2015 (FIRST)</td>
                                <td>August 27, 2015</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Starting Dose</td>
                                <td>75 mg Q2W (titratable)</td>
                                <td>140 mg Q2W (fixed)</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Alternative Dosing</td>
                                <td>300 mg Q4W</td>
                                <td>420 mg monthly</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Pediatric Age</td>
                                <td>8+ years</td>
                                <td>10+ years</td>
                            </tr>
                            <tr>
                                <td class="feature-name">LDL-C Reduction</td>
                                <td>50-60%</td>
                                <td>50-70%</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Landmark Trial</td>
                                <td>ODYSSEY OUTCOMES (n=18,924)</td>
                                <td>FOURIER (n=27,564)</td>
                            </tr>
                            <tr>
                                <td class="feature-name">MACE Reduction</td>
                                <td>15% (HR 0.85)</td>
                                <td>15-20% (HR 0.85)</td>
                            </tr>
                            <tr style="background: rgba(116, 185, 255, 0.1);">
                                <td class="feature-name"><strong>Mortality Benefit</strong></td>
                                <td><strong>Yes (HR 0.85, p=0.026)</strong></td>
                                <td><strong>No (HR 1.04)</strong></td>
                            </tr>
                            <tr>
                                <td class="feature-name">ISR Rate</td>
                                <td>7.2%</td>
                                <td>5.7%</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Immunogenicity</td>
                                <td>5% ADA, <1% neutralizing</td>
                                <td>0.3% ADA, rare neutralizing</td>
                            </tr>
                            <tr>
                                <td class="feature-name">2025 Sales</td>
                                <td>~$400-500M</td>
                                <td>~$1.3B</td>
                            </tr>
                            <tr>
                                <td class="feature-name">List Price (2025)</td>
                                <td>$5,850/year</td>
                                <td>$5,850/year</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Patent Expiry</td>
                                <td>2027-2028</td>
                                <td>Late 2027</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Key Advantage</td>
                                <td>Lower starting dose, mortality signal</td>
                                <td>Larger trial, lower ISR rate</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Clinical Positioning</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">When to Choose Each Agent</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div style="padding: 20px; background: rgba(245, 87, 108, 0.05); border-radius: 8px;">
                                    <strong>Consider Praluent When:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Lower starting dose desired for tolerability</li>
                                        <li>Titration flexibility needed</li>
                                        <li>Q4W dosing preferred (300 mg option)</li>
                                        <li>Younger pediatric patients (8+ vs 10+)</li>
                                        <li>Very high-risk patients (mortality benefit)</li>
                                    </ul>
                                </div>
                                <div style="padding: 20px; background: rgba(102, 126, 234, 0.05); border-radius: 8px;">
                                    <strong>Consider Repatha When:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Fixed dosing simplicity preferred</li>
                                        <li>Lower injection site reaction risk important</li>
                                        <li>Extensive long-term safety data desired</li>
                                        <li>Monthly single-dose option needed</li>
                                        <li>Lower immunogenicity concerns</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>Clinical Equivalence:</strong> Both agents are considered therapeutically equivalent for LDL-C reduction and CV risk reduction. Choice often based on formulary coverage, patient preference for dosing regimen, and individual tolerability. The mortality signal with Praluent may influence choice in highest-risk patients.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Dynamics</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Commercial Performance Comparison</div>
                        <div class="mechanism-content">
                            <strong>Sales Performance Gap:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Repatha outsells Praluent ~3:1 despite similar efficacy</li>
                                <li>Amgen's stronger cardiovascular portfolio presence</li>
                                <li>Better payer relationships and formulary positioning</li>
                                <li>2019 partnership restructure impacted Praluent momentum</li>
                            </ul>
                            
                            <strong>Biosimilar Impact (2028+):</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Both face similar patent cliffs</li>
                                <li>Expected 40-60% price erosion</li>
                                <li>May actually increase utilization through improved access</li>
                                <li>Outcomes data will sustain relevance vs newer agents</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tab contents
            const tabContents = document.querySelectorAll('.tab-content');
            tabContents.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected tab content
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }

        // Animate bars on first view
         observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growBar 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        });

        const chartContainers = document.querySelectorAll('.efficacy-bar-chart');
        chartContainers.forEach(container => {
            observer.observe(container);
        });

        // Add animation keyframe
        const style = document.createElement('style');
        style.textContent = `
            @keyframes growBar {
                from { transform: scaleY(0); }
                to { transform: scaleY(1); }
            }
        `;
        document.head.appendChild(style);

        // Add hover effects for timeline items
        document.querySelectorAll('.timeline-content').forEach(item => {
            item.addEventListener('mouseenter', function() {
                this.style.transform = 'scale(1.05)';
            });
            item.addEventListener('mouseleave', function() {
                this.style.transform = 'scale(1)';
            });
        });

        // Add smooth scrolling for internal navigation
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                document.querySelector(this.getAttribute('href')).scrollIntoView({
                    behavior: 'smooth'
                });
            });
        });
    </script>
</body>
</html>


<!-- repar -->

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Repatha¬Æ (evolocumab) - Comprehensive Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 50%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(35deg);
        }

        .drug-title {
            position: relative;
            z-index: 1;
        }

        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
        }

        .drug-subtitle {
            font-size: 24px;
            opacity: 0.9;
            margin-bottom: 5px;
        }

        .drug-company {
            font-size: 18px;
            opacity: 0.8;
        }

        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e9ecef;
            padding: 0;
            overflow-x: auto;
        }

        .nav-tab {
            padding: 20px 30px;
            cursor: pointer;
            border: none;
            background: none;
            font-size: 16px;
            font-weight: 500;
            color: #6c757d;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }

        .nav-tab:hover {
            color: #667eea;
            background: rgba(102, 126, 234, 0.05);
        }

        .nav-tab.active {
            color: #667eea;
            background: white;
        }

        .nav-tab.active::after {
            content: '';
            position: absolute;
            bottom: -2px;
            left: 0;
            right: 0;
            height: 3px;
            background: #667eea;
        }

        .content {
            padding: 40px;
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .section {
            margin-bottom: 40px;
        }

        .section-title {
            font-size: 28px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 3px solid #667eea;
        }

        .mechanism-card {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }

        .mechanism-title {
            font-size: 22px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 15px;
        }

        .mechanism-content {
            color: #5a6c7d;
            line-height: 1.8;
            font-size: 16px;
        }

        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .dosing-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.2);
            border-color: #667eea;
        }

        .dosing-label {
            font-size: 14px;
            color: #6c757d;
            margin-bottom: 10px;
        }

        .dosing-value {
            font-size: 28px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .dosing-detail {
            font-size: 14px;
            color: #5a6c7d;
        }

        .timeline-container {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }

        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            transform: translateX(-50%);
        }

        .timeline-item {
            position: relative;
            margin: 30px 0;
            display: flex;
            align-items: center;
        }

        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }

        .timeline-content {
            width: 45%;
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
            cursor: pointer;
        }

        .timeline-content:hover {
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.3);
            border-color: #667eea;
        }

        .timeline-date {
            font-size: 18px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 8px;
        }

        .timeline-description {
            font-size: 14px;
            color: #6c757d;
            line-height: 1.6;
        }

        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: white;
            border: 4px solid #667eea;
            border-radius: 50%;
            z-index: 2;
        }

        .timeline-tooltip {
            position: absolute;
            background: #2c3e50;
            color: white;
            padding: 15px;
            border-radius: 8px;
            font-size: 14px;
            width: 300px;
            opacity: 0;
            pointer-events: none;
            transition: opacity 0.3s;
            z-index: 1000;
            box-shadow: 0 10px 30px rgba(0,0,0,0.3);
        }

        .timeline-content:hover .timeline-tooltip {
            opacity: 1;
        }

        .trials-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin-top: 20px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            border-radius: 12px;
            overflow: hidden;
        }

        .trials-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }

        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .trials-table tbody tr {
            border-bottom: 1px solid #e9ecef;
            transition: all 0.3s;
        }

        .trials-table tbody tr:hover {
            background: rgba(102, 126, 234, 0.05);
            transform: translateX(5px);
        }

        .trials-table td {
            padding: 15px;
            font-size: 14px;
            color: #5a6c7d;
        }

        .trial-name {
            font-weight: 600;
            color: #2c3e50;
        }

        .trial-phase {
            display: inline-block;
            padding: 4px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            background: #e9ecef;
            color: #6c757d;
        }

        .trial-phase.phase3 {
            background: #d4edda;
            color: #155724;
        }

        .outcome-chart {
            margin: 30px 0;
            padding: 20px;
            background: #f8f9fa;
            border-radius: 12px;
        }

        .chart-container {
            position: relative;
            height: 400px;
            margin-top: 20px;
        }

        .efficacy-bar-chart {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 300px;
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            margin: 0 10px;
        }

        .bar {
            width: 60px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 8px 8px 0 0;
            transition: all 0.3s;
            position: relative;
            margin-bottom: 10px;
        }

        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(102, 126, 234, 0.4);
        }

        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            color: #667eea;
            font-size: 18px;
        }

        .bar-label {
            text-align: center;
            font-size: 12px;
            color: #6c757d;
            margin-top: 10px;
            max-width: 100px;
        }

        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .safety-card {
            background: white;
            border: 1px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }

        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }

        .safety-title {
            font-size: 18px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }

        .safety-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            margin-right: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
        }

        .safety-content {
            color: #6c757d;
            line-height: 1.8;
        }

        .safety-list {
            list-style: none;
            margin-top: 10px;
        }

        .safety-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f1f3f5;
            display: flex;
            justify-content: space-between;
        }

        .safety-list li:last-child {
            border-bottom: none;
        }

        .percentage {
            font-weight: 600;
            color: #667eea;
        }

        .market-timeline {
            position: relative;
            padding: 30px 0;
        }

        .market-event {
            background: white;
            border-left: 4px solid #667eea;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 12px 12px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
        }

        .market-event:hover {
            transform: translateX(10px);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.2);
        }

        .market-year {
            font-size: 20px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .market-description {
            color: #5a6c7d;
            line-height: 1.6;
        }

        .price-tag {
            display: inline-block;
            background: #ffeaa7;
            color: #2d3436;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .competition-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .competitor-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .competitor-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
            border-color: #667eea;
        }

        .competitor-name {
            font-size: 18px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .competitor-detail {
            font-size: 14px;
            color: #6c757d;
            margin: 5px 0;
        }

        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 10px auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">Repatha¬Æ (evolocumab)</div>
                <div class="drug-subtitle">PCSK9 Monoclonal Antibody</div>
                <div class="drug-company">Amgen ‚Ä¢ FDA/EMA Approved 2015</div>
            </div>
        </div>

        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('market')">Market & Commercial</button>
        </div>

        <div class="content">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="section">
                    <h2 class="section-title">Mechanism of Action</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">PCSK9 Inhibition via Monoclonal Antibody</div>
                        <div class="mechanism-content">
                            Repatha is a fully human monoclonal antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream. By inhibiting PCSK9's interaction with LDL receptors (LDL-R) on hepatocytes, it prevents receptor degradation, leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li style="margin: 8px 0;">Increased LDL-R recycling on liver surface</li>
                                <li style="margin: 8px 0;">Enhanced clearance of LDL cholesterol from blood</li>
                                <li style="margin: 8px 0;">Substantial reductions in circulating LDL-C levels (50-70%)</li>
                                <li style="margin: 8px 0;">Rapid onset of effect (peak reduction within 1-2 weeks)</li>
                            </ul>
                            <div style="margin-top: 20px; padding: 15px; background: rgba(102, 126, 234, 0.1); border-radius: 8px;">
                                <strong>Key Differentiators:</strong> Unlike statins (which upregulate LDL-R expression) or inclisiran (which silences PCSK9 gene via siRNA), evolocumab acts post-translationally on circulating PCSK9, providing immediate effect without genetic modification.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Dosing & Administration</h2>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">140 mg</div>
                            <div class="dosing-detail">Every 2 weeks (Q2W)<br>OR<br>420 mg monthly</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value">12-26</div>
                            <div class="dosing-detail">Subcutaneous self-injection after training</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HoFH Patients</div>
                            <div class="dosing-value">420 mg</div>
                            <div class="dosing-detail">Monthly, can increase to Q2W after 12 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Administration Sites</div>
                            <div class="dosing-value">3 Sites</div>
                            <div class="dosing-detail">Abdomen, thigh, or upper arm</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Patient Populations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Approved Indications</div>
                        <div class="mechanism-content">
                            <strong>Adults:</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>Heterozygous Familial Hypercholesterolemia (HeFH)</li>
                                <li>Homozygous Familial Hypercholesterolemia (HoFH)</li>
                                <li>Clinical ASCVD requiring additional LDL-C lowering</li>
                                <li>CV risk reduction (MI, stroke, coronary revascularization)</li>
                            </ul>
                            <strong>Pediatric (Age 10+):</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>HeFH or HoFH patients</li>
                            </ul>
                            <div style="margin-top: 15px; padding: 10px; background: #fff3cd; border-radius: 5px;">
                                <strong>Note:</strong> No dose adjustments required for renal/hepatic impairment, age, or weight
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="section">
                    <h2 class="section-title">FDA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">August 27, 2015</div>
                                <div class="timeline-title">Initial FDA Approval</div>
                                <div class="timeline-description">
                                    Approved for HeFH, clinical ASCVD, and HoFH in adults/adolescents 13+. Second PCSK9 inhibitor approved in US.
                                </div>
                                <div class="timeline-tooltip">
                                    Adjunct to diet and maximally tolerated statin therapy. No CRLs or safety delays during review.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 11, 2016</div>
                                <div class="timeline-title">Pushtronex System Approval</div>
                                <div class="timeline-description">
                                    First single monthly injection device for 420 mg dosing (on-body infusor).
                                </div>
                                <div class="timeline-tooltip">
                                    Automated delivery system, though later discontinued in some markets due to patient experience issues.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">December 1, 2017</div>
                                <div class="timeline-title">CV Outcomes Indication</div>
                                <div class="timeline-description">
                                    First PCSK9 inhibitor with outcomes-based indication for MI, stroke, and revascularization reduction.
                                </div>
                                <div class="timeline-tooltip">
                                    Based on FOURIER trial data showing 15% MACE reduction in established CVD patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">February 2021</div>
                                <div class="timeline-title">Pediatric Expansion</div>
                                <div class="timeline-description">
                                    Age limit lowered from 13+ to 10+ years for HeFH/HoFH patients.
                                </div>
                                <div class="timeline-tooltip">
                                    Based on HAUSER-RCT pediatric trial showing safety and efficacy in younger patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2024</div>
                                <div class="timeline-title">Label Updates</div>
                                <div class="timeline-description">
                                    Pregnancy/lactation data added from post-marketing reports.
                                </div>
                                <div class="timeline-tooltip">
                                    Insufficient evidence of fetal harm but discontinuation advised during pregnancy. No new safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>

                    <h2 class="section-title">EMA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 17, 2015</div>
                                <div class="timeline-title">EMA Marketing Authorization</div>
                                <div class="timeline-description">
                                    Approved for primary hypercholesterolemia and mixed dyslipidemia. Included statin-intolerant patients.
                                </div>
                                <div class="timeline-tooltip">
                                    Broader initial indication than FDA, predated US approval by one month.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">February 21, 2017</div>
                                <div class="timeline-title">Automated Mini-Doser</div>
                                <div class="timeline-description">
                                    420 mg single-dose delivery option approved for European market.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May 16, 2018</div>
                                <div class="timeline-title">CV Risk Reduction</div>
                                <div class="timeline-description">
                                    Expanded indication for MI, stroke, and PAD risk reduction based on FOURIER.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">June 28, 2024</div>
                                <div class="timeline-title">Latest Revision</div>
                                <div class="timeline-description">
                                    Updated SmPC, labeling, and package leaflet. No major safety changes.
                                </div>
                                <div class="timeline-tooltip">
                                    Continuous monitoring via PBRERs. Pricing disputes in France but no safety-related restrictions.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Clinical Development Program</h2>
                    
                    <table class="trials-table">
                        <thead>
                            <tr>
                                <th>Trial Name</th>
                                <th>Phase</th>
                                <th>N</th>
                                <th>Year</th>
                                <th>Primary Endpoint</th>
                                <th>Key Results</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="trial-name">MENDEL</td>
                                <td><span class="trial-phase">Phase 2</span></td>
                                <td>406</td>
                                <td>2013</td>
                                <td>% LDL-C change at week 12</td>
                                <td>39-53% reduction vs placebo/ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">GAUSS</td>
                                <td><span class="trial-phase">Phase 2</span></td>
                                <td>160</td>
                                <td>2013</td>
                                <td>% LDL-C change (statin-intolerant)</td>
                                <td>Similar efficacy in statin-intolerant patients</td>
                            </tr>
                            <tr>
                                <td class="trial-name">LAPLACE-2</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,896</td>
                                <td>2014</td>
                                <td>% LDL-C change at weeks 10-12</td>
                                <td>63-75% reduction vs placebo</td>
                            </tr>
                            <tr>
                                <td class="trial-name">DESCARTES</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>901</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 52</td>
                                <td>57% sustained reduction</td>
                            </tr>
                            <tr>
                                <td class="trial-name">RUTHERFORD-2</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>331</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 12 (HeFH)</td>
                                <td>~60% reduction in HeFH patients</td>
                            </tr>
                            <tr>
                                <td class="trial-name">TESLA/TAUSSIG</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>106</td>
                                <td>2015</td>
                                <td>LDL-C reduction (HoFH)</td>
                                <td>31% reduction in HoFH</td>
                            </tr>
                            <tr style="background: rgba(102, 126, 234, 0.05);">
                                <td class="trial-name"><strong>FOURIER</strong></td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td><strong>27,564</strong></td>
                                <td><strong>2017</strong></td>
                                <td><strong>CV death, MI, stroke, UA, revasc</strong></td>
                                <td><strong>HR 0.85 (15% RRR), p<0.001</strong></td>
                            </tr>
                            <tr>
                                <td class="trial-name">EBBINGHAUS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,974</td>
                                <td>2017</td>
                                <td>Cognitive function</td>
                                <td>No cognitive impairment vs placebo</td>
                            </tr>
                            <tr>
                                <td class="trial-name">EVOPACS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>308</td>
                                <td>2019</td>
                                <td>% LDL-C change at week 8 (ACS)</td>
                                <td>77% reduction, safe in-hospital start</td>
                            </tr>
                            <tr>
                                <td class="trial-name">FOURIER-OLE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>6,635</td>
                                <td>2022</td>
                                <td>Long-term MACE (up to 8.6 years)</td>
                                <td>15% RRR sustained, low AE rates</td>
                            </tr>
                            <tr>
                                <td class="trial-name">EVOLVE-MI</td>
                                <td><span class="trial-phase">Phase 4</span></td>
                                <td>Ongoing</td>
                                <td>2022-</td>
                                <td>MACE post-MI</td>
                                <td>Interim: Feasible early initiation</td>
                            </tr>
                            <tr>
                                <td class="trial-name">VESALIUS-CV</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>TBD</td>
                                <td>2026</td>
                                <td>Primary prevention MACE</td>
                                <td>Results pending</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Efficacy Outcomes</h2>
                    <div class="efficacy-bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 60%;">
                                <span class="bar-value">60%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(Average)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 59%; background: linear-gradient(180deg, #48dbfb 0%, #0984e3 100%);">
                                <span class="bar-value">59%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 30%; background: linear-gradient(180deg, #fdcb6e 0%, #e17055 100%);">
                                <span class="bar-value">30 mg/dL</span>
                            </div>
                            <div class="bar-label">Median LDL<br>Achieved</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 20%; background: linear-gradient(180deg, #a29bfe 0%, #6c5ce7 100%);">
                                <span class="bar-value">20%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 15%; background: linear-gradient(180deg, #55efc4 0%, #00b894 100%);">
                                <span class="bar-value">15%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(Long-term)</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">FOURIER Trial - Detailed Outcomes</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Primary & Secondary Endpoints</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 20px;">
                                <div>
                                    <strong>Primary Composite (MACE-5):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, MI, stroke, UA hospitalization, coronary revascularization</li>
                                        <li><strong>HR 0.85 (95% CI: 0.79-0.92)</strong></li>
                                        <li><strong>20% relative risk reduction, p<0.001</strong></li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Key Secondary (MACE-3):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, MI, stroke</li>
                                        <li><strong>HR 0.80 (95% CI: 0.73-0.88)</strong></li>
                                        <li><strong>20% relative risk reduction</strong></li>
                                    </ul>
                                </div>
                            </div>
                            <div style="margin-top: 20px; padding: 15px; background: #fff3cd; border-radius: 8px;">
                                <strong>Note on Mortality:</strong> No significant reduction in CV death (HR 1.05) or all-cause mortality (HR 1.04), likely due to short median follow-up of 2.2 years. Longer follow-up in FOURIER-OLE showed trend toward mortality benefit.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Safety Profile Overview</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Cumulative Exposure:</strong> ~2.5 million patient-years as of May 2024<br>
                            <strong>Black Box Warnings:</strong> None<br>
                            <strong>Major Safety Signals:</strong> None identified<br>
                            <strong>Discontinuation Rate:</strong> ~1.6% due to adverse events
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Common Adverse Events</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">1</div>
                                Most Common AEs
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Nasopharyngitis <span class="percentage">10.5%</span></li>
                                    <li>Upper respiratory infection <span class="percentage">9.3%</span></li>
                                    <li>Influenza <span class="percentage">7.5%</span></li>
                                    <li>Back pain <span class="percentage">6.2%</span></li>
                                    <li>Injection site reactions <span class="percentage">5.7%</span></li>
                                    <li>Myalgia <span class="percentage">5.4%</span></li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">2</div>
                                Injection Site Reactions
                            </div>
                            <div class="safety-content">
                                Overall incidence: 5.7%
                                <ul class="safety-list">
                                    <li>Erythema <span class="percentage">2.1%</span></li>
                                    <li>Pain <span class="percentage">1.8%</span></li>
                                    <li>Bruising <span class="percentage">1.2%</span></li>
                                </ul>
                                Generally mild and transient
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">3</div>
                                Serious Adverse Events
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Overall SAEs <span class="percentage">2.4%</span></li>
                                    <li>Similar to placebo <span class="percentage">2.3%</span></li>
                                    <li>Hypersensitivity (rare) <span class="percentage"><1%</span></li>
                                    <li>Anaphylaxis <span class="percentage">Very rare</span></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Neurocognitive Safety</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">EBBINGHAUS Study Results</div>
                        <div class="mechanism-content">
                            <strong>Primary Finding:</strong> No impact on cognitive function despite very low LDL-C levels<br><br>
                            
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Cognitive Domains Tested:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Executive function</li>
                                        <li>Working memory</li>
                                        <li>Memory function</li>
                                        <li>Psychomotor speed</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Results:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Neurocognitive AEs: 1.6% vs 1.5% placebo</li>
                                        <li>No correlation with LDL level</li>
                                        <li>No difference in any cognitive domain</li>
                                        <li>8+ year follow-up confirms safety</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>2024 Update:</strong> Study of 3,000+ patients with very low LDL (<20 mg/dL) showed no cognitive association over 5+ years. Meta-analyses confirm no neurocognitive risk.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Special Populations & Monitoring</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">P</div>
                                Pregnancy & Lactation
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ Insufficient evidence of fetal harm</li>
                                    <li>‚Ä¢ Discontinuation advised during pregnancy</li>
                                    <li>‚Ä¢ Limited data on breastfeeding</li>
                                    <li>‚Ä¢ 2024 label update with post-marketing data</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">I</div>
                                Immunogenicity
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ Binding antibodies: 0.3%</li>
                                    <li>‚Ä¢ Neutralizing antibodies: Rare</li>
                                    <li>‚Ä¢ No impact on efficacy</li>
                                    <li>‚Ä¢ No cross-reactivity concerns</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">D</div>
                                Diabetes Risk
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>‚Ä¢ New-onset diabetes: HR 1.05</li>
                                    <li>‚Ä¢ Not statistically significant</li>
                                    <li>‚Ä¢ Safe in T1D patients (2025 data)</li>
                                    <li>‚Ä¢ No glucose monitoring required</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div id="market" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Pricing Evolution</h2>
                    <div class="market-timeline">
                        <div class="market-event">
                            <div class="market-year">2015</div>
                            <div class="market-description">
                                <span class="price-tag">US: $14,000-14,600/year</span>
                                <span class="price-tag">EU: ~$6,780/year</span><br>
                                Launch pricing led to significant payer pushback and strict prior authorizations
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2018</div>
                            <div class="market-description">
                                <span class="price-tag">60% price cut to $5,850/year</span><br>
                                Post-FOURIER price reduction to improve access. Net price ~$4,500 with rebates
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2020</div>
                            <div class="market-description">
                                Only 3% of eligible high-risk ASCVD patients receiving therapy due to access barriers
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2025</div>
                            <div class="market-description">
                                <span class="price-tag">Annual sales: ~$1.3 billion</span><br>
                                Sales plateaued. France pricing disputes. Biosimilars approaching in 2028
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Access Challenges</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Prior Authorization Requirements:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>~80% initial denial rate in US</li>
                                <li>Must prove statin failure/intolerance</li>
                                <li>LDL threshold requirements (>100-130 mg/dL)</li>
                                <li>Documentation of CV risk factors</li>
                                <li>Step therapy through other lipid agents</li>
                            </ul>
                            
                            <strong>Payer Restrictions:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Express Scripts/UnitedHealth: Strict step therapy protocols</li>
                                <li>VA/CMS: Negotiated discounts but limited to severe cases</li>
                                <li>NICE/HTA: Only for LDL >3.5-5 mmol/L in high-risk (ICER >¬£30,000/QALY)</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Competitive Landscape</h2>
                    <div class="competition-grid">
                        <div class="competitor-card">
                            <div class="competitor-name">Praluent (alirocumab)</div>
                            <div class="competitor-detail">PCSK9 mAb - Sanofi/Regeneron</div>
                            <div class="competitor-detail">Similar efficacy, first to market</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Leqvio (inclisiran)</div>
                            <div class="competitor-detail">siRNA - Novartis</div>
                            <div class="competitor-detail">Twice-yearly dosing advantage</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Oral PCSK9i</div>
                            <div class="competitor-detail">Merck (Phase 3)</div>
                            <div class="competitor-detail">Convenience of oral dosing</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Lerodalcibep</div>
                            <div class="competitor-detail">LIB Therapeutics</div>
                            <div class="competitor-detail">Monthly dosing, Phase 3</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Future Outlook</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Patent Expiry & Biosimilars</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>US Market:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Exclusivity ends late 2027</li>
                                        <li>Biosimilars possible from 2028</li>
                                        <li>Expected 30-50% price reduction</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>EU Market:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Similar timeline to US</li>
                                        <li>Earlier entries if patents challenged</li>
                                        <li>Pricing pressures from inclisiran deals</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: rgba(102, 126, 234, 0.1); border-radius: 8px;">
                                <strong>Strategic Position:</strong> Despite competition from newer agents, Repatha's extensive outcomes data (FOURIER) and established safety profile ensure continued relevance. Biosimilar competition may actually improve access by reducing costs.
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tab contents
            const tabContents = document.querySelectorAll('.tab-content');
            tabContents.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected tab content
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }

        // Animate bars on first view
        = observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growBar 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        });

         chartContainers = document.querySelectorAll('.efficacy-bar-chart');
        chartContainers.forEach(container => {
            observer.observe(container);
        });

        // Add animation keyframe
        const style = document.createElement('style');
        style.textContent = `
            @keyframes growBar {
                from { transform: scaleY(0); }
                to { transform: scaleY(1); }
            }
        `;
        document.head.appendChild(style);
    </script>
</body>
</html>

<!-- other -->

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lipid-Lowering Competitors - Comprehensive Analysis</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .main-container {
            max-width: 1600px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .main-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 30px 40px;
            position: relative;
            overflow: hidden;
        }
        
        .main-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.05);
            transform: rotate(45deg);
        }
        
        .main-title {
            font-size: 36px;
            font-weight: bold;
            margin-bottom: 10px;
            position: relative;
            z-index: 1;
        }
        
        .main-subtitle {
            font-size: 18px;
            opacity: 0.95;
            position: relative;
            z-index: 1;
        }
        
        .drug-nav-container {
            display: flex;
            background: #f0f0f0;
            overflow-x: auto;
            white-space: nowrap;
            border-bottom: 3px solid #ddd;
        }
        
        .drug-nav-tab {
            padding: 15px 25px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 15px;
            font-weight: 600;
            color: #555;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }
        
        .drug-nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
            color: #667eea;
        }
        
        .drug-nav-tab.active {
            color: white;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
        }
        
        .drug-content {
            display: none;
        }
        
        .drug-content.active {
            display: block;
        }
        
        .drug-header {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            padding: 30px 40px;
            border-bottom: 2px solid #e0e0e0;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: bold;
            color: #333;
            margin-bottom: 5px;
        }
        
        .drug-subtitle {
            font-size: 18px;
            color: #666;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 16px;
            color: #888;
        }
        
        .status-badge {
            display: inline-block;
            background: #667eea;
            color: white;
            padding: 6px 12px;
            border-radius: 20px;
            margin-top: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 12px 20px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 14px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
        }
        
        .nav-tab.active {
            color: #667eea;
            border-bottom: 3px solid #667eea;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 30px 40px;
            min-height: 500px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 25px;
            margin: 25px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.08);
            border: 1px solid #e0e0e0;
        }
        
        .info-card-title {
            font-size: 16px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 28px;
            height: 28px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
            line-height: 1.5;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            border-left: 4px solid #667eea;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
            font-size: 16px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
            font-size: 14px;
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 12px;
            padding: 25px;
            margin-bottom: 25px;
        }
        
        .mechanism-title {
            font-size: 20px;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
            font-size: 14px;
        }
        
        .mechanism-highlight {
            background: rgba(102, 126, 234, 0.2);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #667eea;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 10px;
            padding: 15px;
            transition: all 0.3s;
        }
        
        .dosing-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
            border-color: #667eea;
        }
        
        .dosing-label {
            font-size: 12px;
            color: #888;
            margin-bottom: 5px;
        }
        
        .dosing-value {
            font-size: 20px;
            font-weight: bold;
            color: #333;
        }
        
        .dosing-detail {
            font-size: 12px;
            color: #666;
            margin-top: 5px;
        }
        
        .timeline-container {
            margin: 25px 0;
            padding: 25px;
            background: #f8f9fa;
            border-radius: 12px;
        }
        
        .timeline-header {
            font-size: 18px;
            font-weight: bold;
            margin-bottom: 25px;
            color: #333;
        }
        
        .timeline-item {
            background: white;
            padding: 15px;
            margin-bottom: 15px;
            border-radius: 8px;
            border-left: 4px solid #667eea;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }
        
        .timeline-date {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 5px;
            font-size: 14px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
            color: #333;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .efficacy-chart {
            background: white;
            border-radius: 12px;
            padding: 25px;
            margin: 20px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.08);
        }
        
        .chart-title {
            font-size: 18px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 250px;
            gap: 15px;
            padding: 20px 0;
        }
        
        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
        }
        
        .bar {
            width: 100%;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 8px 8px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 15px rgba(102, 126, 234, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -25px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 16px;
            color: #667eea;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 12px;
            color: #666;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 15px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f8f9fa 100%);
            border: 2px solid #e0e0e0;
            border-radius: 10px;
            padding: 15px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
        }
        
        .safety-percentage {
            font-size: 28px;
            font-weight: bold;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 12px;
            color: #666;
            margin-top: 8px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 12px;
            padding: 25px;
            margin: 20px 0;
        }
        
        .price-estimate {
            font-size: 28px;
            font-weight: bold;
            color: #667eea;
            margin: 15px 0;
        }
        
        .market-projection {
            display: flex;
            align-items: center;
            gap: 30px;
            margin: 20px 0;
        }
        
        .projection-value {
            font-size: 22px;
            font-weight: bold;
            color: #333;
        }
        
        .projection-label {
            font-size: 13px;
            color: #666;
        }
        
        @media (max-width: 768px) {
            .info-grid {
                grid-template-columns: 1fr;
            }
            
            .drug-nav-container {
                overflow-x: scroll;
            }
            
            .bar-chart {
                height: 200px;
            }
        }
        .bar {
    width: 100%;
    background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
    border-radius: 8px 8px 0 0;
    position: relative;
    transition: all 0.3s;
}
.bar-chart {
    display: flex;
    align-items: flex-end;
    height: 250px; /* This must be set */
    gap: 15px;
    padding: 20px 0;
}
.bar-group {
    flex: 1;
    display: flex;
    flex-direction: column;
    align-items: center;
    justify-content: flex-end;
}
    </style>
</head>
<body>
    
    <div class="main-container">
        <div class="main-header">
            <div class="main-title">Cholesterol-Lowering Competitors Analysis</div>
            <div class="main-subtitle">Comprehensive Drug Portfolio Assessment - PCSK9 & Alternative Mechanisms</div>
        </div>
        
        <div class="drug-nav-container">
            <button class="drug-nav-tab active" onclick="showDrug('statins')">Statins</button>
            <button class="drug-nav-tab" onclick="showDrug('ezetimibe')">Ezetimibe</button>
            <button class="drug-nav-tab" onclick="showDrug('bempedoic')">Bempedoic Acid</button>
            <button class="drug-nav-tab" onclick="showDrug('obicetrapib')">Obicetrapib</button>
            <button class="drug-nav-tab" onclick="showDrug('evinacumab')">Evinacumab</button>
        </div>
        
        <!-- STATINS -->
        <div id="statins" class="drug-content active">
            <div class="drug-header">
                <div class="drug-name">Statins</div>
                <div class="drug-subtitle">HMG-CoA Reductase Inhibitors</div>
                <div class="drug-company">Multiple Manufacturers (Generic)</div>
                <span class="status-badge">First-Line Therapy</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('statins', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('statins', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('statins', 'regulatory')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('statins', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('statins', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('statins', 'future')">Future Outlook</button>
            </div>
            
            <div class="content-area">
                <div id="statins-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üíä</div>
                                Key Examples
                            </div>
                            <ul class="info-list">
                                <li>Atorvastatin (Lipitor)</li>
                                <li>Rosuvastatin (Crestor)</li>
                                <li>Simvastatin (Zocor)</li>
                                <li>Pravastatin (Pravachol)</li>
                                <li>Lovastatin (Mevacor)</li>
                                <li>Fluvastatin (Lescol)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                Efficacy Profile
                            </div>
                            <ul class="info-list">
                                <li>30-50% LDL-C reduction (moderate/high intensity)</li>
                                <li>25-35% CV risk reduction per mmol/L LDL drop</li>
                                <li>Proven mortality benefit</li>
                                <li>Upregulates LDL receptors</li>
                                <li>Paradoxically increases PCSK9 (feedback)</li>
                                <li>Foundation of all lipid therapy</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Market Position
                            </div>
                            <ul class="info-list">
                                <li>Mandatory first-line therapy globally</li>
                                <li>Generic pricing ($3-10/month)</li>
                                <li>Gateway to all advanced therapies</li>
                                <li>5-10% intolerance creates market for alternatives</li>
                                <li>Required before PCSK9 inhibitor approval</li>
                                <li>Complementary to inclisiran, not competitive</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Strategic Importance</div>
                        <div class="highlight-content">
                            Statins remain the foundational therapy that all new drugs must justify adding to, not replacing. 
                            Their low cost and proven outcomes create a high bar for cost-effectiveness. Inclisiran and other 
                            PCSK9 inhibitors are positioned as add-ons for patients not at goal on maximally tolerated statins, 
                            making statins more ally than adversary in the treatment paradigm.
                        </div>
                    </div>
                </div>
                
                <div id="statins-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Statins work by <span class="mechanism-highlight">inhibiting HMG-CoA reductase</span>, the rate-limiting 
                            enzyme in cholesterol synthesis. This leads to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced intracellular cholesterol in hepatocytes</li>
                                <li>Upregulation of LDL receptors via SREBP-2 activation</li>
                                <li>Increased clearance of LDL from circulation</li>
                                <li>Compensatory increase in PCSK9 production (limiting factor)</li>
                                <li>Pleiotropic effects: anti-inflammatory, plaque stabilization</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">High-Intensity</div>
                            <div class="dosing-value">‚â•50% ‚Üì</div>
                            <div class="dosing-detail">Atorva 40-80mg, Rosuva 20-40mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Moderate-Intensity</div>
                            <div class="dosing-value">30-49% ‚Üì</div>
                            <div class="dosing-detail">Atorva 10-20mg, Rosuva 5-10mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Low-Intensity</div>
                            <div class="dosing-value"><30% ‚Üì</div>
                            <div class="dosing-detail">Simva 10mg, Prava 10-20mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Administration</div>
                            <div class="dosing-value">Daily</div>
                            <div class="dosing-detail">Usually evening (except atorva/rosuva)</div>
                        </div>
                    </div>
                </div>
                
                <div id="statins-regulatory" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">Landmark Trial Outcomes</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 31%;">
                                    <div class="bar-value">31%</div>
                                </div>
                                <div class="bar-label">4S Trial<br>Mortality ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 24%;">
                                    <div class="bar-value">24%</div>
                                </div>
                                <div class="bar-label">JUPITER<br>MACE ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 21%;">
                                    <div class="bar-value">21%</div>
                                </div>
                                <div class="bar-label">PROVE-IT<br>Events ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 35%;">
                                    <div class="bar-value">35%</div>
                                </div>
                                <div class="bar-label">Meta-analysis<br>CV Risk ‚Üì/mmol</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Evidence Base</div>
                        <div class="highlight-content">
                            Statins have the most robust outcomes data of any lipid therapy, with dozens of trials showing 
                            consistent cardiovascular and mortality benefits. This irrefutable evidence makes them the 
                            cornerstone of preventive cardiology and the benchmark against which all new therapies are measured.
                        </div>
                    </div>
                </div>
                
                <div id="statins-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">5-10%</div>
                            <div class="safety-label">Muscle Symptoms</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage"><0.1%</div>
                            <div class="safety-label">Rhabdomyolysis</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">9%</div>
                            <div class="safety-label">Diabetes Risk ‚Üë</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Rare</div>
                            <div class="safety-label">Hepatotoxicity</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚ö†Ô∏è</div>
                                Key Safety Considerations
                            </div>
                            <ul class="info-list">
                                <li>Statin-associated muscle symptoms (SAMS) main issue</li>
                                <li>True intolerance likely overestimated (nocebo effect)</li>
                                <li>Creates substantial market for alternatives</li>
                                <li>Drug interactions with CYP3A4 inhibitors</li>
                                <li>Contraindicated in pregnancy</li>
                                <li>Generally very safe with decades of use</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="statins-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">$3-10/month</div>
                        <div style="color: #666; margin-bottom: 30px;">Generic pricing globally</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">Required</div>
                                <div class="projection-label">Before PCSK9 inhibitor approval</div>
                            </div>
                            <div>
                                <div class="projection-value">Foundation</div>
                                <div class="projection-label">Of all lipid management</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Commercial Reality</div>
                        <div class="highlight-content">
                            Statins set an "essentially free and very effective" benchmark that new therapies must justify 
                            exceeding. They are gatekeepers rather than competitors - payers require maximally tolerated 
                            statin therapy before approving expensive alternatives, making them complementary to inclisiran's 
                            market positioning.
                        </div>
                    </div>
                </div>
                
                <div id="statins-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                5-10 Year Outlook
                            </div>
                            <ul class="info-list">
                                <li>Will remain foundational therapy</li>
                                <li>No replacement in primary prevention</li>
                                <li>Earlier combination therapy in guidelines</li>
                                <li>Stack with PCSK9 inhibitors, not replaced</li>
                                <li>Continued generic pricing pressure</li>
                                <li>Precision medicine for intolerance</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- EZETIMIBE -->
        <div id="ezetimibe" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Ezetimibe (Zetia¬Æ)</div>
                <div class="drug-subtitle">Cholesterol Absorption Inhibitor</div>
                <div class="drug-company">Merck (now generic)</div>
                <span class="status-badge">Second-Line Add-On</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('ezetimibe', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'clinical')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'future')">Future Role</button>
            </div>
            
            <div class="content-area">
                <div id="ezetimibe-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üî¨</div>
                                Key Features
                            </div>
                            <ul class="info-list">
                                <li>Blocks NPC1L1 transporter in intestine</li>
                                <li>15-25% LDL-C reduction</li>
                                <li>Once-daily oral dosing (10mg)</li>
                                <li>Generic since 2016</li>
                                <li>Often combined with statins</li>
                                <li>No muscle side effects</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                Clinical Position
                            </div>
                            <ul class="info-list">
                                <li>IMPROVE-IT: 6-7% MACE reduction</li>
                                <li>Guideline-recommended second-line</li>
                                <li>Required before PCSK9 inhibitors</li>
                                <li>Modest but proven benefit</li>
                                <li>2% absolute risk reduction</li>
                                <li>Reinforces LDL hypothesis</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üí∞</div>
                                Market Impact
                            </div>
                            <ul class="info-list">
                                <li>~$10-20/month generic</li>
                                <li>Payer-mandated step therapy</li>
                                <li>Delays need for expensive drugs</li>
                                <li>Co-formulated with statins (Vytorin)</li>
                                <li>Shrinks addressable market for PCSK9</li>
                                <li>Easy add-on for clinicians</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Competitive Dynamic</div>
                        <div class="highlight-content">
                            Ezetimibe acts as another gatekeeper before expensive therapies. Many patients achieve goals 
                            with statin + ezetimibe, never needing PCSK9 inhibitors. Its cheap generic status and benign 
                            safety profile make it an automatic second step, potentially limiting inclisiran's addressable 
                            market to those still above goal after both statin and ezetimibe.
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Ezetimibe selectively inhibits <span class="mechanism-highlight">NPC1L1 (Niemann-Pick C1-Like 1)</span> 
                            transporter at the intestinal brush border, leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced absorption of dietary and biliary cholesterol</li>
                                <li>Decreased cholesterol delivery to liver</li>
                                <li>Compensatory upregulation of hepatic LDL receptors</li>
                                <li>Enhanced clearance of LDL from circulation</li>
                                <li>Complementary mechanism to statins</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">10 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">15-25%</div>
                            <div class="dosing-detail">As monotherapy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Statin</div>
                            <div class="dosing-value">+15%</div>
                            <div class="dosing-detail">Additional reduction</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Food Effect</div>
                            <div class="dosing-value">None</div>
                            <div class="dosing-detail">Can take any time</div>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-clinical" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">Key Clinical Evidence</div>
                        <div class="timeline-item">
                            <div class="timeline-date">2015</div>
                            <div class="timeline-title">IMPROVE-IT Trial</div>
                            <div class="timeline-description">
                                18,144 post-ACS patients on simvastatin ¬± ezetimibe. Added ezetimibe achieved 
                                17 mg/dL additional LDL drop and 6.4% relative risk reduction in MACE over 7 years. 
                                Absolute event reduction: 2% (32.7% vs 34.7%).
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">Ongoing</div>
                            <div class="timeline-title">Combination Studies</div>
                            <div class="timeline-description">
                                Multiple trials combining ezetimibe with newer agents (bempedoic acid as Nexlizet, 
                                obicetrapib fixed-dose combinations). Shows additive effects with different mechanisms.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">Minimal</div>
                            <div class="safety-label">Muscle Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Rare</div>
                            <div class="safety-label">Liver Issues</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">GI Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Long-term Harms</div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Safety Advantage</div>
                        <div class="highlight-content">
                            Ezetimibe's excellent safety profile (essentially placebo-like tolerability) makes it an 
                            easy add-on that clinicians reach for reflexively. This "why not try ezetimibe first?" 
                            mentality creates another hurdle before injectable therapies are considered.
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">$10-20/month</div>
                        <div style="color: #666; margin-bottom: 30px;">Generic pricing (since 2016)</div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üè•</div>
                                Impact on PCSK9 Market
                            </div>
                            <ul class="info-list">
                                <li>Payers require ezetimibe trial first</li>
                                <li>Many patients reach goal with statin+ezetimibe</li>
                                <li>Reduces pool needing expensive therapies</li>
                                <li>Creates "step therapy" barrier</li>
                                <li>Combination pills increase usage</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                Future Role
                            </div>
                            <ul class="info-list">
                                <li>Remains baseline therapy with statins</li>
                                <li>Component of fixed-dose combinations</li>
                                <li>May combine with oral PCSK9 inhibitors</li>
                                <li>Continues as cheap generic option</li>
                                <li>Extra 15% reduction always valuable</li>
                                <li>Part of "maximize orals first" approach</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- BEMPEDOIC ACID -->
        <div id="bempedoic" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Bempedoic Acid (Nexletol¬Æ)</div>
                <div class="drug-subtitle">ACL Inhibitor - Oral Non-Statin</div>
                <div class="drug-company">Esperion Therapeutics</div>
                <span class="status-badge">FDA Approved with CV Outcomes</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('bempedoic', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'regulatory')">Regulatory & Trials</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'future')">Future Outlook</button>
            </div>
            
            <div class="content-area">
                <div id="bempedoic-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Key Differentiators
                            </div>
                            <ul class="info-list">
                                <li>First oral non-statin with CV outcomes</li>
                                <li>No muscle side effects (liver-specific)</li>
                                <li>18-25% LDL reduction</li>
                                <li>13% MACE reduction proven (CLEAR)</li>
                                <li>23% MI reduction in statin-intolerant</li>
                                <li>Once-daily oral (180mg)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Regulatory Milestones
                            </div>
                            <ul class="info-list">
                                <li>FDA approved Feb 2020</li>
                                <li>EMA approved 2020 (Nilemdo)</li>
                                <li>CLEAR Outcomes positive March 2023</li>
                                <li>CV risk reduction label 2023</li>
                                <li>No CRLs or major delays</li>
                                <li>Orphan designation for HoFH</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üèÜ</div>
                                Competitive Position
                            </div>
                            <ul class="info-list">
                                <li>Fills statin-intolerant niche</li>
                                <li>Oral alternative to injections</li>
                                <li>Now has outcomes data advantage</li>
                                <li>Combo with ezetimibe (Nexlizet)</li>
                                <li>May become gatekeeper to PCSK9</li>
                                <li>$400/month vs $6000+ for mAbs</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Market Impact on Inclisiran</div>
                        <div class="highlight-content">
                            With proven CV outcomes, bempedoic acid can now market itself as preventing heart attacks - 
                            something inclisiran cannot yet claim. Payers may require trying bempedoic acid (¬±ezetimibe) 
                            before approving expensive injectables, creating another step therapy barrier. The 35% LDL 
                            reduction with bempedoic+ezetimibe may satisfy many patients, shrinking inclisiran's addressable market.
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Bempedoic acid inhibits <span class="mechanism-highlight">ATP citrate lyase (ACL)</span>, 
                            an enzyme upstream of HMG-CoA reductase in cholesterol synthesis. Key features:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Prodrug activated by ACSVL1 enzyme (liver-specific)</li>
                                <li>Not activated in muscle tissue (avoiding myopathy)</li>
                                <li>Reduces hepatic cholesterol synthesis</li>
                                <li>Upregulates LDL receptors</li>
                                <li>Complementary to statin mechanism</li>
                                <li>Can be used with or without statins</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">180 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">18-25%</div>
                            <div class="dosing-detail">Monotherapy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Ezetimibe</div>
                            <div class="dosing-value">35-38%</div>
                            <div class="dosing-detail">Nexlizet combo</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Time to Effect</div>
                            <div class="dosing-value">4 weeks</div>
                            <div class="dosing-detail">Maximum LDL drop</div>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-regulatory" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">CLEAR Outcomes Trial Results</div>
                        <div class="timeline-item">
                            <div class="timeline-date">March 2023</div>
                            <div class="timeline-title">Primary Endpoint Met</div>
                            <div class="timeline-description">
                                13,970 statin-intolerant patients, 3.4 years follow-up. 13% reduction in 4-point MACE 
                                (11.7% vs 13.3%, p=0.004). Absolute risk reduction: 1.6%.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">Key Results</div>
                            <div class="timeline-title">Component Outcomes</div>
                            <div class="timeline-description">
                                ‚Ä¢ Myocardial infarction: 23% reduction (4.7% vs 6.1%)<br>
                                ‚Ä¢ Coronary revascularization: 19% reduction<br>
                                ‚Ä¢ Stroke: 19% reduction (not significant alone)<br>
                                ‚Ä¢ CV death: No difference<br>
                                ‚Ä¢ LDL reduction: 21% placebo-adjusted
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2023</div>
                            <div class="timeline-title">Label Expansion</div>
                            <div class="timeline-description">
                                FDA approved new indication to reduce risk of MI, stroke, and coronary revascularization 
                                in adults with ASCVD or HeFH. First non-statin oral with CV risk reduction claim.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">3.5%</div>
                            <div class="safety-label">Gout (vs 2.1% placebo)</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">0.5%</div>
                            <div class="safety-label">Tendon Rupture</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">‚Üë</div>
                            <div class="safety-label">Uric Acid</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Muscle Issues</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚ö†Ô∏è</div>
                                Safety Considerations
                            </div>
                            <ul class="info-list">
                                <li>Raises uric acid - monitor for gout</li>
                                <li>Tendon rupture warning (Achilles)</li>
                                <li>Small increase in creatinine/BUN</li>
                                <li>No hepatotoxicity</li>
                                <li>No myalgia (liver-specific activation)</li>
                                <li>Generally well tolerated</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$400/month</div>
                        <div style="color: #666; margin-bottom: 30px;">US list price (significantly less than PCSK9 mAbs)</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">Growing</div>
                                <div class="projection-label">Post-outcomes uptake</div>
                            </div>
                            <div>
                                <div class="projection-value">2033</div>
                                <div class="projection-label">Patent expiry estimate</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Payer Dynamics</div>
                        <div class="highlight-content">
                            With outcomes data, payers may mandate trying bempedoic acid before expensive injectables. 
                            At $400/month vs $6000+ for PCSK9 mAbs, it's an attractive intermediate option. Could become 
                            standard step therapy: statin ‚Üí +ezetimibe ‚Üí +bempedoic ‚Üí then PCSK9 if needed.
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                Future Positioning
                            </div>
                            <ul class="info-list">
                                <li>Entrenched in statin-intolerant segment</li>
                                <li>Part of oral combination strategies</li>
                                <li>Generic by early 2030s</li>
                                <li>May combine with oral PCSK9 inhibitors</li>
                                <li>Triple oral therapy possible</li>
                                <li>Further squeezes injectable market</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- OBICETRAPIB -->
        <div id="obicetrapib" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Obicetrapib</div>
                <div class="drug-subtitle">Next-Generation CETP Inhibitor</div>
                <div class="drug-company">NewAmsterdam Pharma</div>
                <span class="status-badge">EMA Review - Phase III</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('obicetrapib', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'regulatory')">Regulatory Status</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'clinical')">Clinical Trials</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'commercial')">Commercial</button>
            </div>
            
            <div class="content-area">
                <div id="obicetrapib-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üî¨</div>
                                Key Features
                            </div>
                            <ul class="info-list">
                                <li>35-45% LDL reduction as monotherapy</li>
                                <li>~50% with ezetimibe combo</li>
                                <li>Raises HDL >100%</li>
                                <li>Once-daily oral (10mg)</li>
                                <li>No blood pressure effects</li>
                                <li>Potential cognitive benefits (p-tau‚Üì)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                CETP Class History
                            </div>
                            <ul class="info-list">
                                <li>Torcetrapib: Failed (‚Üëmortality)</li>
                                <li>Anacetrapib: 9% MACE‚Üì but shelved</li>
                                <li>Evacetrapib: Failed (no benefit)</li>
                                <li>Obicetrapib: Clean safety profile</li>
                                <li>Solves prior class issues</li>
                                <li>"Rebirth of CETP inhibitors"</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Strategic Position
                            </div>
                            <ul class="info-list">
                                <li>EMA MAA validated Aug 2025</li>
                                <li>EU approval possible 2024/25</li>
                                <li>PREVAIL outcomes trial ongoing</li>
                                <li>Menarini partnership for Europe</li>
                                <li>Fixed-dose combo with ezetimibe</li>
                                <li>Different mechanism vs PCSK9</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Competitive Threat to Inclisiran</div>
                        <div class="highlight-content">
                            An all-oral triple therapy (statin + obicetrapib + ezetimibe) could rival injectable PCSK9 
                            inhibitor efficacy. With ~50% LDL reduction from obicetrapib+ezetimibe combo, many patients 
                            might achieve goals without injections. If approved before oral PCSK9 inhibitors, could gain 
                            foothold as the preferred oral intensification option.
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Obicetrapib inhibits <span class="mechanism-highlight">CETP (Cholesteryl Ester Transfer Protein)</span>, 
                            leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced transfer of cholesteryl esters from HDL to VLDL/LDL</li>
                                <li>Enhanced reverse cholesterol transport</li>
                                <li>Indirect upregulation of LDL receptors</li>
                                <li>Substantial HDL-C increase (>100%)</li>
                                <li>Reduction in VLDL remnants</li>
                                <li>No off-target aldosterone effects (unlike torcetrapib)</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">10 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">35-45%</div>
                            <div class="dosing-detail">On top of statin</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Ezetimibe</div>
                            <div class="dosing-value">~50%</div>
                            <div class="dosing-detail">Fixed combo</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HDL Increase</div>
                            <div class="dosing-value">>100%</div>
                            <div class="dosing-detail">Substantial rise</div>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-regulatory" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">Regulatory Timeline</div>
                        <div class="timeline-item">
                            <div class="timeline-date">2023-2024</div>
                            <div class="timeline-title">Phase 3 Trials Complete</div>
                            <div class="timeline-description">
                                BROADWAY (2,500 pts), BROOKLYN (HeFH), and TANDEM (combo) trials completed. 
                                Strong LDL reduction without safety issues seen with prior CETP inhibitors.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">August 2025</div>
                            <div class="timeline-title">EMA MAA Validated</div>
                            <div class="timeline-description">
                                Marketing authorization application accepted for review by EMA for both obicetrapib 
                                monotherapy and fixed-dose combination with ezetimibe.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2024/25 (Expected)</div>
                            <div class="timeline-title">EU Approval</div>
                            <div class="timeline-description">
                                Potential approval based on LDL surrogate endpoint. FDA likely requires outcomes data.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">~2026</div>
                            <div class="timeline-title">PREVAIL Outcomes Trial</div>
                            <div class="timeline-description">
                                Large cardiovascular outcomes trial to determine MACE reduction. Critical for FDA approval 
                                and broader adoption.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-clinical" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">Phase 3 LDL-C Reduction Results</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 33%;">
                                    <div class="bar-value">33%</div>
                                </div>
                                <div class="bar-label">BROADWAY<br>84 days</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 45%;">
                                    <div class="bar-value">45%</div>
                                </div>
                                <div class="bar-label">BROOKLYN<br>HeFH</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 50%;">
                                    <div class="bar-value">50%</div>
                                </div>
                                <div class="bar-label">TANDEM<br>+Ezetimibe</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Exploratory Finding</div>
                        <div class="highlight-content">
                            BROADWAY substudy showed 1.1% reduction in CSF p-tau217 (Alzheimer's biomarker) vs placebo 
                            increase, suggesting potential neuroprotective effects. While exploratory, this could provide 
                            unique differentiation if confirmed in further studies.
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">No ‚Üë</div>
                            <div class="safety-label">Blood Pressure</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Liver Fat</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">GI Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Short</div>
                            <div class="safety-label">Half-life (no accumulation)</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Safety Advantages vs Prior CETP
                            </div>
                            <ul class="info-list">
                                <li>No blood pressure increase (vs torcetrapib)</li>
                                <li>No tissue accumulation (vs anacetrapib)</li>
                                <li>No electrolyte disturbances</li>
                                <li>Well-tolerated in trials</li>
                                <li>Main AEs: nausea, headache (mild)</li>
                                <li>Solved class safety issues</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$4,000/year</div>
                        <div style="color: #666; margin-bottom: 30px;">Projected pricing (similar to bempedoic acid)</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">2024/25</div>
                                <div class="projection-label">EU launch expected</div>
                            </div>
                            <div>
                                <div class="projection-value">Oral</div>
                                <div class="projection-label">Advantage vs injections</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Market Positioning</div>
                        <div class="highlight-content">
                            If approved before oral PCSK9 inhibitors, obicetrapib could capture the "next oral after 
                            statin+ezetimibe" position. Fixed-dose combination with ezetimibe offers ~50% LDL reduction 
                            in one pill. Different mechanism allows combination with PCSK9 inhibitors for extreme LDL lowering.
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- EVINACUMAB -->
        <div id="evinacumab" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Evinacumab (Evkeeza¬Æ)</div>
                <div class="drug-subtitle">ANGPTL3 Monoclonal Antibody</div>
                <div class="drug-company">Regeneron/Ultragenyx</div>
                <span class="status-badge">FDA/EMA Approved (HoFH Only)</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('evinacumab', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'clinical')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'commercial')">Commercial</button>
            </div>
            
            <div class="content-area">
                <div id="evinacumab-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üß¨</div>
                                Unique Features
                            </div>
                            <ul class="info-list">
                                <li>LDL receptor-independent mechanism</li>
                                <li>47% LDL reduction in HoFH</li>
                                <li>Works when PCSK9 inhibitors fail</li>
                                <li>Monthly IV infusion (15mg/kg)</li>
                                <li>Orphan drug designation</li>
                                <li>Only for homozygous FH</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üè•</div>
                                Clinical Niche
                            </div>
                            <ul class="info-list">
                                <li>HoFH prevalence: ~1 in 1 million</li>
                                <li>Approved age ‚â•12 years</li>
                                <li>Add-on to other therapies</li>
                                <li>132 mg/dL absolute LDL drop</li>
                                <li>Life-saving for extreme cases</li>
                                <li>Specialist administration only</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üí∞</div>
                                Economic Profile
                            </div>
                            <ul class="info-list">
                                <li>~$450,000/year list price</li>
                                <li>Ultra-orphan drug pricing</li>
                                <li>Insurance restricted to HoFH</li>
                                <li>Tiny commercial market</li>
                                <li>Not competitor to inclisiran</li>
                                <li>Complementary in extreme cases</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Relevance to Inclisiran</div>
                        <div class="highlight-content">
                            Evinacumab doesn't compete with inclisiran - it addresses cases where PCSK9 inhibition fails 
                            (null LDL receptors). Shows that different mechanisms (ANGPTL3) can lower LDL independently 
                            of LDLR, providing options for genetic conditions requiring orthogonal approaches. More 
                            complementary than competitive in the treatment landscape.
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Evinacumab blocks <span class="mechanism-highlight">ANGPTL3 (Angiopoietin-like 3)</span>, 
                            a protein that inhibits lipoprotein and endothelial lipases:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>LDL receptor-independent pathway</li>
                                <li>Enhanced clearance of VLDL remnants</li>
                                <li>Reduced conversion of VLDL to LDL</li>
                                <li>Dramatically lowers triglycerides</li>
                                <li>Works even with null LDL receptors</li>
                                <li>Complementary to PCSK9 inhibition</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Dose</div>
                            <div class="dosing-value">15 mg/kg</div>
                            <div class="dosing-detail">Weight-based</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Frequency</div>
                            <div class="dosing-value">Monthly</div>
                            <div class="dosing-detail">Every 4 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Route</div>
                            <div class="dosing-value">IV</div>
                            <div class="dosing-detail">60-min infusion</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Setting</div>
                            <div class="dosing-value">Clinic</div>
                            <div class="dosing-detail">Infusion center</div>
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-clinical" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">ELIPSE-HoFH Trial Results</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 47%;">
                                    <div class="bar-value">47%</div>
                                </div>
                                <div class="bar-label">LDL-C<br>Reduction</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 132%; max-height: 90%;">
                                    <div class="bar-value">132 mg/dL</div>
                                </div>
                                <div class="bar-label">Absolute<br>LDL Drop</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 50%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                    <div class="bar-value">50%</div>
                                </div>
                                <div class="bar-label">Triglyceride<br>Reduction</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">No Outcomes Trial</div>
                        <div class="highlight-content">
                            HoFH is too rare for outcomes studies. Efficacy judged on LDL reduction alone, as any 
                            substantial lowering in HoFH is assumed life-saving given extreme baseline risk. Regulatory 
                            approval based on surrogate endpoint was straightforward given unmet need.
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">Infusion Reactions</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Liver Fat ‚Üë</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">No</div>
                            <div class="safety-label">Muscle Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Good</div>
                            <div class="safety-label">Overall Tolerance</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Safety Profile
                            </div>
                            <ul class="info-list">
                                <li>Main AEs: infusion reactions (mild)</li>
                                <li>No liver enzyme elevation</li>
                                <li>No muscle toxicity</li>
                                <li>Unlike antisense, no liver fat increase</li>
                                <li>No vitamin deficiency seen</li>
                                <li>4 years post-approval, no new signals</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$450,000/year</div>
                        <div style="color: #666; margin-bottom: 30px;">Ultra-orphan drug pricing</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">~1/million</div>
                                <div class="projection-label">HoFH prevalence</div>
                            </div>
                            <div>
                                <div class="projection-value">Specialty</div>
                                <div class="projection-label">Lipid clinics only</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Not a Competitor</div>
                        <div class="highlight-content">
                            Evinacumab exemplifies targeting a different pathway (ANGPTL3) for cases where PCSK9/LDLR 
                            approaches fail. It's a highly specialized tool for rare genetic conditions, not a threat 
                            to inclisiran's mainstream market. Shows the diversity of mechanisms being explored in 
                            lipid management.
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showDrug(drugId) {
            // Hide all drug contents
            const drugContents = document.querySelectorAll('.drug-content');
            drugContents.forEach(content => content.classList.remove('active'));
            
            // Remove active class from all drug nav tabs
            const drugTabs = document.querySelectorAll('.drug-nav-tab');
            drugTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected drug content
            document.getElementById(drugId).classList.add('active');
            
            // Add active class to clicked drug tab
            event.target.classList.add('active');
            
            // Reset to first sub-tab when switching drugs
            const firstSubTab = document.querySelector(`#${drugId} .nav-tab`);
            if (firstSubTab) {
                firstSubTab.click();
            }
        }
        
        function showTab(drugId, tabName) {
            // Hide all tabs for this drug
            const tabs = document.querySelectorAll(`#${drugId} .tab-content`);
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs for this drug
            const navTabs = document.querySelectorAll(`#${drugId} .nav-tab`);
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(`${drugId}-${tabName}`).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>

<!-- VERVER -->

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>VERVE-101/102 - In Vivo Base Editing for PCSK9</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary: #0066CC;
            --primary-light: #E8F2FF;
            --success: #00A86B;
            --warning: #F39C12;
            --danger: #E74C3C;
            --text-primary: #2C3E50;
            --text-secondary: #7F8C8D;
            --border: #E1E8ED;
            --background: #FFFFFF;
            --background-alt: #F8FAFB;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.08);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 25px rgba(0,0,0,0.1);
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Inter', Roboto, sans-serif;
            background: var(--background-alt);
            color: var(--text-primary);
            line-height: 1.6;
            font-size: 14px;
        }
        
        /* Header */
        .header {
            background: white;
            border-bottom: 1px solid var(--border);
            padding: 16px 24px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: var(--shadow-sm);
        }
        
        .header-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .back-button {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: var(--background-alt);
            border: 1px solid var(--border);
            border-radius: 6px;
            color: var(--text-primary);
            text-decoration: none;
            font-size: 14px;
            transition: all 0.2s;
        }
        
        .back-button:hover {
            background: var(--primary-light);
            border-color: var(--primary);
            color: var(--primary);
        }
        
        .header-badges {
            display: flex;
            gap: 8px;
        }
        
        .status-badge {
            padding: 8px 16px;
            background: #FDEDEC;
            color: var(--danger);
            border: 1px solid var(--danger);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        .acquisition-badge {
            padding: 8px 16px;
            background: #E6F7ED;
            color: var(--success);
            border: 1px solid var(--success);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 24px;
        }
        
        /* Hero Section */
        .hero-section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 32px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .drug-title {
            margin-bottom: 24px;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .drug-company {
            font-size: 16px;
            color: var(--text-secondary);
            margin-bottom: 12px;
        }
        
        .drug-mechanism {
            display: inline-block;
            padding: 6px 16px;
            background: var(--primary-light);
            color: var(--primary);
            border-radius: 20px;
            font-size: 14px;
            font-weight: 500;
        }
        
        /* Stats Grid */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin-bottom: 24px;
        }
        
        .stat-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            box-shadow: var(--shadow-sm);
        }
        
        .stat-value {
            font-size: 24px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .stat-label {
            font-size: 12px;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        /* Navigation Tabs */
        .nav-tabs {
            display: flex;
            gap: 8px;
            margin-bottom: 24px;
            background: white;
            padding: 8px;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 10px 20px;
            background: transparent;
            border: none;
            border-radius: 6px;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.2s;
            font-size: 14px;
            font-weight: 500;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: var(--background-alt);
            color: var(--text-primary);
        }
        
        .nav-tab.active {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Tab Content */
        .tab-content {
            display: none;
        }
        
        .tab-content.active {
            display: block;
        }
        
        /* Section Styles */
        .section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 24px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .section-header {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }
        
        /* Alert Boxes */
        .alert {
            padding: 16px;
            border-radius: 6px;
            margin: 16px 0;
            display: flex;
            align-items: flex-start;
            gap: 12px;
        }
        
        .alert-danger {
            background: #FDEDEC;
            border: 1px solid var(--danger);
            color: #721C24;
        }
        
        .alert-warning {
            background: #FFF4E6;
            border: 1px solid var(--warning);
            color: #856404;
        }
        
        .alert-info {
            background: var(--primary-light);
            border: 1px solid var(--primary);
            color: var(--primary);
        }
        
        .alert-success {
            background: #E6F7ED;
            border: 1px solid var(--success);
            color: #155724;
        }
        
        .alert-icon {
            font-size: 16px;
            flex-shrink: 0;
        }
        
        .alert-content {
            flex: 1;
            font-size: 13px;
            line-height: 1.5;
        }
        
        /* Info Cards */
        .info-card {
            background: var(--background-alt);
            border-left: 4px solid var(--primary);
            padding: 16px;
            border-radius: 4px;
            margin-bottom: 16px;
        }
        
        .info-card h3 {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .info-card p,
        .info-card ul {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .info-card ul {
            margin-left: 20px;
            margin-top: 8px;
        }
        
        /* Process Steps */
        .process-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 16px;
            margin: 20px 0;
        }
        
        .process-step {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            text-align: center;
            position: relative;
            transition: all 0.2s;
        }
        
        .process-step:hover {
            box-shadow: var(--shadow-md);
            transform: translateY(-2px);
        }
        
        .step-number {
            position: absolute;
            top: -10px;
            left: 50%;
            transform: translateX(-50%);
            background: var(--primary);
            color: white;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 12px;
            font-weight: bold;
        }
        
        .step-title {
            font-size: 13px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
            margin-top: 8px;
        }
        
        .step-description {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Timeline */
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 12px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: var(--border);
        }
        
        .timeline-item {
            position: relative;
            padding-left: 40px;
            margin-bottom: 24px;
        }
        
        .timeline-dot {
            position: absolute;
            left: 4px;
            top: 4px;
            width: 18px;
            height: 18px;
            background: white;
            border: 3px solid var(--primary);
            border-radius: 50%;
        }
        
        .timeline-item.complete .timeline-dot {
            background: var(--primary);
        }
        
        .timeline-item.paused .timeline-dot {
            background: var(--danger);
            border-color: var(--danger);
        }
        
        .timeline-item.future .timeline-dot {
            border-style: dashed;
            background: var(--background-alt);
        }
        
        .timeline-content {
            background: var(--background-alt);
            padding: 12px 16px;
            border-radius: 6px;
            border: 1px solid var(--border);
        }
        
        .timeline-date {
            font-size: 12px;
            font-weight: 600;
            color: var(--primary);
            margin-bottom: 4px;
        }
        
        .timeline-title {
            font-size: 14px;
            color: var(--text-primary);
            font-weight: 500;
            margin-bottom: 4px;
        }
        
        .timeline-description {
            font-size: 12px;
            color: var(--text-secondary);
            margin-top: 4px;
        }
        
        /* Data Tables */
        .data-table {
            width: 100%;
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
            box-shadow: var(--shadow-sm);
        }
        
        .data-table thead {
            background: var(--background-alt);
        }
        
        .data-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 2px solid var(--border);
        }
        
        .data-table td {
            padding: 12px 16px;
            font-size: 13px;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }
        
        .data-table tbody tr:hover {
            background: var(--background-alt);
        }
        
        .data-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Comparison Table */
        .comparison-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 16px;
        }
        
        .comparison-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }
        
        .comparison-title {
            font-size: 16px;
            font-weight: 600;
            color: var(--text-primary);
        }
        
        /* Efficacy Chart */
        .efficacy-chart {
            background: var(--background-alt);
            padding: 20px;
            border-radius: 8px;
            margin-top: 16px;
        }
        
        .chart-container {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 200px;
            margin-top: 20px;
        }
        
        .chart-bar-wrapper {
            display: flex;
            flex-direction: column;
            align-items: center;
            flex: 1;
        }
        
        .chart-value {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .chart-bar {
            width: 60px;
            background: var(--primary);
            border-radius: 4px 4px 0 0;
            transition: all 0.3s;
        }
        
        .chart-bar.secondary {
            background: var(--text-secondary);
        }
        
        .chart-bar.success {
            background: var(--success);
        }
        
        .chart-bar.warning {
            background: var(--warning);
        }
        
        .chart-label {
            font-size: 11px;
            color: var(--text-secondary);
            text-align: center;
            margin-top: 8px;
        }
        
        /* Safety Grid */
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 12px;
            margin-top: 16px;
        }
        
        .safety-item {
            background: white;
            border: 1px solid var(--border);
            border-radius: 6px;
            padding: 12px;
            text-align: center;
        }
        
        .safety-item.resolved {
            border-left: 3px solid var(--success);
        }
        
        .safety-item.concern {
            border-left: 3px solid var(--danger);
        }
        
        .safety-item.monitoring {
            border-left: 3px solid var(--warning);
        }
        
        .safety-value {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .safety-label {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Badge */
        .badge {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
            margin-left: 8px;
        }
        
        .badge-danger {
            background: #FDEDEC;
            color: var(--danger);
        }
        
        .badge-warning {
            background: #FFF4E6;
            color: var(--warning);
        }
        
        .badge-success {
            background: #E6F7ED;
            color: var(--success);
        }
        
        .badge-info {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Pipeline Visual */
        .pipeline-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin: 20px 0;
        }
        
        .pipeline-item {
            background: white;
            border: 2px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            text-align: center;
            transition: all 0.2s;
        }
        
        .pipeline-item.active {
            border-color: var(--primary);
            background: var(--primary-light);
        }
        
        .pipeline-item:hover {
            box-shadow: var(--shadow-md);
            transform: translateY(-2px);
        }
        
        .pipeline-name {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .pipeline-target {
            font-size: 12px;
            color: var(--text-secondary);
            margin-bottom: 8px;
        }
        
        .pipeline-status {
            font-size: 11px;
            color: var(--primary);
            font-weight: 500;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .container {
                padding: 16px;
            }
            
            .drug-name {
                font-size: 24px;
            }
            
            .stats-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .process-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .nav-tabs {
                overflow-x: auto;
            }
            
            .pipeline-grid {
                grid-template-columns: 1fr;
            }
        }
        
        /* Links */
        a {
            color: var(--primary);
            text-decoration: none;
        }
        
        a:hover {
            text-decoration: underline;
        }
        
        .source-link {
            font-size: 11px;
            color: var(--primary);
            margin-left: 4px;
        }
    </style>
</head>
<body>
    
    <header class="header">
        <div class="header-content">
            <a href="index.html" class="back-button">
                ‚Üê Back to Dashboard
            </a>
            <div class="header-badges">
                <div class="status-badge">PHASE 1 - PAUSED/PIVOTED</div>
                <div class="acquisition-badge">LILLY ACQUISITION $1B</div>
            </div>
        </div>
    </header>

    <div class="container">
        <!-- Hero Section -->
        <div class="hero-section">
            <div class="drug-title">
                <h1 class="drug-name">VERVE-101 / VERVE-102</h1>
                <div class="drug-company">Verve Therapeutics ‚Üí Eli Lilly (Acquired July 25, 2025)</div>
                <div class="drug-mechanism">First-in-Class In Vivo Base Editing Therapy</div>
            </div>
            
            <div class="stats-grid">
                <div class="stat-card">
                    <div class="stat-value">One-Time</div>
                    <div class="stat-label">Treatment Paradigm</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">50-70%</div>
                    <div class="stat-label">LDL Reduction (Permanent)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">2028-2030</div>
                    <div class="stat-label">Potential Approval</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">$1-2M</div>
                    <div class="stat-label">Expected Price Range</div>
                </div>
            </div>
        </div>

        <!-- Navigation Tabs -->
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('technology')">Technology</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('future')">Future Outlook</button>
        </div>

        <!-- Overview Tab -->
        <div id="overview" class="tab-content active">
            <div class="alert alert-danger">
                <span class="alert-icon">üéØ</span>
                <div class="alert-content">
                    <strong>Paradigm Shift Alert:</strong> One-time IV infusion permanently inactivates PCSK9 gene in liver cells, potentially providing lifelong LDL-C reduction. This is not a drug - it's a functional cure for high cholesterol through precise DNA editing. <a href="https://fiercebiotech.com" class="source-link">[Source]</a>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Key Information</h2>
                
                <div class="info-card">
                    <h3>What is VERVE-101/102?</h3>
                    <p>An investigational gene-editing therapy using CRISPR-derived base-editing technology to permanently reduce cholesterol. It makes a single-letter change in the DNA of liver cells to turn off PCSK9 production forever.</p>
                    <ul>
                        <li>Uses adenine base editor (ABE) - no double-strand DNA breaks</li>
                        <li>Delivered via lipid nanoparticle (LNP) to liver</li>
                        <li>Single IV infusion intended to last a lifetime</li>
                        <li>Mimics natural PCSK9 mutations that protect against heart disease</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Current Status</h3>
                    <ul>
                        <li><strong>VERVE-101:</strong> Paused April 2024 due to safety concerns (liver enzyme elevation, low platelets)</li>
                        <li><strong>VERVE-102:</strong> Improved version with better LNP formulation, IND cleared March 2025</li>
                        <li><strong>Heart-2 Trial:</strong> Starting H2 2025 with VERVE-102</li>
                        <li><strong>Lilly Acquisition:</strong> Completed July 25, 2025 for ~$1 billion <a href="https://fiercebiotech.com" class="source-link">[Source]</a></li>
                    </ul>
                </div>

                <h3 style="margin-top: 24px; margin-bottom: 16px; font-size: 16px;">Pipeline Programs</h3>
                <div class="pipeline-grid">
                    <div class="pipeline-item active">
                        <div class="pipeline-name">VERVE-102</div>
                        <div class="pipeline-target">PCSK9 (HeFH/ASCVD)</div>
                        <div class="pipeline-status">Phase 1b/2 Starting</div>
                    </div>
                    <div class="pipeline-item">
                        <div class="pipeline-name">VERVE-201</div>
                        <div class="pipeline-target">ANGPTL3 (HoFH)</div>
                        <div class="pipeline-status">IND-Enabling</div>
                    </div>
                    <div class="pipeline-item">
                        <div class="pipeline-name">VERVE-301</div>
                        <div class="pipeline-target">Lp(a) Reduction</div>
                        <div class="pipeline-status">Research Stage</div>
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Competitive Positioning</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Approach</th>
                            <th>Frequency</th>
                            <th>LDL Reduction</th>
                            <th>Reversibility</th>
                            <th>Market Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr style="background: var(--primary-light);">
                            <td><strong>VERVE Gene Editing</strong></td>
                            <td>Once lifetime</td>
                            <td>50-70%</td>
                            <td>Irreversible</td>
                            <td>2028-2030</td>
                        </tr>
                        <tr>
                            <td>Inclisiran (siRNA)</td>
                            <td>2x/year</td>
                            <td>50%</td>
                            <td>Reversible</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>PCSK9 mAbs</td>
                            <td>Monthly</td>
                            <td>60%</td>
                            <td>Reversible</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>Oral PCSK9i</td>
                            <td>Daily</td>
                            <td>60%</td>
                            <td>Reversible</td>
                            <td>2026-2027</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Technology Tab -->
        <div id="technology" class="tab-content">
            <div class="section">
                <h2 class="section-header">How Base Editing Works</h2>
                
                <div class="process-grid">
                    <div class="process-step">
                        <div class="step-number">1</div>
                        <div class="step-title">Delivery</div>
                        <div class="step-description">LNP carries mRNA for base editor + guide RNA to liver via IV</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">2</div>
                        <div class="step-title">Targeting</div>
                        <div class="step-description">Guide RNA directs editor to PCSK9 gene in hepatocytes</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">3</div>
                        <div class="step-title">Editing</div>
                        <div class="step-description">ABE makes precise A‚ÜíG change without cutting DNA</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">4</div>
                        <div class="step-title">Result</div>
                        <div class="step-description">Introduces stop codon, halting PCSK9 production</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">5</div>
                        <div class="step-title">Effect</div>
                        <div class="step-description">50-70% of liver cells edited, 80-90% PCSK9‚Üì</div>
                    </div>
                    <div class="process-step">
                        <div class="step-number">6</div>
                        <div class="step-title">Outcome</div>
                        <div class="step-description">50-70% LDL reduction sustained indefinitely</div>
                    </div>
                </div>

                <div class="info-card">
                    <h3>Technical Specifications</h3>
                    <ul>
                        <li><strong>Editor Type:</strong> Adenine Base Editor (ABE) - Cas9 nickase + TadA deaminase</li>
                        <li><strong>Target:</strong> PCSK9 gene exon 1 - introduces premature stop codon</li>
                        <li><strong>Delivery:</strong> Liver-targeted LNP (similar to COVID vaccines but optimized)</li>
                        <li><strong>Editing Efficiency:</strong> 50-70% of hepatocytes at therapeutic doses</li>
                        <li><strong>Off-target Rate:</strong> <0.1% genome-wide (WGS validated)</li>
                        <li><strong>Germline Risk:</strong> Minimal - no gonadal LNP distribution shown <a href="https://fiercebiotech.com" class="source-link">[Source]</a></li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">VERVE-101 vs VERVE-102</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Feature</th>
                            <th>VERVE-101</th>
                            <th>VERVE-102 (Improved)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>LNP Formulation</strong></td>
                            <td>First-generation LNP</td>
                            <td>GalNAc-conjugated (enhanced liver targeting)</td>
                        </tr>
                        <tr>
                            <td><strong>Status</strong></td>
                            <td><span class="badge badge-danger">Paused April 2024</span></td>
                            <td><span class="badge badge-success">IND Cleared March 2025</span></td>
                        </tr>
                        <tr>
                            <td><strong>Tolerability</strong></td>
                            <td>Grade 3 ALT elevations, thrombocytopenia</td>
                            <td>Expected improved safety profile</td>
                        </tr>
                        <tr>
                            <td><strong>Dosing</strong></td>
                            <td>0.1-0.6 mg/kg tested</td>
                            <td>Potentially lower doses needed</td>
                        </tr>
                        <tr>
                            <td><strong>Trial</strong></td>
                            <td>Heart-1 (paused)</td>
                            <td>Heart-2 (starting H2 2025)</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Regulatory Tab -->
        <div id="regulatory" class="tab-content">
            <div class="section">
                <h2 class="section-header">FDA Regulatory Timeline</h2>
                
                <div class="alert alert-warning">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        As the first in vivo base editing therapy, VERVE faces unprecedented regulatory scrutiny. Every step sets precedent for the entire field.
                    </div>
                </div>
                
                <div class="timeline">
                    <div class="timeline-line"></div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">October 2022</div>
                            <div class="timeline-title">IND Submission</div>
                            <div class="timeline-description">First IND for in vivo base editing submitted to FDA</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">November 2022</div>
                            <div class="timeline-title">FDA Clinical Hold</div>
                            <div class="timeline-description">Concerns: germline editing, off-targets, potency, LNP safety <a href="https://fiercebiotech.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">2022-2023</div>
                            <div class="timeline-title">Ex-US Trial Start</div>
                            <div class="timeline-description">Trials began in New Zealand and UK while FDA hold active</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">October 2023</div>
                            <div class="timeline-title">FDA Hold Lifted</div>
                            <div class="timeline-description">Comprehensive safety data satisfied FDA concerns <a href="https://fiercebiotech.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">April 2024</div>
                            <div class="timeline-title">Voluntary Pause</div>
                            <div class="timeline-description">Heart-1 paused due to Grade 3 ALT elevation and thrombocytopenia</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">March 2025</div>
                            <div class="timeline-title">VERVE-102 IND Cleared</div>
                            <div class="timeline-description">FDA approves improved version with better LNP</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">July 25, 2025</div>
                            <div class="timeline-title">Lilly Acquisition</div>
                            <div class="timeline-description">$1B deal complete, enhanced resources <a href="https://biopharmadive.com" class="source-link">[Source]</a></div>
                        </div>
                    </div>
                    
                    <div class="timeline-item future">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">H2 2025</div>
                            <div class="timeline-title">Heart-2 Start</div>
                            <div class="timeline-description">Phase 1b/2 trial initiation expected</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item future">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">2028-2030</div>
                            <div class="timeline-title">Potential BLA</div>
                            <div class="timeline-description">If Phase 3 successful, multi-year follow-up required</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Global Regulatory Status</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Region</th>
                            <th>Status</th>
                            <th>Key Events</th>
                            <th>Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>FDA (US)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>Hold lifted, VERVE-102 IND cleared</td>
                            <td>BLA ~2028-2030</td>
                        </tr>
                        <tr>
                            <td><strong>EMA (EU)</strong></td>
                            <td><span class="badge badge-warning">Pre-clinical</span></td>
                            <td>No hold, more permissive initially</td>
                            <td>MAA ~2030</td>
                        </tr>
                        <tr>
                            <td><strong>MHRA (UK)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>First to approve human trials</td>
                            <td>Active sites</td>
                        </tr>
                        <tr>
                            <td><strong>Medsafe (NZ)</strong></td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>Enabled first-in-human dosing</td>
                            <td>Active sites</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Clinical Trials Tab -->
        <div id="clinical" class="tab-content">
            <div class="section">
                <h2 class="section-header">Clinical Development Program</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Status</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Preclinical</strong></td>
                            <td>Pre</td>
                            <td>~50</td>
                            <td>Non-human primates</td>
                            <td>Complete</td>
                            <td>89% PCSK9‚Üì, 69% LDL‚Üì >2.5yr <a href="https://fiercebiotech.com" class="source-link">[Source]</a></td>
                        </tr>
                        <tr>
                            <td><strong>Heart-1</strong><br>(NCT05398029)</td>
                            <td>1b</td>
                            <td>44 planned<br>~12 dosed</td>
                            <td>HeFH/ASCVD</td>
                            <td><span class="badge badge-danger">Paused</span></td>
                            <td>83% PCSK9‚Üì, 55% LDL‚Üì<br>Safety issues at 0.6 mg/kg</td>
                        </tr>
                        <tr>
                            <td><strong>Heart-2</strong><br>(VERVE-102)</td>
                            <td>1b/2</td>
                            <td>~100</td>
                            <td>HeFH/CAD</td>
                            <td><span class="badge badge-info">Starting H2 2025</span></td>
                            <td>‚Äî</td>
                        </tr>
                        <tr>
                            <td><strong>Long-term Registry</strong></td>
                            <td>4</td>
                            <td>All pts</td>
                            <td>All treated</td>
                            <td>Ongoing</td>
                            <td>5-15 year follow-up planned</td>
                        </tr>
                    </tbody>
                </table>

                <div class="alert alert-info">
                    <span class="alert-icon">üìä</span>
                    <div class="alert-content">
                        <strong>No CV Outcomes Trials Yet:</strong> Approval will rely on LDL-C as surrogate endpoint with post-marketing outcomes commitment. Expected 50-80% lifetime MACE reduction if given early, based on genetic data.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Efficacy Results</h2>
                
                <div class="efficacy-chart">
                    <h3 style="font-size: 14px; margin-bottom: 16px;">Heart-1 Interim Data (High Dose Cohort)</h3>
                    <div class="chart-container">
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">83%</div>
                            <div class="chart-bar" style="height: 83%;"></div>
                            <div class="chart-label">PCSK9<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">55%</div>
                            <div class="chart-bar" style="height: 55%;"></div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Day 180)</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">46%</div>
                            <div class="chart-bar" style="height: 46%;"></div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Low dose)</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">45%</div>
                            <div class="chart-bar secondary" style="height: 45%;"></div>
                            <div class="chart-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">30%</div>
                            <div class="chart-bar warning" style="height: 30%;"></div>
                            <div class="chart-label">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">88%</div>
                            <div class="chart-bar success" style="height: 88%;"></div>
                            <div class="chart-label">Projected<br>CAD Risk‚Üì</div>
                        </div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 20px;">
                    <h3>Durability Profile</h3>
                    <ul>
                        <li><strong>Primate Data:</strong> >2.5 years sustained effect with no rebound</li>
                        <li><strong>Human Projection:</strong> Expected lifelong effect from single infusion</li>
                        <li><strong>Editing Coverage:</strong> 50-70% hepatocytes edited at therapeutic doses</li>
                        <li><strong>Genetic Comparison:</strong> Mimics PCSK9 R46L carriers (88% lower CAD risk)</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Safety Tab -->
        <div id="safety" class="tab-content">
            <div class="section">
                <h2 class="section-header">Safety Profile</h2>
                
                <div class="alert alert-danger">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>Critical Safety Event:</strong> Heart-1 paused April 2024 due to Grade 3 ALT elevation and thrombocytopenia at 0.6 mg/kg dose. Led to complete redesign with VERVE-102.
                    </div>
                </div>
                
                <div class="safety-grid">
                    <div class="safety-item concern">
                        <div class="safety-value">Grade 3</div>
                        <div class="safety-label">ALT Elevation<br>(Led to pause)</div>
                    </div>
                    <div class="safety-item concern">
                        <div class="safety-value">Low Platelets</div>
                        <div class="safety-label">Thrombocytopenia<br>(0.6 mg/kg)</div>
                    </div>
                    <div class="safety-item resolved">
                        <div class="safety-value"><0.1%</div>
                        <div class="safety-label">Off-Target Edits<br>(WGS validated)</div>
                    </div>
                    <div class="safety-item resolved">
                        <div class="safety-value">Minimal</div>
                        <div class="safety-label">Germline Risk<br>(No gonadal uptake)</div>
                    </div>
                    <div class="safety-item monitoring">
                        <div class="safety-value">70%</div>
                        <div class="safety-label">Pre-existing Anti-Cas9<br>(Managed w/ steroids)</div>
                    </div>
                    <div class="safety-item monitoring">
                        <div class="safety-value">20-30%</div>
                        <div class="safety-label">Infusion Reactions<br>(Mild, transient)</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Long-term Monitoring Requirements</h3>
                    <ul>
                        <li><strong>5-15 Year Follow-up:</strong> All patients in mandatory registry</li>
                        <li><strong>Cancer Surveillance:</strong> Annual screening for hepatocellular carcinoma</li>
                        <li><strong>Genomic Monitoring:</strong> Periodic WGS for emergent off-targets</li>
                        <li><strong>Liver Function:</strong> Quarterly LFTs year 1, then biannual</li>
                        <li><strong>Reproductive Health:</strong> Counseling on theoretical germline risks</li>
                    </ul>
                </div>

                <div class="alert alert-success" style="margin-top: 20px;">
                    <span class="alert-icon">‚úì</span>
                    <div class="alert-content">
                        <strong>Safety Advantages vs Other Gene Therapies:</strong>
                        No double-strand DNA breaks (unlike CRISPR), no viral vectors, liver-specific targeting, single nucleotide change only, precedent from healthy PCSK9 LOF humans.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Brain Safety & Low Cholesterol</h2>
                
                <div class="info-card">
                    <h3>No Cognitive Risk Expected</h3>
                    <p>PCSK9 inhibition doesn't cross blood-brain barrier. Brain cholesterol is synthesized independently from plasma LDL.</p>
                    <ul>
                        <li>Genetic PCSK9 knockouts show no cognitive deficits</li>
                        <li>Meta-analyses of PCSK9 inhibitors (LDL <20 mg/dL) show no dementia risk over 5+ years</li>
                        <li>All trials monitor neurocognition - no signals reported</li>
                        <li>EBBINGHAUS study (evolocumab) confirmed cognitive safety</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Commercial Tab -->
        <div id="commercial" class="tab-content">
            <div class="section">
                <h2 class="section-header">Pricing & Market Strategy</h2>
                
                <div class="alert alert-warning">
                    <span class="alert-icon">üí∞</span>
                    <div class="alert-content">
                        <strong>Expected Pricing:</strong> $1-2 million upfront, justified by lifetime benefit vs ~$100K+ in chronic drugs/events over decades. Payment models likely include annuities, outcomes-based rebates.
                    </div>
                </div>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-value">~1M</div>
                        <div class="stat-label">US HeFH/ASCVD Patients</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">30-50%</div>
                        <div class="stat-label">Initial Approval Rate</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">15-20 yrs</div>
                        <div class="stat-label">Break-even vs Chronic Rx</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">$2-3B</div>
                        <div class="stat-label">Peak Sales (Base Case)</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Reimbursement Challenges</h3>
                    <ul>
                        <li><strong>High upfront cost:</strong> Budget impact concerns for payers</li>
                        <li><strong>Insurance churn:</strong> Patient may switch insurers after cure</li>
                        <li><strong>Irreversibility:</strong> Ethical and practical concerns</li>
                        <li><strong>Prior auth:</strong> Extensive documentation, step therapy failures required</li>
                        <li><strong>Coverage restrictions:</strong> Initially only severe cases with multiple therapy failures</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Delivery Infrastructure</h3>
                    <ul>
                        <li>Initially at specialized centers (like CAR-T model)</li>
                        <li>Medical benefit, not pharmacy</li>
                        <li>Eventually may expand to infusion centers</li>
                        <li>Requires long-term follow-up infrastructure</li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Market Scenarios</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Timeframe</th>
                            <th>Conservative</th>
                            <th>Base Case</th>
                            <th>Optimistic</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>2025-2027</strong></td>
                            <td>Clinical trials only</td>
                            <td>Phase 2/3 progression</td>
                            <td>Accelerated approval pathway</td>
                        </tr>
                        <tr>
                            <td><strong>2028-2030</strong></td>
                            <td>Limited HoFH approval</td>
                            <td>HeFH approval, slow uptake</td>
                            <td>Broad HeFH use, ASCVD trials</td>
                        </tr>
                        <tr>
                            <td><strong>2030-2035</strong></td>
                            <td>Niche for severe cases</td>
                            <td>Standard for genetic dyslipidemia</td>
                            <td>Primary prevention consideration</td>
                        </tr>
                        <tr>
                            <td><strong>Peak Sales</strong></td>
                            <td>$500M</td>
                            <td>$2-3B</td>
                            <td>$5B+</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Future Outlook Tab -->
        <div id="future" class="tab-content">
            <div class="section">
                <h2 class="section-header">Critical Success Factors</h2>
                
                <div class="info-card">
                    <h3>What Must Go Right</h3>
                    <ul>
                        <li><strong>Safety Validation:</strong> No long-term adverse effects over 5+ years</li>
                        <li><strong>Efficacy Durability:</strong> Truly permanent LDL reduction demonstrated</li>
                        <li><strong>Manufacturing Scale:</strong> Consistent, scalable production achieved</li>
                        <li><strong>Regulatory Alignment:</strong> FDA/EMA satisfied with safety profile</li>
                        <li><strong>Payer Acceptance:</strong> Sustainable reimbursement models developed</li>
                        <li><strong>Public Trust:</strong> "Gene editing" fears overcome through transparency</li>
                    </ul>
                </div>

                <div class="alert alert-danger" style="margin-top: 20px;">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>Key Risks:</strong> Unknown long-term effects, potential for delayed adverse events, regulatory delays, public/physician resistance to irreversible therapy, competition from safer/simpler approaches.
                    </div>
                </div>

                <div class="alert alert-success" style="margin-top: 20px;">
                    <span class="alert-icon">‚úì</span>
                    <div class="alert-content">
                        <strong>Why Lilly's Acquisition Makes Sense:</strong> Hedging across entire PCSK9 landscape, access to transformative technology, leverage existing CV infrastructure, first-mover in gene editing for common diseases, platform potential beyond PCSK9.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Precedents & Competition</h2>
                
                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">Casgevy (Vertex/CRISPR)</div>
                        <span class="badge badge-success">FDA/EMA 2023</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        First CRISPR therapy approved for sickle cell. Price: $2.2M. Ex vivo editing (not in vivo like VERVE). 
                        Shows regulatory pathway possible, high price accepted for genetic diseases.
                    </p>
                </div>

                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">NTLA-2001 (Intellia)</div>
                        <span class="badge badge-info">Phase 3</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        In vivo CRISPR for ATTR amyloidosis. 87% TTR reduction, no major safety issues. 
                        Most similar precedent - shows in vivo editing feasible.
                    </p>
                </div>

                <div class="comparison-card">
                    <div class="comparison-header">
                        <div class="comparison-title">Zolgensma (Novartis)</div>
                        <span class="badge badge-success">FDA/EMA 2019</span>
                    </div>
                    <p style="font-size: 13px; color: var(--text-secondary);">
                        One-time AAV gene therapy for SMA. Price: $2.1M. 
                        Payer acceptance of high-cost cures, but 20-30% abandonment rate.
                    </p>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Bottom Line Assessment</h2>
                
                <div class="info-card" style="background: linear-gradient(135deg, #E8F2FF 0%, #F8FAFB 100%); border-left-color: var(--primary); border-left-width: 4px;">
                    <h3>Strategic Outlook</h3>
                    <p style="line-height: 1.8;">
                        <strong>Near-term (2025-2027):</strong> Minimal commercial impact - still in trials<br>
                        <strong>Medium-term (2028-2030):</strong> Potential approval for severe genetic dyslipidemia<br>
                        <strong>Long-term (2030+):</strong> Could revolutionize CV prevention if safety proven<br><br>
                        <strong>Probability of Success:</strong> ~40-50% for HeFH indication by 2030<br>
                        <strong>Market Disruption:</strong> Extreme if successful, minimal if safety issues emerge<br>
                        <strong>Strategic Value:</strong> Critical optionality for future of lipid management
                    </p>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Mark nav tab as active
            event.target.classList.add('active');
        }
        
        // Animate elements on scroll
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    // Animate chart bars
                    const chartBars = entry.target.querySelectorAll('.chart-bar');
                    chartBars.forEach((bar, index) => {
                        const height = bar.style.height;
                        bar.style.height = '0';
                        setTimeout(() => {
                            bar.style.height = height;
                        }, index * 100);
                    });
                    
                    observer.unobserve(entry.target);
                }
            });
        }, { threshold: 0.1 });
        
        // Observe all sections
        document.querySelectorAll('.section').forEach(section => {
            observer.observe(section);
        });
    </script>
</body>
</html>

<!-- EVAHASFHAI -->

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ebronucimab (AK102) - PCSK9 Monoclonal Antibody</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary: #0066CC;
            --primary-light: #E8F2FF;
            --success: #00A86B;
            --warning: #F39C12;
            --danger: #E74C3C;
            --text-primary: #2C3E50;
            --text-secondary: #7F8C8D;
            --border: #E1E8ED;
            --background: #FFFFFF;
            --background-alt: #F8FAFB;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.08);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 25px rgba(0,0,0,0.1);
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Inter', Roboto, sans-serif;
            background: var(--background-alt);
            color: var(--text-primary);
            line-height: 1.6;
            font-size: 14px;
        }
        
        /* Header */
        .header {
            background: white;
            border-bottom: 1px solid var(--border);
            padding: 16px 24px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: var(--shadow-sm);
        }
        
        .header-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .back-button {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: var(--background-alt);
            border: 1px solid var(--border);
            border-radius: 6px;
            color: var(--text-primary);
            text-decoration: none;
            font-size: 14px;
            transition: all 0.2s;
        }
        
        .back-button:hover {
            background: var(--primary-light);
            border-color: var(--primary);
            color: var(--primary);
        }
        
        .status-badge {
            padding: 8px 16px;
            background: #E6F7ED;
            color: var(--success);
            border: 1px solid var(--success);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 24px;
        }
        
        /* Hero Section */
        .hero-section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 32px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .drug-title {
            margin-bottom: 24px;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .drug-company {
            font-size: 16px;
            color: var(--text-secondary);
            margin-bottom: 12px;
        }
        
        .drug-mechanism {
            display: inline-block;
            padding: 6px 16px;
            background: var(--primary-light);
            color: var(--primary);
            border-radius: 20px;
            font-size: 14px;
            font-weight: 500;
        }
        
        /* Quick Stats Grid */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin-bottom: 24px;
        }
        
        .stat-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            box-shadow: var(--shadow-sm);
        }
        
        .stat-value {
            font-size: 24px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .stat-label {
            font-size: 12px;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        /* Navigation Tabs */
        .nav-tabs {
            display: flex;
            gap: 8px;
            margin-bottom: 24px;
            background: white;
            padding: 8px;
            border-radius: 8px;
            border: 1px solid var(--border);
        }
        
        .nav-tab {
            padding: 10px 20px;
            background: transparent;
            border: none;
            border-radius: 6px;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.2s;
            font-size: 14px;
            font-weight: 500;
        }
        
        .nav-tab:hover {
            background: var(--background-alt);
            color: var(--text-primary);
        }
        
        .nav-tab.active {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Tab Content */
        .tab-content {
            display: none;
        }
        
        .tab-content.active {
            display: block;
        }
        
        /* Section Styles */
        .section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 24px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .section-header {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }
        
        /* Info Cards */
        .info-card {
            background: var(--background-alt);
            border-left: 4px solid var(--primary);
            padding: 16px;
            border-radius: 4px;
            margin-bottom: 16px;
        }
        
        .info-card h3 {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .info-card p,
        .info-card ul {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .info-card ul {
            margin-left: 20px;
            margin-top: 8px;
        }
        
        /* Dosing Cards */
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 16px;
            margin-top: 16px;
        }
        
        .dosing-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 20px;
            text-align: center;
            transition: all 0.2s;
        }
        
        .dosing-card:hover {
            box-shadow: var(--shadow-md);
            border-color: var(--primary);
        }
        
        .dosing-card.featured {
            border: 2px solid var(--primary);
            background: var(--primary-light);
        }
        
        .dosing-frequency {
            font-size: 28px;
            font-weight: 700;
            color: var(--primary);
            margin-bottom: 8px;
        }
        
        .dosing-details {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .dosing-details strong {
            color: var(--text-primary);
            display: block;
            margin-bottom: 4px;
        }
        
        /* Timeline */
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 12px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: var(--border);
        }
        
        .timeline-item {
            position: relative;
            padding-left: 40px;
            margin-bottom: 24px;
        }
        
        .timeline-dot {
            position: absolute;
            left: 4px;
            top: 4px;
            width: 18px;
            height: 18px;
            background: white;
            border: 3px solid var(--primary);
            border-radius: 50%;
        }
        
        .timeline-item.complete .timeline-dot {
            background: var(--primary);
        }
        
        .timeline-content {
            background: var(--background-alt);
            padding: 12px 16px;
            border-radius: 6px;
            border: 1px solid var(--border);
        }
        
        .timeline-date {
            font-size: 12px;
            font-weight: 600;
            color: var(--primary);
            margin-bottom: 4px;
        }
        
        .timeline-title {
            font-size: 14px;
            color: var(--text-primary);
            font-weight: 500;
        }
        
        .timeline-description {
            font-size: 12px;
            color: var(--text-secondary);
            margin-top: 4px;
        }
        
        /* Data Tables */
        .data-table {
            width: 100%;
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
            box-shadow: var(--shadow-sm);
        }
        
        .data-table thead {
            background: var(--background-alt);
        }
        
        .data-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 2px solid var(--border);
        }
        
        .data-table td {
            padding: 12px 16px;
            font-size: 13px;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }
        
        .data-table tbody tr:hover {
            background: var(--background-alt);
        }
        
        .data-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Efficacy Chart */
        .efficacy-chart {
            background: var(--background-alt);
            padding: 20px;
            border-radius: 8px;
            margin-top: 16px;
        }
        
        .chart-container {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 200px;
            margin-top: 20px;
        }
        
        .chart-bar-wrapper {
            display: flex;
            flex-direction: column;
            align-items: center;
            flex: 1;
        }
        
        .chart-value {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .chart-bar {
            width: 60px;
            background: var(--primary);
            border-radius: 4px 4px 0 0;
            transition: all 0.3s;
            position: relative;
        }
        
        .chart-bar:hover {
            opacity: 0.8;
        }
        
        .chart-bar.secondary {
            background: var(--text-secondary);
        }
        
        .chart-bar.success {
            background: var(--success);
        }
        
        .chart-label {
            font-size: 11px;
            color: var(--text-secondary);
            text-align: center;
            margin-top: 8px;
        }
        
        /* Safety Grid */
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 12px;
            margin-top: 16px;
        }
        
        .safety-item {
            background: white;
            border: 1px solid var(--border);
            border-radius: 6px;
            padding: 12px;
            text-align: center;
        }
        
        .safety-value {
            font-size: 20px;
            font-weight: 600;
            color: var(--success);
            margin-bottom: 4px;
        }
        
        .safety-label {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Alert Boxes */
        .alert {
            padding: 12px 16px;
            border-radius: 6px;
            margin: 16px 0;
            display: flex;
            align-items: flex-start;
            gap: 12px;
        }
        
        .alert-warning {
            background: #FFF4E6;
            border: 1px solid var(--warning);
            color: #856404;
        }
        
        .alert-info {
            background: var(--primary-light);
            border: 1px solid var(--primary);
            color: var(--primary);
        }
        
        .alert-icon {
            font-size: 16px;
        }
        
        .alert-content {
            flex: 1;
            font-size: 13px;
            line-height: 1.5;
        }
        
        /* Badge */
        .badge {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
            margin-left: 8px;
        }
        
        .badge-warning {
            background: #FFF4E6;
            color: var(--warning);
        }
        
        .badge-success {
            background: #E6F7ED;
            color: var(--success);
        }
        
        /* Progress Bars */
        .progress-bar {
            background: var(--border);
            height: 8px;
            border-radius: 4px;
            overflow: hidden;
            margin: 8px 0;
        }
        
        .progress-fill {
            height: 100%;
            background: var(--primary);
            transition: width 0.5s ease;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .container {
                padding: 16px;
            }
            
            .drug-name {
                font-size: 24px;
            }
            
            .stats-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .dosing-grid {
                grid-template-columns: 1fr;
            }
            
            .nav-tabs {
                overflow-x: auto;
            }
        }
    </style>
</head>
<body>
    
    <header class="header">
        <div class="header-content">
            <a href="index.html" class="back-button">
                ‚Üê Back to Dashboard
            </a>
            <div class="status-badge">NMPA APPROVED 2024</div>
        </div>
    </header>

    <div class="container">
        <!-- Hero Section -->
        <div class="hero-section">
            <div class="drug-title">
                <h1 class="drug-name">Ebronucimab (AK102)</h1>
                <div class="drug-company">Akeso Inc. ‚Ä¢ China</div>
                <div class="drug-mechanism">PCSK9 Monoclonal Antibody</div>
            </div>
            
            <div class="stats-grid">
                <div class="stat-card">
                    <div class="stat-value">65%</div>
                    <div class="stat-label">Max LDL Reduction</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">Q6W</div>
                    <div class="stat-label">Best Dosing Option</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">8-9</div>
                    <div class="stat-label">Injections/Year (Q6W)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">China Only</div>
                    <div class="stat-label">Current Availability</div>
                </div>
            </div>
        </div>

        <!-- Navigation Tabs -->
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Data</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
        </div>

        <!-- Overview Tab -->
        <div id="overview" class="tab-content active">
            <div class="section">
                <h2 class="section-header">Key Information</h2>
                
                <div class="info-card">
                    <h3>Mechanism of Action</h3>
                    <p>Fully human IgG1 monoclonal antibody that binds circulating PCSK9, preventing LDL receptor degradation. This leads to:</p>
                    <ul>
                        <li>Increased hepatic LDL receptor expression</li>
                        <li>Enhanced LDL-C clearance from circulation</li>
                        <li>50-70% LDL-C reduction within 1-2 weeks</li>
                        <li>Minimal impact on triglycerides or HDL-C</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Target Population</h3>
                    <p>Adults with primary hypercholesterolemia (including HeFH) and mixed dyslipidemia who:</p>
                    <ul>
                        <li>Are on maximally tolerated statin therapy</li>
                        <li>Are statin-intolerant</li>
                        <li>Require additional LDL-C reduction beyond current therapy</li>
                    </ul>
                </div>

                <h3 style="margin-top: 24px; margin-bottom: 16px; font-size: 16px; color: var(--text-primary);">Dosing Regimens</h3>
                <div class="dosing-grid">
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q2W</div>
                        <div class="dosing-details">
                            <strong>150 mg</strong>
                            Every 2 weeks<br>
                            26 injections/year<br>
                            65% LDL reduction
                        </div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q4W</div>
                        <div class="dosing-details">
                            <strong>300-450 mg</strong>
                            Monthly<br>
                            12 injections/year<br>
                            66% LDL reduction
                        </div>
                    </div>
                    <div class="dosing-card featured">
                        <div class="dosing-frequency">Q6W ‚≠ê</div>
                        <div class="dosing-details">
                            <strong>420-450 mg</strong>
                            Every 6 weeks<br>
                            8-9 injections/year<br>
                            60% LDL reduction<br>
                            <em style="color: var(--primary);">Key differentiator</em>
                        </div>
                    </div>
                </div>

                <div class="alert alert-info" style="margin-top: 24px;">
                    <span class="alert-icon">üí°</span>
                    <div class="alert-content">
                        <strong>Competitive Positioning:</strong> Q6W dosing offers better convenience than biweekly mAbs (26 injections/year) but still requires more injections than inclisiran (2/year). Success depends on aggressive pricing and securing reimbursement through China's NRDL.
                    </div>
                </div>
            </div>
        </div>

        <!-- Clinical Data Tab -->
        <div id="clinical" class="tab-content">
            <div class="section">
                <h2 class="section-header">Clinical Trials Overview</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Duration</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Dose Escalation</strong></td>
                            <td>I</td>
                            <td>~100</td>
                            <td>Healthy volunteers</td>
                            <td>8 weeks</td>
                            <td>Safety/PK/PD</td>
                            <td>LDL ‚Üì70% (single dose)</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-301</strong></td>
                            <td>III</td>
                            <td>480</td>
                            <td>Primary HC/Mixed</td>
                            <td>52 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>65-66% reduction</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-302</strong></td>
                            <td>III</td>
                            <td>264</td>
                            <td>HeFH</td>
                            <td>12 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>60-65% reduction</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-303</strong></td>
                            <td>III</td>
                            <td>360</td>
                            <td>Primary HC (Q6W)</td>
                            <td>12 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>60% reduction (Q6W)</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-304</strong></td>
                            <td>III</td>
                            <td>240</td>
                            <td>High-risk HC</td>
                            <td>12 weeks</td>
                            <td>% LDL reduction</td>
                            <td>~65% reduction</td>
                        </tr>
                    </tbody>
                </table>

                <div class="alert alert-warning" style="margin-top: 20px;">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>No CV Outcomes Data:</strong> All trials used LDL-C as surrogate endpoint. No MACE reduction studies completed or ongoing. Approval based on biomarker efficacy similar to initial PCSK9 mAb approvals.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Efficacy Profile</h2>
                
                <div class="efficacy-chart">
                    <h3 style="font-size: 14px; margin-bottom: 16px;">LDL-C Reduction by Dosing Regimen</h3>
                    <div class="chart-container">
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">65%</div>
                            <div class="chart-bar" style="height: 65%;"></div>
                            <div class="chart-label">Q2W<br>150mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">66%</div>
                            <div class="chart-bar" style="height: 66%;"></div>
                            <div class="chart-label">Q4W<br>450mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">60%</div>
                            <div class="chart-bar" style="height: 60%;"></div>
                            <div class="chart-label">Q6W<br>420mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">50%</div>
                            <div class="chart-bar secondary" style="height: 50%;"></div>
                            <div class="chart-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">80-90%</div>
                            <div class="chart-bar success" style="height: 85%;"></div>
                            <div class="chart-label">Achieved<br>&lt;70 mg/dL</div>
                        </div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 20px;">
                    <h3>Key Efficacy Points</h3>
                    <ul>
                        <li>Consistent 60-66% LDL reduction across all dosing regimens</li>
                        <li>80-90% of patients achieved guideline LDL goals (&lt;70 mg/dL)</li>
                        <li>Sustained efficacy over 52 weeks in long-term extension</li>
                        <li>Q6W dosing maintains smooth LDL control without trough spikes</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Regulatory Tab -->
        <div id="regulatory" class="tab-content">
            <div class="section">
                <h2 class="section-header">Regulatory Timeline</h2>
                
                <div class="timeline">
                    <div class="timeline-line"></div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">November 2018</div>
                            <div class="timeline-title">Phase I Completion</div>
                            <div class="timeline-description">Safety and PK/PD established, up to 70% LDL reduction with single dose</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">December 2021</div>
                            <div class="timeline-title">Phase III Enrollment Complete</div>
                            <div class="timeline-description">All four pivotal trials fully enrolled</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">May 2023</div>
                            <div class="timeline-title">Phase III Results Announced</div>
                            <div class="timeline-description">60-66% LDL reduction demonstrated across regimens</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">June 2, 2023</div>
                            <div class="timeline-title">NDA Accepted by NMPA</div>
                            <div class="timeline-description">Application for hypercholesterolemia accepted for review</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">September 30, 2024</div>
                            <div class="timeline-title"><strong>APPROVAL GRANTED</strong></div>
                            <div class="timeline-description">Approved based on four Phase III trials. Trade name: ‰ºäÂñúÂÆÅ (Yixining)</div>
                        </div>
                    </div>
                </div>

                <div class="alert alert-warning">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>International Status:</strong> No FDA or EMA filings as of 2025. Global expansion would require bridging studies in diverse populations and GMP inspections of Chinese manufacturing sites. Potential Western partnership could accelerate international development.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Regulatory Comparison</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Region</th>
                            <th>Status</th>
                            <th>Filing Date</th>
                            <th>Approval Date</th>
                            <th>Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>China (NMPA)</strong></td>
                            <td><span class="badge badge-success">Approved</span></td>
                            <td>June 2023</td>
                            <td>Sept 2024</td>
                            <td>15-month review, no issues</td>
                        </tr>
                        <tr>
                            <td><strong>United States (FDA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>Would need bridging studies</td>
                        </tr>
                        <tr>
                            <td><strong>Europe (EMA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>Potential Menarini partnership</td>
                        </tr>
                        <tr>
                            <td><strong>Japan (PMDA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>No current plans</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Safety Tab -->
        <div id="safety" class="tab-content">
            <div class="section">
                <h2 class="section-header">Safety Profile</h2>
                
                <p style="margin-bottom: 20px; font-size: 14px;">Cumulative exposure: ~2,000 patient-years by 2025. No black-box warnings.</p>
                
                <div class="safety-grid">
                    <div class="safety-item">
                        <div class="safety-value">70-80%</div>
                        <div class="safety-label">Overall AEs (similar to placebo)</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">5-10%</div>
                        <div class="safety-label">Serious AEs</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">&lt;2%</div>
                        <div class="safety-label">Discontinuation due to AEs</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">5-10%</div>
                        <div class="safety-label">Injection site reactions</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">8-12%</div>
                        <div class="safety-label">Nasopharyngitis</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">1-3%</div>
                        <div class="safety-label">Anti-drug antibodies</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Neurocognitive Safety</h3>
                    <p>No signals in trials despite 20-30% achieving very low LDL (&lt;25 mg/dL). Memory impairment and confusion &lt;1%, similar to placebo. Consistent with PCSK9 class data showing no cognitive decline even at LDL &lt;15 mg/dL over 5+ years.</p>
                </div>

                <div class="info-card">
                    <h3>Immunogenicity</h3>
                    <p>As a fully human monoclonal antibody, immunogenic potential is low. Anti-drug antibodies detected in 1-3% of patients with no impact on efficacy or safety. No neutralizing antibodies reported.</p>
                </div>

                <div class="info-card">
                    <h3>Special Populations</h3>
                    <ul>
                        <li><strong>Elderly:</strong> No dose adjustment needed, similar safety profile</li>
                        <li><strong>Renal impairment:</strong> No dose adjustment (mAbs not renally cleared)</li>
                        <li><strong>Hepatic impairment:</strong> Limited data, use with caution</li>
                        <li><strong>Pregnancy:</strong> Category B equivalent (animal studies negative)</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Commercial Tab -->
        <div id="commercial" class="tab-content">
            <div class="section">
                <h2 class="section-header">Market Position</h2>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-value">¬•8-12K</div>
                        <div class="stat-label">Expected Annual Cost</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">30-50%</div>
                        <div class="stat-label">Below Import Price</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">Pending</div>
                        <div class="stat-label">NRDL Status</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">10-20%</div>
                        <div class="stat-label">Est. First Year Uptake</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Pricing Strategy</h3>
                    <p>Expected ¬•8,000-12,000/year (approximately $1,100-1,650 USD), positioning 30-50% below imported PCSK9 mAbs like Repatha. Final pricing pending NRDL negotiations.</p>
                </div>

                <div class="info-card">
                    <h3>Reimbursement Outlook</h3>
                    <p>Not yet on National Reimbursement Drug List (NRDL). Inclusion in 2025-2026 cycles could provide 70-80% coverage, dramatically improving access. Government CV disease initiatives favor domestic products.</p>
                    <div class="progress-bar">
                        <div class="progress-fill" style="width: 10%;"></div>
                    </div>
                    <small style="color: var(--text-secondary);">Current reimbursement coverage: ~10%</small>
                </div>

                <div class="info-card">
                    <h3>Competitive Advantages</h3>
                    <ul>
                        <li>Q6W dosing offers improved convenience (8-9 injections/year)</li>
                        <li>Domestic production avoids import costs and supply chain issues</li>
                        <li>Government "Healthy China 2030" initiative supports local innovation</li>
                        <li>First domestic PCSK9 mAb in large Chinese market</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Market Challenges</h3>
                    <ul>
                        <li>Inclisiran entering China with 2x/year dosing advantage</li>
                        <li>Oral PCSK9 inhibitors coming by 2026-2027</li>
                        <li>No CV outcomes data vs proven benefit for Repatha/Praluent</li>
                        <li>Limited global expansion potential without partner</li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Future Outlook</h2>
                
                <div class="info-card">
                    <h3>Near-term (2025-2027)</h3>
                    <ul>
                        <li>Focus on NRDL inclusion for broader reimbursement</li>
                        <li>Real-world evidence collection in Chinese population</li>
                        <li>Potential partnership discussions for global development</li>
                        <li>Competition from inclisiran China launch</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Long-term (2028-2030)</h3>
                    <ul>
                        <li>Biosimilar competition from Repatha/Praluent</li>
                        <li>Oral PCSK9 inhibitors may dominate new prescriptions</li>
                        <li>May become niche option for specific populations</li>
                        <li>Potential EMA/FDA filing if partnered with Western company</li>
                    </ul>
                </div>

                <div class="alert alert-info" style="margin-top: 24px;">
                    <span class="alert-icon">üéØ</span>
                    <div class="alert-content">
                        <strong>Strategic Summary:</strong> Ebronucimab's success depends on aggressive pricing, securing NRDL inclusion, and leveraging Q6W dosing convenience. Without CV outcomes data or global presence, it faces challenges from inclisiran's superior dosing and upcoming oral alternatives. Best positioned as China's domestic champion in the near term.
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Mark nav tab as active
            event.target.classList.add('active');
        }
        
        // Animate progress bars and charts on scroll
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    // Animate progress bars
                    const progressFills = entry.target.querySelectorAll('.progress-fill');
                    progressFills.forEach(fill => {
                        const width = fill.style.width;
                        fill.style.width = '0';
                        setTimeout(() => {
                            fill.style.width = width;
                        }, 100);
                    });
                    
                    // Animate chart bars
                    const chartBars = entry.target.querySelectorAll('.chart-bar');
                    chartBars.forEach((bar, index) => {
                        const height = bar.style.height;
                        bar.style.height = '0';
                        setTimeout(() => {
                            bar.style.height = height;
                        }, index * 100);
                    });
                    
                    observer.unobserve(entry.target);
                }
            });
        }, { threshold: 0.1 });
        
        // Observe all sections
        document.querySelectorAll('.section').forEach(section => {
            observer.observe(section);
        });
    </script>
</body>
</html>